Physiological effects of treatments in obstructive sleep apnoea syndrome. by Moss, James.
Learning and IT Services 
Collegiate Learning Centro 
Coilegiate Crescent Campus 
Sheffield S10 2BP
ProQuest Number: 10702865
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10702865
Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Physiological effects of treatments in obstructive 
sleep apnoea syndrome
James Moss
This thesis is submitted in partial fulfilm ent of the requirements of 
Sheffield Hallam University for award of the degree Doctor of Philosophy
June 2013
In collaboration with Sheffield Teaching Hospitals NHS Foundation Trust
Contents
Acknowledgements....................................................................................................................viii
Statement of originality...............................................................................................................ix
Original scientific material arising from this research............................................................x
Abbreviations.................................................................................................................................xi
Structure of the thesis............................................................................................................... xiv
List of tables............................................................................................................................... xviii
List of figures................................................................................................................................ xix
Abstract...........................................................................................................................................xx
Section 1 -  Introduction and literature review ...................................................................... 1
1 Chapter 1 -  General in troduction ....................................................................................2
2 Chapter 2 -  Literature re v ie w ..........................................................................................5
2.1 What is obstructive sleep apnoea syndrome?....................................................... 5
2.1.1 O verview .................................................................................................................5
2.1.2 Pathogenesis.......................................................................................................... 6
2.1.3 Events o f the apnoeic cycle................................................................................. 8
2.2 Historical perspectives................................................................................................ 8
2.2.1 Obstructive sleep apnoea syndrom e................................................................ 8
2.2.2 L ifestyle ................................................................................................................... 9
2.3 Diagnosis......................................................................................................................10
2.4 Epidemiology...............................................................................................................14
2.5 Pathophysiology......................................................................................................... 15
2.5.1 Oxidative stress................................................................................................... 17
2.5.2 Sym pathoexcitation........................................................................................... 18
2.5.3 In flam m ation........................................................................................................ 19
2.5.4 Intrathoracic pressure oscillations...................................................................20
2.5.5 Endothelial dysfunction .....................................................................................21
2.6 Consequences of obstructive sleep apnoea syndrom e.......................................24
2.6.1 Cardiovascular m orbid ity and m o rta lity .......................................................... 25
2.6.1.1 Hypertension..............................................................................................25
2.6.1.2 Coronary artery disease and s troke ...................................................... 26
2.6.1.3 Other cardiovascular sequelae..............................................................27
2.6.2 Daytime som nolence........................................................................................ 28
2.6.3 Exercise capacity................................................................................................ 29
2.6.4 Economic im pact................................................................................................ 30
2.7 Obesity, metabolic syndrome and obstructive sleep apnoea syndrom e 31
2.8 Treatment paradigms............................................................................................... 33
2.8.1 Continuous positive airway pressure...............................................................33
2.8.2 Oral appliances.............................................................................................  35
2.8.3 Surgical in te rven tion .........................................................................................36
2.8.4 Supplemental oxygen and pharmacological in te rven tions....................... 37
2.8.5 Other therap ies...................................................................................................38
2.9 Adjunct therapies fo r obstructive sleep apnoea syndrom e...............................38
2.9.1 Dietary in terven tion .......................................................................................... 39
2.9.2 Exercise in te rven tio n .........................................................................................41
2.9.3 Combined dietary and exercise in te rven tio n ..................................................44
2.9.4 Sum m ary..............................................................................................................48
2.10 Assessing the impact o f clinical tria ls ................................................................. 48
2.11 Rationale..................................................................................................................50
Section 2 -  Lifestyle intervention in obstructive sleep apnoea syndrome -  a 
randomised controlled feasibility study.................................................................................52
3 Chapter 3 -  In troduction ................................................................................................53
4 Chapter 4 -  Methods .......................................................................................................55
4.1 Study design.................................................................................................................55
4.2 R ecru itm ent.................................................................................................................56
4.2.1 S trategy................................................................................................................ 56
4.2.2 Familiarisation..........................................................................................  57
4.3 Inclusion crite ria .......................................................................................................... 57
4.4 Exclusion c rite ria ......................................................................................................... 58
4.5 Lifestyle in te rven tion ................................................................................................58
4.5.1 O verview .............................................................................................................. 58
4.5.2 Role o f supervision............................................................................................. 59
iii
4.5.3 Exercise................................................................................................................ 59
4.5.3.1 Safety and considerations.......................................................................59
4.5.3.2 Principles of exercise prescrip tion ........................................................ 60
4.5.4 Dietary advice...................................................................................................... 63
4.5.5 Behaviour change............................................................................................... 66
4.6 Primary outcome measures - feas ib ility ............................................................... 66
4.6.1 R ecru itm ent.........................................................................................................68
4.6.2 Retention.............................................................................................................. 68
4.6.3 Compliance...........................................................................................................68
4.6.4 Safety.....................................................................................................................69
4.7 Secondary outcome measures - e fficacy..............................................................69
4.7.1 A n th ropom etry ...................................................................................................69
4.7.2 Blood-borne biom arkers................................................................................... 70
4.7.3 Microvascular fu n c tio n ......................................................................................71
4.7.3.3 Endothelium-dependent vasod ila tion ..................................................76
4.7.3.4 Endothelium-independent vasodila tion...............................................78
4.7.3.5 Offline analysis o f laser Doppler flow m etry scans............................. 78
4.7.4 Quality of life ....................................................................................................... 80
4.7.5 Exercise capacity.................................................................................................80
4.8 Statistical analyses.................................................................................................... 82
4.9 Reliability of m ethods...............................................................................................83
4.9.1 Analysis o u tlin e ...................................................................................................83
4.9.2 Results...................................................................................................................83
5 Chapter 5 -  Results.......................................................................................................... 85
5.1 Baseline characteristics.............................................................................................85
5.2 Primary outcome measures - feas ib ility ............................................................... 87
5.2.1 R ecru itm ent.........................................................................................................87
5.2.2 Retention.............................................................................................................. 89
5.2.3 Compliance...........................................................................................................89
5.2.4 Safety.....................................................................................................................89
5.3 Secondary outcome measures -  e fficacy.............................................................90
iv
5.3.1 A n th ropom etry ................................................................................................. 90
5.3.2 Cardiovascular r isk ............................................................................................94
5.3.3 Vascular fu n c tio n .............................................................................................. 98
5.3.4 Quality of life .................................................................................................... 101
5.3.5 Exercise capacity............................................................................................. 103
5.3.6 Correlations...................................................................................................... 107
6 Chapter 6 -  Discussion.................................................................................................. 109
6.1 O verview ................................................................................................................... 109
6.2 Characteristics.......................................................................................................... 110
6.3 Feasibility .................................................................................................................. 110
6.4 Efficacy.......................................................................................................................116
6.4.1 A n th ropom etry ................................................................................................116
6.4.2 Cardiovascular r is k .......................................................................................... 117
6.4.3 Exercise capacity..............................................................................................119
6.4.4 Quality o f life .................................................................................................... 121
6.5 Lim itations.................................................................................................................121
6.6 Future research........................................................................................................122
6.7 Sum m ary................................................................................................................... 123
Section 3 -  Effects of obstructive sleep apnoea syndrome and its treatment with 
CPAP on macrovascular and microvascular function........................................................ 124
7 Chapter 7 -  In troduction ............................................................................................... 125
8 Chapter 8 -  Methods...................................................................................................... 127
8.1 Study design............................................................................................................. 127
8.1.1 Outcome measures.........................................................................................127
8.1.2 Sample size ca lcu la tion .................................................................................. 128
8.2 R ecru itm ent..............................................................................................................128
8.2.1 Strategy 1 - recruitm ent o f patients from  local sleep clin ics..................128
8.2.1.1 Untreated g ro u p .....................................................................................128
8.2.1.2 High-compliance and low-compliance groups.................................. 129
8.2.2 Strategy 2 - recruitm ent o f obstructive sleep apnoea syndrome-free
control participants from  the com m un ity ................................................................129
v
8.2.3 Familiarisation and overnight polysomnography...................................... 129
8.3 Inclusion crite ria .......................................................................................................130
8.4 Exclusion c rite ria ......................................................................................................131
8.5 Primary outcome measures...................................................................................131
8.5.1 Vascular fu n c tio n ............................................................................................. 131
8.5.1.1 Post-occlusion reactive hyperaemia....................................................132
8.5.1.2 Local thermal hyperaem ia.....................................................................134
8.5.1.3 Flow-mediated d ila ta tion ....................................................................... 136
8.5.1.4 GTN-mediated d ila ta tio n ....................................................................... 138
8.5.2 Offline laser Doppler flow m etry analysis..................................................... 139
8.5.3 Offline vascular ultrasound analysis............................................................. 142
8.6 Secondary outcome measures.............................................................................. 144
8.6.1 A n th ropom e try .................................................................................................144
8.6.2 Blood-borne biom arkers................................................................................. 144
8.6.3 Questionnaires.................................................................................................. 144
8.6.4 Exercise capacity...............................................................................................144
8.7 Statistical analyses...................................................................................................145
9 Chapter 9 -  Results.........................................................................................................146
9.1 Baseline characteristics...........................................................................................146
9.2 Macrovascular fu n c tio n ..........................................................................................148
9.3 Microvascular fu n c tio n ...........................................................................................151
9.4 A n th ropom e try ........................................................................................................ 152
9.5 Cardiovascular r isk ...................................................................................................153
9.6 Exercise capacity...................................................................................................... 154
10 Chapter 10 -  Discussion...............................................................................................155
10.1 O verview ..................................................................................................................155
10.2 Vascular fu n c tio n ...................................................................................................155
10.3 Secondary outcomes............................................................................................. 157
10.3.1 A n th ropom etry ............................................................................................. 157
10.3.2 Cardiovascular r isk ........................................................................................157
10.3.3 Questionnaires.............................................................................................. 158
vi
10.3.4 Exercise capacity.......................................................................................... 159
10.4 Lim itations..............................................................................................................159
10.4.1 Recruitment and sample size..................................................................... 159
10.5 Future research..................................................................................................... 162
10.6 Sum m ary................................................................................................................ 162
Section 4 -  Conclusions............................................................................................................ 164
11 Chapter 1 1 -  Summary o f find ings .............................................................................165
References.................................................................................................................................. 170
Appendices.................................................................................................................................. 200
vii
Acknowledgements
The doctoral process has been, fo r me, an undulating rollercoaster o f successes and 
failures, and has instilled feelings of tum ultuous joy and unbridled despair. I am 
indebted to  several people fo r the ir support throughout. I extend thanks to  you all.
Firstly, to  my loving family; my parents Paul and Angela, your backgrounds in 
healthcare have been the greatest influence on my choice to  pursue a career in 
medical research; to my brother, Jonnie, fo r so much more than I expect you will ever 
know. Secondly, to  my friends who on countless occasions have provided clarity, 
advice and humour; Steve, thank you fo r your candidness, sarcasm and your ability to 
look on the bright side of everything; Joel, thank you fo r our chats about research 
design and the occasional game of chess. I cannot th ink o f two people I'd rather have 
made this journey w ith; and Joe, fo r showing me how Ph.D. data collection should be 
done. Thirdly to  my supervisory team who have equipped me w ith the skills tha t allow 
me to  practice as an independent researcher. In particular to Edward, thank you for 
your history lessons, your cupboard doors and fo r always having an open door 
(literally!); and to  Garry, your supervision and guidance has been an invaluable 
experience. I have learnt so much from  you both, fo r which I'm very grateful.
I would like to  extend special thanks to  those who have supported my research 
programme, including the adm inistrative and technical staff at the Centre fo r Sport 
and Exercise Science and the physiology and medical staff at Sheffield Teaching 
Hospitals NHS Foundation Trust. Also to  my students, teaching you has been a pleasure 
and a welcomed distraction.
And finally, to  my fiancee Louise, who has endured this process along w ith me. You 
have provided daily the right dose o f motivation, inspiration and encouragement to 
allow me to finish my doctoral studies. I dedicate this thesis to you.
Statement of originality
I hereby certify that I am solely responsible fo r the work contained in this thesis, unless 
otherwise acknowledged. Others work has been duly cited and the locations o f source 
material can be found in the epilogue. I confirm that neither this thesis, nor the data 
included w ith in it, has been submitted to  Sheffield Hallam University or any other 
institution in partial or complete fu lfilm ent fo r an undergraduate or postgraduate 
degree.
Study one was conceived by M r Martin Stout and Dr Stephen Bianchi, who also 
secured funding. Ethics approval was obtained by Dr Garry Tew. The overwhelm ing 
m ajority (>99%) of study activities such as participant recruitment, fam iliarisation and 
assessment were conducted by myself (w ith occasional support from  Centre fo r Sport 
and Exercise Science staff). Similarly, the delivery o f the lifestyle intervention, and data 
collection were completed by myself. Data analyses were also conducted by myself 
w ith guidance from two independent external biostatisticians (based at University 
College London and University of Sheffield).
Study two was my own concept and design. I and Dr Stephen Bianchi secured funding 
fo r the study and I applied fo r research ethics approval. I conducted all recru itm ent 
(w ith support from  Mrs Leslie Mattock), fam iliarisation and assessment activities w ith 
no exceptions. Data analyses were conducted by myself w ith support and verification 
o f findings from  Dr Garry Tew.
ix
Original scientific material arising from this research
Original journal articles:
Moss, J., Tew, G.A., Copeland, R.J., Stout, M., Billings, C.G., Saxton, J.M., W inter, E.M., 
Bianchi, S.B. (XXXX) Lifestyle intervention in obstructive sleep apnoea - a feasibility 
study. Sleep and Breathing. (In review)
Presentations:
Sleep Apnoea Trust Association Annual General Meeting (October 2012): Results of 
SATA-funded research: Effects o f a lifestyle intervention in obstructive sleep apnoea. 
Oxford, UK. (Oral communication; invited speaker)
21st Meeting of the European Sleep Research Society (September 2012): Effects o f a 
lifestyle intervention in overweight OSA patients treated w ith CPAP. Paris, France. 
(Oral communication)
22nd European Respiratory Society Annual Congress (September 2012): Effects o f a 
lifestyle intervention in overweight OSA patients treated w ith CPAP. Vienna, Austria. 
(Poster communication)
British Association o f Sport and Exercise Sciences (September 2011): Effects o f a 
lifestyle intervention in patients being treated fo r obstructive sleep apnoea. Essex, UK. 
(Oral communication)
Published abstracts:
Moss, J., Tew, G.A., Copeland, R.J., Saxton, J.M., W inter, E.M., Bianchi, S.M. Effects o f a 
lifestyle intervention in obstructive sleep apnoea patients treated w ith continuous 
positive airway pressure (2012) Journal o f Sleep Research, 21 (suppl. 1): S90-S91.
Moss, J., Tew, G.A., Copeland, R.J., Saxton, J.M., W inter, E.M., Bianchi, S.M. Effects o f a 
lifestyle intervention in patients being treated fo r obstructive sleep apnoea (2011) 
BASES supplement abstracts, Journal o f Sports Sciences, 29 (suppl. 2): S40-S41.
x
Abbreviations
ACE angiotensin-converting enzyme
ACh acetylcholine
ACSM American College of Sports Medicine
AF atrial fib rilla tion
AHI apnoea hypopnoea index
ANOVA analysis of variance
ANCOVA analysis o f co-variance
APU arbitrary perfusion units
BL baseline
BMI body mass index
CAD coronary artery disease
CBT cognitive behavioural therapy
Cl confidence interval
CIH chronic in te rm itten t hypoxia
CONSORT consolidated standards fo r reporting clinical trials
COPD chronic obstructive pulmonary disease
COX cyclooxygenase
CPAP continuous positive airway pressure
CPET cardiopulmonary exercise test
CRP C-reactive protein
CSA central sleep apnoea
CV coefficient o f variation
CVC cutaneous vascular conductance
CVD cardiovascular disease
DBP diastolic blood pressure
DXA dual-energy x-ray absorbtiometry
EDS excessive daytime somnolence
EEG electroencephalogram
EP end-point
xi
EPC endothelial progenitor cell
EQVAS EuroQol visual analogue scale
ESS Epworth sleepiness scale
FITT frequency, intensity, time, type
FMD flow-mediated dilatation
FU follow-up
GTN glyceryl trin itra te
HDL high density lipoprotein
HOMA-IR homeostatic model of assessment - insulin resistance
HR heart rate
HRR heart rate reserve
HRT hormone replacement therapy
ICAM intercellular adhesion molecule
ICC intra-class correlation coefficient
IL-6 lnterleukin-6
IQR interquartile range
ISWD incremental shuttle walk distance
ISWT incremental shuttle walking test
LDF laser Doppler flow m etry
LDL low-density lipoprotein
LED low energy diet
LOCF last observation carried forward
LTH local therm al hyperaemia
MAD mandibular advancement device
MAP mean arterial pressure
MCID minimal clinically im portant difference
MID minimal im portant difference
MPA medroxyprogesterone acetate
MRI magnetic resonance imaging
MSA mixed sleep apnoea
MSNA muscle sympathetic nerve activity
NHS National Health Service
xii
NO nitric oxide
OCP oral contraceptive pill
ODI oxygen desaturation index
OSAS obstructive sleep apnoea syndrome
OSA-LC low-compliance OSAS patients
OSA-HC high-compliance OSAS patients
OSA-UN untreated OSAS patients
P-eNOS phosphorylated endothelial nitric oxide synthase
PBF percentage body fat
p g i2 prostacyclin
PIS participant inform ation sheet
PORH post-occlusion reactive hyperaemia
PSG polysomnogram
RCT randomised controlled trial
RDI respiratory disturbance index
REM rapid-eye movement
ROI region o f interest
ROS reactive oxygen species
RPE rating of perceived exertion
SBP systolic blood pressure
SD standard deviation
SDB sleep disordered breathing
SEM standard error of the mean
SNP sodium nitroprusside
TEM technical error of measurement
TNF-a tum our necrosis factor alpha
TSD tongue stabling device
TTM trans-theoretical model
UPPP uvulopalatopharyngoplasty
VLED very low energy diet
VSMC vascular smooth muscle cell
Structure of the thesis
Purpose of the thesis
The increasing prevalence of obesity and its associated morbidities are well reported. 
Obesity is an independent risk factor fo r obstructive sleep apnoea syndrome (OSAS), 
which in turn has been identified as an independent cardiovascular risk factor. OSAS 
contributes to  the development of vascular atheroma and clinical events such as 
myocardial infarction and stroke. The aetiology of OSAS is m ultifactorial; however the 
principal modifiable cause is w idely regarded to  be obesity. Consequently, the 
bidirectional relationship o f OSAS and obesity has been exploited by inducing a state of 
negative energy balance using paradigms tha t address energy intake, energy 
expenditure or both to  reduce adiposity and its associated obstructive events. 
Prevalence and public awareness of OSAS is likely to  increase in coming years. 
Although continuous positive airway pressure (CPAP) is effective it is not a patient- 
preferred treatm ent and interventions to  address the causes of airway obstruction 
(e.g. cervical obesity) as opposed to  simple management are warranted. Furthermore, 
not all patients are fu lly compliant w ith CPAP fo r several reasons, including apathy 
towards its importance (especially in the absence of daytime symptoms), mask 
discomfort and intolerance to  the air pressure. Consequently, many patients w ith in  the 
population have low compliance, yet rarely are such patients included (let alone 
allocated together in a low compliance group) in medical research - perhaps because 
of problems defining what exactly constitutes a low-compliance patient. Consequently, 
there is a paucity o f evidence regarding what level o f protection  occasional CPAP use 
offers in terms of the management o f daytime symptoms and the prevention o f fu ture  
com orbidity (e.g. cardiovascular disease).
Therefore, the purpose of this thesis was to  investigate the feasibility of a combined 
lifestyle intervention in the management of OSAS and to  improve our understanding of 
how treatm ent o f OSAS w ith CPAP (in particular when compliance w ith treatm ent is 
suboptimal) affects vascular endothelial function in the macro- and microvasculature.
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Abstract
The original research in this thesis aimed to  investigate physiological effects of 
d ifferent treatm ent approaches in obstructive sleep apnoea syndrome (OSAS). OSAS is 
a prevalent public health concern independently associated w ith increased 
cardiovascular risk. Specifically, study 1 examined the feasibility of conducting a 
pragmatic lifestyle intervention in patients reporting compliance w ith continuous 
positive airway pressure (CPAP) and collected provisional data about its efficacy, and 
study 2 investigated the physiological effects of low compliance to  CPAP therapy in a 
four-arm  observational study.
The intervention in study 1 involved supervised exercise, dietary advice and behaviour 
change counselling. Primary outcome measures were recruitment, retention and 
compliance data and secondary outcome measures assessed anthropometries, 
cardiovascular risk, quality of life and exercise capacity. Study 2 investigated macro- 
and microvascular function, anthropometries, quality of life, cardiovascular risk and 
exercise capacity.
The novel findings of this research were: 1) the lifestyle intervention was feasible to  
deliver; 2) the intervention improved key health outcomes such as exercise capacity (A 
+16%) and serum C-reactive protein (A -57%), which were maintained after 3 months 
of independence (A +22% and -57%, respectively); 3) self-reported CPAP compliance is 
an unreliable indicator of actual compliance; 4) it is d ifficu lt to  recruit low-compliance 
patients onto research trials, and recruiting newly diagnosed patients is also d ifficu lt 
w ithout in terrupting the patient pathway; 5) vascular function seems impaired in low- 
compliance patients versus high-compliance patients, although fu rther work is needed 
to  confirm this.
These findings contribute to  the growing evidence base fo r the role o f lifestyle 
intervention in OSAS, and provide provisional data on the effects o f low compliance to  
CPAP therapy on vascular endothelial function. In summary, fu ture  research 
investigating pragmatic lifestyle interventions in OSAS and the physiological effects of 
low-compliance to  CPAP is certainly warranted.
xx
Chapter 1 -  General introduction
Medicine is a relatively new word fo r a discipline tha t is at least 5 millennia old. 
Evidence of Ancient Egyptian practice from  approximately 2000 B.C. describes several 
ailments and injuries, the ir prognoses and recommended treatm ents. Several o ther 
texts based on empiricism also date to  the second millennium B.C. From the ancient 
world to recent history, d ifferent civilisations have developed the ir own methods 
according to  the ir experiences and beliefs. Similar developments based partly on 
observation, religion and spiritualism have been identified in Ancient China, India, 
Greece and Rome (Porter, 1999). Hippocrates (b. ~480 BC) and Galen (b. ~ 129 AD) are 
often credited w ith the development of the academic teaching and practice of 
medicine, although until the last 200 years this was not w idely accepted. Medicine in 
Medieval England was principally practiced by Barber Surgeons who trained through 
apprenticeships and learnt by tria l and error.
It is im portant when considering the state-of-the-art to  credit the im portant 
discoveries or pioneering procedures tha t have contributed to  the progression of 
modern medicine. To name a few, the development o f the antiseptic principles o f 
surgery by Joseph Lister in 1867 had emphatic results on post-operative outcomes and 
quickly became ubiquitous (Lister, 1867), the discovery o f penicillin by Alexander 
Fleming in 1928 revolutionised the treatm ent o f bacterial infection (Fleming, 1929), 
and the first successful organ transplant (kidney) by Joseph Murray and colleagues in 
1954 confirmed the feasibility o f replacing a dysfunctional human organ w ith a healthy 
donor organ (Porter, 1999). On the cutting edge, after the existence of p luripotent 
stem cells was firs t purported in the early 1900s, research exploded during the late 
1990s, which promises one day to yield laboratory techniques tha t w ill a llow 
physicians to  simply grow a patient a replacement organ using the ir own cells - 
abolishing the issues of organ-matching and organ rejection. Although such wonderfu l 
endeavours will help some branches of medicine, others still require alternatives.
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Since the m id-twentieth century the prevalence of obesity has increased dramatically. 
This epidemic can be fundam entally a ttributed to  a sustained period of positive energy 
balance w ith in the population; however the precise factors responsible fo r this have 
not yet been unequivocally identified. Two common-cited culprits are the augmented 
energy intake (e.g. the availability and consumption of energy-dense foods) and 
decreased daily energy expenditure consequent of technological advances and modern 
conveniences. Changes in diet patterns from  home-cooked meals prepared w ith local 
produce to  store-bought pre-prepared meals have increased the amount o f complex 
carbohydrates and saturated fats consumed. Similarly, urbanisation, improved 
transport (e.g. personal m otor vehicles and public transport) and an increase in 
sedentary behaviour both in the workplace (e.g. working at a desk) and at home (e.g. 
watching television or playing computer games) has affected all developed countries, 
both sexes, all ages and all levels o f socioeconomic class. Beyond these, more novel 
factors have been proposed including infections, maternal age, sleep debt and ambient 
tem perature (McAllister et ol., 2009). The m ajority of evidence investigating these 
factors is retrospective and correlative, and it is often impractical or unethical to 
conduct randomised controlled trials to  properly test these hypotheses. Current 
treatm ents fo r obesity include interventions to promote positive changes in lifestyle 
(e.g. adoption of healthy eating and increased physical activity), surgery (e.g. gastric 
banding) and pharmacological therapy to  reduce energy intake (e.g. Orlistat therapy).
The role of exercise training in the prevention, management and treatm ent o f chronic 
disease has gained increasing interest from  medical researchers in recent decades fo r 
several reasons. Firstly, regular exercise is associated w ith holistic personal benefits 
such as improved fitness, improved vita lity, weight loss, improved self-image, 
improved mood and expanded social networks (Burnham, 1998; Penedo & Dahn, 
2005). Secondly, compared w ith other treatm ents such as medication or surgery, the 
provision of exercise can be very cost-effective. Thirdly, the intensity, duration, 
frequency and type of exercise are reasonably w ith in the control o f the patient, which 
allows patients to reduce or w ithdraw  the exercise stimulus at the firs t sign o f any 
adverse reactions. Evidence of the public health burden of physical inactiv ity has
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accumulated over recent decades and the recognition of Sport and Exercise Medicine 
as a stand-alone section of the Royal Society of Medicine is testam ent to  this.
It is im portant to  discern the difference between exercise and physical activity, which 
are often incorrectly used interchangeably. Definitions proposed by Caspersen et al. 
(1985) described physical activity as deliberate bodily movement resulting from  
coordinated contraction o f skeletal muscle groups; and, exercise as a planned, 
structured and goal-directed subset of physical activity. However, such definitions have 
the ir lim itations by including movement as a requisite feature, which excludes 
activities involving isometric muscular activation (W inter & Fowler, 2009). These 
authors proposed an alternative definition fo r exercise: "o potentia l disruption to 
homeostasis by muscle activity tha t is either exclusively, or in combination, concentric, 
eccentric or isometric". However, it is unclear using this defin ition how one could 
discern the difference between exercise and non-exercise physical activity. Hereafter, 
physical activity will refer to  routine activities tha t require meaningful e ffo rt (e.g. 
climbing three flights o f stairs instead of using an elevator) and exercise will refer to an 
allocated period of tim e used fo r purposeful activity of at least moderate intensity.
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Chapter 2 -  Literature review
2.1 What is obstructive sleep apnoea syndrome?
2.1.1 Overview
Obstructive sleep apnoea syndrome (OSAS) is the most common form  of sleep 
disordered breathing (SDB), and is characterised by episodes of obstructed ventilation 
during sleep. This leads to  reduced arterial blood oxygen saturation, intrathoracic 
pressure fluctuations and subsequent centrally-stimulated microarousals to  restore 
airway patency. The aetiology of these obstructions is often m ultifactorial, w ith 
excessive cervical adiposity, reduced nocturnal tonus of airway smooth muscle and 
enlarged soft structures of the oropharynx usually implicated. The degree of 
obstruction can vary from  complete cessation o f a irflow  (apnoea) to  reduced (and 
inadequate) a irflow  (hypopnoea; defined as <20% air flow). The frequency of apnoeic 
events is referred to  as the apnoea hypopnoea index (AHI), which constitutes the 
defining criteria fo r d ifferent severities o f OSAS (National Institute fo r Care and Health 
Excellence, 2010); mild (5 to 15 events per hour), moderate (15 to  30 events per hour) 
and severe (more than 30 events per hour).
The nocturnal symptoms include habitual excessive snoring (caused by tu rbu len t 
airflow  through the upper airway), witnessed pauses in breathing and awakening w ith  
a choking sensation. However, the principal symptoms for OSAS are excessive daytime 
sleepiness (EDS) and fatigue which are often dismissed as triv ia l by patients and 
general practitioners alike - consequently it is likely tha t only a small proportion of 
people afflicted have actually received a diagnosis and are receiving treatm ent. In 
addition to EDS, OSAS can contribute to  impaired cognitive function, reduced 
concentration, irritab ility  and increased risk of falling asleep during the day (possibly 
when driving a m otor vehicle, which could have potentia lly fatal consequences).
The most common treatm ent for OSAS involves positive airway pressure therapy 
delivered continuously via a full-face or nasal mask interface. This high-pressure air 
provides an internal pneumatic splint that increases airway patency and thereby 
reduces the collapsibility o f the airway (see section 2.8.1). This mainstay trea tm ent
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provides management only and does not constitute a cure; patients must adhere to 
therapy while trying to  address modifiable underlying causes (such as obesity). 
Although other treatm ent options (e.g. mandibular repositioning devices and surgery) 
are available they are not as widespread. Many are useful only in particular aetiologies 
or fo r lower severities of OSAS.
2.1.2 Pathogenesis
SDB can be described as irregular breathing patterns during sleep and classified as 
obstructive (i.e. the airway is mostly or completely occluded), central (i.e. impaired 
autonomic respiratory control) or mixed (both obstructive and central). When SDB is 
obstructive and completely occludes airflow  it is termed apnoea, and airflow  reduced 
to  20 per cent of normal is called hypopnoea. Obstructive events mostly occur in the 
upper airway in the retropalatal and retroglossal parts of the oropharynx and less 
often in the nasopharynx and laryngopharynx. Apnoea occur in healthy individuals and 
SDB is only present when the mean event frequency exceeds five per hour o f sleep. If 
the apnoea frequency is normalised w ith the application of positive airway pressure 
then a diagnosis of OSAS can be made.
Patients w ith OSAS are generally considered to  have an airway tha t has an anatomical 
predisposition to  collapse, although there is no direct evidence to  support this. This 
likely involves a narrower-than-normal airway, which itself could be hereditary or 
acquired (caused by inflammation or increased pharyngeal fa t deposits). Fatty 
infiltrates in the glossus and soft palate increase the mass o f these structures, which 
compounds congestion in the upper airway and reduces airway calibre from  the 
anterior direction. Similarly, increased parapharyngeal fa t stores reduce airway calibre 
bilaterally, which contributes to  reduced cross-sectional area of the airway and an 
increased propensity fo r collapse. Apnoea are absent during wakefulness because of 
upregulated activation of the smooth muscle o f the airway, which maintains the 
patency. In addition to ventilation, upper airway patency is im portant fo r deglutition 
and speech. Also, when the thorax is upright gravity pulls loose structures in a 
downward direction -  when supine gravity pulls them in a transverse direction across 
the airway and occluding it. Once an individual begins sleeping, the upper airway 
musculature tha t is under voluntary control (e.g. which controls the complex
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movements required fo r speech) is no longer activated. Similarly, activation of the 
involuntary d ilator muscles is reduced (hypotonic) and the aforementioned gross 
structures can easily cause obstruction in response to  the negative pressures caused 
by inspiration. Moreover, there is evidence to support a rostral flu id  shift as a 
contributory factor to airway collapse in OSAS. This theory proposes tha t the gravity- 
induced flu id accumulation in the lower extrem ities during the daytime redistributes 
overnight when in a supine position, which induces mild oedema in tissue around the 
neck tha t contributes to  airway narrowing. Experimental evidence has shown 
significant relationship between the frequency of apnoeic events and the volume of 
flu id displaced from  the legs (Redolfi et al., 2009).
Obstructive events are much more common than central events and a discrete risk 
profile has been identified tha t includes, in likely order o f importance, obesity 
(Dempsey et al., 2002), the male sex (Young et al., 1993) and particular craniofacial 
structures (Dempsey et al., 2002). There is evidence to  suggest tha t age is a risk factor 
fo r OSAS during middle-age (40 to  60 years), however beyond 60 its effects are 
negligible (Young et al., 2002a). The contribution o f obesity to  the development of 
OSAS is discussed further in section 2.7. Briefly, increasing obesity is associated w ith  an 
increased risk o f developing OSAS -  a 10% increase in body mass is associated w ith a 
six-fold increase in risk of developing OSAS over four year period (Peppard et al., 
2000a). Observational studies have also identified relationships between neck girth, 
adiposity and visceral fat to the presence and/or severity of OSAS (Vgontzas et al., 
2003). Tendency fo r Western populations becoming 'Tatter'" over the last 40 years 
suggests tha t the incidence of obstructive SDB is probably increasing. Incidence of 
other obesity-related ailments such as hypertension, diabetes and arthritis has also 
increased over the same period (W helton, 1994; W iner & Sowers, 2004; Reginster, 
2002).
There could also be a familial component to  the risk profile fo r OSAS, although 
evidence is unclear whether this is an environmental (familial eating habits, lifestyle 
behaviours or socioeconomic status) or genetic (inherited craniofacial structures or 
genes tha t promote obesity) link. Varvarigou et al. (2011) reviewed the fie ld o f OSAS 
genetics and highlighted that although several studies have provided evidence, these 
studies have potentially been underpowered. They are also relatively scarce; the
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authors tried to meta-analyse current literature but acknowledged the small pool of 
suitable studies, and the absence of reported covariates (e.g. age, sex, apnoea 
frequency) as lim itations.
2.1.3 Events of the apnoeic cycle
The apnoeic cycle starts w ith an obstruction of the upper airway tha t leads to  a state 
o f hypoxia and hypercapnia. This activates peripheral chemoreceptors causing a 
compensatory increase in pulmonary e ffo rt tha t is unable to  restore airflow. 
Eventually, hypoxaemia activates central chemoreceptors which cause a microarousa! 
(the patient rouses just enough to  change body position and restore upper airway 
patency) and a subsequent period of hyperventilation to  counter the hypoxia and 
hypercapnia (Wiegand & Zwillich, 1994). These arousals are associated w ith a brie f rise 
in blood pressure (Davies et al., 1993). The frequency of apnoea per hour o f sleep is 
presented as the apnoea hypopnoea index (AHI). The cyclic desaturation and 
reoxygenation that accompanies each apnoea can produce excess reactive oxygen 
species (ROS; Lavie et al., 2003), or free radicals, which play a key role in cell damage 
(Valko et al., 2007). This is discussed fu rther in section 2.5.1.
2.2 Historical perspectives
2.2.1 Obstructive sleep apnoea syndrome
Although potential evidence of SDB has been identified as long ago as 300 BC 
(Michalopoulos et al., 2003), the physiological manifestations of OSAS were firs t 
described not by scientists or physicians, but by English novelist Charles Dickens (b. 
1812 AD) in 1836 (Dickens, 1949) in a regular publication entitled "The Pickwick 
Papers". Dickens described a fat boy w ith an enormous appetite, who had a tendency 
to  fall asleep at inconvenient times. The obesity and daytime sleepiness to  which he 
referred would in due course become hallmarks of OSAS.
Caton (1889) published a case study describing an obese patient who had gained 43 kg 
in weight over 2 years and had started suffering from  chronic sleepiness, falling asleep 
whenever he sat down and occasionally when upright. Caton observed his patient 
asleep and noticed the upper airway closure, fu tile  hypercontraction o f respiratory
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muscles and cyanotic skin. This was followed by an arousal which did not awaken the 
patient, but restored airway patency, reversed the cyanosis and stimulated a brief 
deeper-than-usual period o f ventilation. In his article, Caton pleaded fo r assistance 
from  readers as to  how to  manage this patient as he could find no prior evidence of 
the condition in medical literature. His provisional diagnosis was narcolepsy, which had 
been described w ith a similar presentation nine years prior byJean-Edouard Gelineau 
(1881).
Later in 1889, Morison described how a patient would fall asleep while engaged in an 
enjoyable game of cards and begin snoring (Morison, 1889). Morison w rote "I have 
myself observed him asleep in bed w ith an intensely cyanotic countenance, a condition 
from  which he was aroused after a snorting and choking sound issued fro m  his 
respiratory passages, the cyanosis then gradually disappearing". Resulting from 
Dickens' description half a century prior, Morison coined the condition he observed as 
Pickwickian Syndrome. Burwell et al. (1956) published a case study describing a patient 
presenting w ith obesity, fatigue and somnolence. Their patient described a recent 
weight gain and a tendency to  fall asleep during daily routine.
Historically, obesity was regarded as fashionable and an indicator o f esteem, wealth 
and power. Consequently, many prom inent historical figures reported to  have been 
obese may have suffered from  OSAS. Researchers have identified historical reports of 
now-established symptoms being exhibited by prom inent leaders such as included 
Queen Victoria o f the British Empire (Brewer, 2000), Emperor Napoleon Bonaparte 
(Chouard et al., 1988) and President W illiam H. Taft o f the United States (Sotos, 2003). 
The potential impact of undiagnosed OSAS on the ir decision-making and leadership 
and how treatm ent may have changed the course o f history is worth consideration 
(Polkey et al., 2004).
2.2.2 Lifestyle
The bidirectional relationship between lifestyle (diet and exercise) and health is not a 
novel idea. Prominent Ancient Greek philosopher Hippocrates and Galen of Ancient 
Rome advocated the role of exercise in health and wellbeing. Hippocrates is reported 
to  have said tha t "Eating alone w ill not keep a man healthy; he must also take exercise. 
For food  and exercise, while possessing opposite qualities, yet work together to
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produce health." (Jones & W ithington, 1952). His statement promotes the importance 
of balanced sustenance and physical activity in the maintenance of good health. 
Similarly, Galen's theory o f health involved six non-natural (or what we would now 
refer to  as modifiable) components tha t included diet and exercise independently (as 
well as air, sleep, excretion and thought) as factors o f which too much or too little  
would contribute to disease (Berryman, 1989). This thesis was still maintained by 
physicians during the sixteenth (Mendez, 1960) and eighteenth (Fuller, 1718; Buchan 
et al., 1774) centuries. In the modern medical literature the appreciable role of 
exercise (or a lack thereof) resurfaced in the m id-twentieth century and the American 
College o f Sports Medicine (ACSM) was form ed (1953), which is now an influential 
organisation in the field o f sports medicine. Similarly, books such as Kraus & Raab 
(1961) explored the impact o f a sedentary lifestyle on the prevalence of disease. 
Throughout history, the importance of a balanced lifestyle has been appreciated and 
w ith the current economic downfall, therapies (adjunct or otherwise) utilising the 
relative low cost o f lifestyle modification must continue to  be investigated.
2.3 Diagnosis
A positive diagnosis fo r OSAS requires confirmation of frequent nocturnal apnoea. This 
can be evidenced by m onitoring ventilation dynamics and/or oxyhaemoglobin 
saturation during sleep. Overnight polysomnography (PSG) is the measurement 
m ultiple variables during sleep to  diagnose sleep disorders. Common inputs include 
a irflow  (using a nasal cannula and pressure transducer to  detect interruptions in the 
sinus breathing pattern), chest expansion (using a thoracic pressure band; expansion in 
the absence of a irflow  indicates an apnoea), electroencephalography (to determ ine 
states o f sleep using brain activity), electrooculography (to identify rapid eye 
movement sleep), pulse oximetry (to identify periodic blood oxygen desaturations as a 
consequence of interrupted breathing) and heart rate (Flemons et al., 2003). An 
example o f what a typical apnoeic trace could look like is presented in Figure 2.1. Note 
the peri-apnoeic cessation of nasal airflow, reduction in oxygen saturation and 
increase in heart rate, and the post-apnoeic increase in respiratory muscle activation,
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increased depth of inspiration that steadily normalises, a return to pre-apnoeic oxygen 
saturation, increased skeletal muscle activity and EEG changes.
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Figure 2.1 Polysomnogram Multiple channels of an overnight polysomnogram, showing 
recruitment of the respiratory musculature, nasal airflow, pulse oximetry, heart rate, skeletal muscular 
activity (to change position and restore airway patency) and encephalography to show brain activity. 
The period of apnoea and microarousal are highlighted at the bottom of the figure. Adapted from Kapur 
etal. (2010).
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Overnight PSG is usually performed during normal sleeping hours in a sleep centre. 
This test is expensive, uncomfortable and often inconvenient fo r patients. Some 
centres use a simplified take-home version which can be complicated fo r patients to 
set up themselves. Routine clinical practice often utilises overnight pulse oximetry 
alone to  confirm or exclude OSAS, which is more practical as the device is simple to 
attach and switch on and can be performed in the patient's own home. Afterwards, 
data are downloaded from  the device and the frequency of nocturnal oxyhaemoglobin 
desaturation (oxygen desaturation index; ODI) can be measured. At this stage, it is not 
possible to  make a conclusive diagnosis of OSAS as central sleep apnoea (CSA) and 
mixed sleep apnoea (MSA) could provide similar oximetry. To distinguish between 
these, patients are issued w ith a positive airway pressure device fo r a tria l period, w ith  
the final night involving concurrent pulse oximetry. This device uses pressurised air to  
splint the airway and prevent the previously observed desaturations (discussed further 
in section 2.8.1); a normal ODI is indicative o f OSAS, an improved but abnormal ODI 
suggests MSA, and an unchanged ODI indicates CSA. The events per hour thresholds 
fo r mild, moderate and severe used fo r AHI are often shared by ODI in clinical practice, 
despite the tw o  not necessarily being equivalent.
Several questionnaires have been devised to  facilitate the identification o f potential 
OSAS and to  assess its impact on subjective tiredness. The Berlin Sleep Questionnaire 
is a useful tool fo r evaluating the OSAS risk by asking m ultiple choice questions tha t 
assess sleep habits, daytime tiredness and general health (blood pressure, BMI). Two 
or more positive categories are highly suggestive of OSAS. This questionnaire has been 
validated as a screening tool (Chung et al., 2008). The Epworth Sleepiness Scale (ESS) 
devised by Johns (1991) is a subjective questionnaire tha t quantifies patients' self- 
reported daytime somnolence. Patients are asked the ir likelihood o f falling asleep in 
eight d ifferent situations (such as watching television or as a passenger in a car) by 
providing a response between 0 (not likely at all) and 3 (very likely). The scores fo r the 
eight domains are summed to provide an overall score - less than 10 is considered 
normal and 10 or above suggests the presence of a daytime sleepiness (and potentia lly 
a sleep disorder). The ESS has been shown to  be valid in OSAS, although its 
reproducibility is unclear (Nguyen et al., 2006; Knutson et al., 2006).
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2.4 Epidemiology
OSAS has received appreciable attention only in recent decades in part because of 
population-based prevalence studies in Sweden (Gislason et al., 1988), Australia 
(Bearpark et al., 1995) and the USA (Young et al., 1993; Kripke et al., 1997). These 
studies identified a higher-than-expected prevalence tha t stimulated interest in the 
causes and consequences of OSAS. Prevalence surveys suggest tha t 2% women and 4% 
of men at middle age are affected by this syndrome and it is becoming increasing 
common w ith the current obesity epidemic (Young et al., 2002b). Punjabi et al. (2008) 
put this number between 3 and 7% in the general public. Estimates o f prevalence are 
varied as a result o f d ifferent populations, in d ifferent countries, w ith d iffe rent criteria 
used to  define and measure SDB. Davies and Stradling (1996) reviewed 12 prevalence 
studies from  across the world and concluded tha t 1-5% of com m unity-dwelling adult 
men have SDB, and tha t prevalence increases w ith obesity. The prevalence of 
m inimally symptomatic OSAS (i.e. w ithout daytime symptoms) is estimated to  be 20% 
in the adult population (Young et al., 2002b).
There is some evidence to  suggest tha t female sex hormones have a protective effect 
in pre-menopausal women, w ith incidence in post-menopausal women being 3.5 times 
greater than peri-menopausal counterparts (Young et al., 2003). In fu rthe r support, 
incidence has been shown to  be similar between post-menopausal women and age- 
and BMI-matched men (Resta et al., 2003), and women receiving hormone 
replacement therapy (HRT) to  be half as likely to  have an AHI>15 events-h'1 than those 
not on HRT (Shahar et al., 2003). Although HRT would seem to o ffer benefit in reducing 
SDB, its long-term effects on cardiovascular disease are still unclear (Nabulsi et al., 
1993; Hulley et al., 2002; Manson et al., 2003).
OSAS is an underdiagnosed condition and Young et al. (1997) estimated tha t 82% of 
men and 93% of women w ith moderate-to-severe OSAS remain undiagnosed - this was 
based on findings from  4925 American adults in employment. Moreover, a study of 
5615 community-dwelling adults showed increasing prevalence o f m ild OSAS 
associated w ith age, but a plateauing of moderate or worse disease (approxim ately 
20% in adults aged 60-69, 70-79 and 80-99 years), and an overall prevalence rate of 
18% (defined as AHI>15 events-h1; Young et al., 2002a). The prevalence o f moderate-
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or-worse OSAS was 3 times larger (32 versus 10%) in the obese quartile (BMI>30.9 
kg-m'2) versus the normal weight quartile (BMI<24.4 kg-m'2). Another finding of this 
study was tha t the odds ratio of having an AHI>15 events-h'1 after a BMI increment of
5.3 kg-m' (adjusted fo r sex and race) progressively decreased in a linear trend with 
age, from 2.0 [1.7, 2.4] to 1.3 [1.1, 1.5]. A small study showed a prevalence of 53% (38 
of 72) undiagnosed OSAS sufferers in obese otherwise healthy participants recruited 
from  the community (Yim-Yeh et al., 2010).
Despite the widely-reported high prevalence of occult OSAS, some studies have not 
controlled fo r the possibility o f unsuspected non-symptomatic OSAS in the ir age- and 
BMI-matched control groups. As a result studies evaluating the impact o f obesity alone 
on endothelial dysfunction may report findings tha t were distorted by or attributable 
to  undiagnosed OSAS.
Prevalence of OSAS in children is unclear, and is thought to  affect up to  2% of children 
(Ali et al., 1993; Gislason et al., 1995; Redline et al., 1999). Adenotonsilectomy can 
cure OSAS in between 75 and 100% of children, independently o f obesity (Schechter et 
al., 2002). This suggests that the pathogenesis o f childhood OSAS is simpler than in 
adults, although others consider reduced compensatory upregulation of vasomotor 
tone (Marcus et al., 2000). In fu rthe r support of the inheritab ility  o f OSAS, a case- 
control study comparing 22 children w ith at least one parent w ith confirmed OSAS 
w ith age- and gender-matched controls showed higher incidence of paediatric OSAS in 
those w ith OSAS-afflicted parents (Lucas, 2013). These results suggested higher 
frequency of OSAS symptoms, and possibly the condition itself, in the children w ith 
OSAS and recommended future research to  test this hypothesis.
2.5 Pathophysiology
Pathophysiological consequences of OSAS were not tru ly  appreciated until the 1980s. 
OSAS is independently associated w ith cardiovascular comorbidity, probably caused by 
the transient episodes of hypoxia and hypercapnia, and the cyclical fluctuations in 
intrathoracic pressure. These mechanisms are summarised in Figure 2.1.
15
Obesity
Oxidative
stress
Sympatho-
excitation
Endothelial dysfunction
Metabolic
dysregulation
Systemic
inflammation
Chronic
intermittent
hypoxia
Intrathoracic
pressure
oscillations
OBSTRUCTIVE SLEEP APNOEA
CARDIOVASCULAR DISEASE
Figure 2.2 Potential mechanisms linking obstructive sleep apnoea and 
cardiovascular disease. Arrows w ith complete and dashed lines to be interpreted the 
same. This figure has been adapted from one appearing in Kent et al. (2011)
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2.5.1 Oxidative stress
Hypoxaemia can be measured in a laboratory setting by measuring the partial pressure 
o f oxygen in an arterial blood sample (Pa0 2); however this requires specialist 
equipment and an arterial blood sample, which is more problematic to  collect than its 
venous counterpart. The most convenient alternative is to  measure the oxygen 
content of arterial blood using pulse oximetry. The haemoglobin dissociation curve is 
sigmoidal, and consequently if saturation drops below 90% (or Pa0 2 <60 mmHg) then 
small fu rthe r decrements in Pa0 2 can lead to profound reductions in oxygen saturation. 
Oxygen relies on a pressure gradient both to  bind to haemoglobin in the pulmonary 
circulation and to  diffuse across the vascular endothelium into cells; therefore 
hypoxaemia can lead to  hypoxic stress in the arterial wall.
Although endogenous ROS are produced naturally as a metabolic product, clearance 
mechanisms are in place to  lim it accumulation; if production significantly exceeds 
clearance then cellular damage is likely. The characteristic reoxygenation seen in OSAS 
after apnoea-induced hypoxaemia increases the production of ROS, in a similar 
manner to reperfusion injury seen after a period of ischaemia (Zweier et al., 1988). In 
vivo markers of oxidative stress (such as 8-hydroxy-2'-deoxyguanosine excretion in 
urine) have been used in the quantification of oxidative stress in OSAS. Yamauchi et al 
(2005) showed an independent association between OSAS and oxidative stress and 
tha t ODI correlated better w ith oxidative stress than AHI. Interestingly, superoxide 
dismutase pre-treatm ent reduced ROS form ation during reperfusion o f an ischaemic 
heart (Zweier, 1988). Hypoxaemia also increases expression of intercellular (ICAM) and 
vascular adhesion molecules, which increases adhesion o f leukocytes to  the vascular 
endothelium increasing local oxidative stress (Walzog & Gaehtgens, 2000).
Hypoxaemia can impede aerobic energy production. Circulating 2,3- 
diphosphoglycerate has been shown to  be elevated in OSAS (McKeon et al., 1990). This 
by-product o f glycolysis increases the dissociation o f oxygen from  haemoglobin, which 
probably improves tissue oxygen delivery during hypoxaemia. The ratio o f uric acid to  
creatinine is elevated in OSAS caused by hypoxaemia, and is successfully normalised 
w ith continuous positive airway pressure (CPAP) therapy (McKeon et al., 1990; 
Sahebjami, 1998). Although initia lly dismissed as a useful index o f trea tm ent efficacy
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(McKeon et al., 1990), this possibility has since been reiterated (Sahebjami, 1998). 
Oxidative stress has also been implicated in the pathogenesis of obesity and metabolic 
disease, which themselves are risk factors fo r cardiovascular disease (CVD). It seems 
astute to  assume prolonged periods o f non-treatm ent w ill probably result in 
cardiovascular morbidity.
2.5.2 Sympathoexcitation
Persons w ith OSAS have chronic daytime sympathoexcitation (Carlson et al., 1993) the 
cause of which is currently unknown. Repeated episodes of increased muscle 
sympathetic nerve activity (MSNA) measured using microneurography have been 
observed during apnoea (Hedner et al., 1995). Episodes of nocturnal 
sympathoexcitation have been linked to  activation of the peripheral sympathetic 
chemoreflex by the hypoxaemic/hypercapnic stimuli as the increased sympathetic 
tra ffic  is curtailed by adm inistration of a hyperoxic breathing gas (Leuenberger et al., 
1995). Patients often suffer from  OSAS fo r years before receiving a diagnosis and 
treated so it is possible tha t the pathogenesis o f chronic sympathoexcitation is due, in 
part, to  long-term activation of the peripheral chemoreflex during nocturnal 
desaturations. Further to  this, Greenberg et al. (1999) demonstrated the exaggerated 
sympathetic response to chemoreflex stimulation in a rat model. Narkiewicz et al. 
(1998) demonstrated increased MSNA in obese OSAS patients but not in obese OSAS- 
free controls. Hypoxaemia is detected by specialised chemoreceptors in the carotid 
body, which to  a lesser extent also detect hypercapnia and acidosis. Activation o f the 
carotid chemoreceptors stimulates an increase in sympathetic outflow . This causes 
peripheral vasoconstriction and subsequent increased peripheral resistance and blood 
pressure. Experimental evidence suggests tha t the sympathetic nervous system- 
induced vasoconstriction is the most im portant contributor to  the development o f 
hypertension in OSAS.
Sympathetic nervous system activity can also be investigated experim entally by 
measuring catecholamine concentrations. Although urinary catecholamines have been 
consistently shown to be elevated in OSAS (Stenlof et al., 1996; Dimsdale et al., 1995) 
there is mixed evidence fo r plasma catecholamines (Carlson et al., 1993; Hedner et al., 
1995; Dimsdale et al., 1995). Sustained elevated sympathetic drive is thought to  be
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hypoxia-driven, and not mediated by hypercapnic stimuli. Although there is an acute 
sympathetic response to  the apnoea-induced hypoxaemia, evidence suggests that 
chronic activation of this pathway can lead to  a state of daytime sympathoexcitation 
(Somers et al., 1995; Carlson et al., 1993). Hypoxaemia and increased sympathetic 
nerve activity can cause oxidative stress and endothelial dysfunction, which in turn 
promote the development of cardiovascular disease (Kuniyoshi et al., 2010; Ip et al.,
2004). Some studies have reported reductions in MSNA after treatm ent, however 
evidence suggests short-term  therapy is insufficient to  reverse the sympathetic 
hyperactivity (Jennum et al., 1989; Waradekar et al., 1996), although longer treatm ent 
periods have shown significant reductions (Stenlof et al., 1996; Narkiewicz et al., 
1999).
Experimental evidence has shown the acute post-apnoea systemic blood pressure 
spike to be mediated solely by activation o f the sympathetic nervous system 
(Katragadda et al., 1997; Schneider et al., 2000). This activation has been 
demonstrated (experimentally, using supplemental oxygen therapy) to  be caused by 
chemoreceptor activation and tha t the negative intrathoracic pressures are unlikely to 
be involved (Morgan et al., 1993).
2.5.3 Inflammation
There are several ways OSAS can promote a state of inflammation. Elevated 
sympathetic outflow  increases peripheral vasoconstriction which increases systemic 
vascular pressure. This increases luminal shear stress which in chronic cases can cause 
damage to  the vascular endothelium. This damage, as described in more detail later 
(section 2.5.5), triggers local endothelial cells into a pro-inflam m atory state, which 
increases cytokine and chemokine secretion. Interleukin-6 is a cytokine released in 
response to  tissue damage, which binds to  receptors in the liver and triggers synthesis 
o f C-reactive protein; CRP in turn can induce expression o f ICAMs. Serum CRP 
concentration in healthy adults is stable at <1 mg-L'1; however in pro inflam m atory 
states (such as myocardial infarction) these concentrations can increase exponentially. 
It has been shown tha t even modest increases in CRP are associated w ith increased 
risk o f atherogenesis in otherwise healthy men (Ridker et al., 1997) and women (Ridker 
et al., 2000) and hence it is considered to  be an independent risk factor fo r ischaemic
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heart disease (Ridker et al., 1997; Lind et al., 2003). Serum CRP is elevated in patients 
w ith OSAS compared to non-OSAS controls (Shamsuzzaman et al., 2002). Mills et al. 
(2009) reported a diurnal relationship between CRP and tim e of day; higher between 
10 p.m. and 6 a.m. versus 8 a.m. to  8 p.m. (P<0.001), perhaps resulting from  the 
nocturnal physiological assault caused by repeated apnoea. Koc et al. (2011) suggested 
tha t a 1% increase in delta CRP (midday CRP minus 6 a.m. CRP) reflects a 58% increase 
in risk of cardiovascular events. Elevated plasma CRP almost exclusively indicates 
inflammation; however there is no way to  ascertain the location, type or cause of 
inflammation from  its measurement. Other circulating markers o f systemic 
inflammation including plasma cytokines (Minoguchi et al., 2007), serum amyloid-A 
(Svatikova et al., 2003) and adhesion molecules (Ohga et al., 2003) are also elevated in 
OSAS.
2.5.4 Intrathoracic pressure oscillations
The presence of respiratory e ffo rt is the principal difference between OSAS and CSA. In 
OSAS, apnoeic events include repeated fu tile  contractions of respiratory muscles 
despite no airflow  through the conducting airway. This causes transient reductions in 
intrathoracic pressure, leading to reductions in left ventricular stroke volume, cardiac 
output and systolic blood pressure (caused by less blood entering the circuit). Once 
ventilation is restored, stroke volume and cardiac output return to  normal, ejecting 
high pressure blood into a systemic circulation w ith increased resistance caused by 
sympathetic vasoconstriction. This causes a tem porary elevation o f systolic blood 
pressure tha t quickly subsides.
It has been reported tha t moderate to  severe OSAS is associated w ith abnormal 
ventricular filling and impaired diastolic function (Otto et al., 2007), ventricular 
dysfunction (Romero-Corral et al., 2007) and le ft ventricular afterload (Arias et al.,
2005). This causes decreases in intrathoracic pressure, which increases transmural 
pressure gradients on the chambers o f the heart and thoracic conduit vessels (Buda et 
al., 1979) leading to  myocardial remodelling (Chan et al., 2009) and haemodynamic 
instability (Somers et al., 1993).
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2.5.5 Endothelial dysfunction
The vascular endothelium is the single-cell layer o f the luminal surface of blood 
vessels, which until the early 1980s was thought to do little  more than act as a barrier 
to  separate circulating blood and tissue. Since then, a m ultitude of vital roles have 
been identified, which include the control o f coagulation and vascular tone. Indeed, it 
could be considered to  be the largest paracrine and endocrine structure in the human 
body (Anggard et al., 1990). The healthy endothelium secretes substances tha t create 
an anti- or pro-throm botic environment as required (Wu et al., 1996). These include 
heparin sulphate and prostacyclin (PGI2) tha t impair clot form ation, and von 
W illebrand's factor and factor V which promote clot form ation. Endothelial 
dysfunction disrupts normal coagulative processes, which may cause hypercoagulation 
under normal circumstances and hypocoagulation in response to  haemorrhagic injury 
-  increasing the possibility o f infarction and uncontrolled blood loss, respectively.
The ability o f blood vessels to  self-regulate the ir tone is critical in the management of 
blood pressure (e.g. during critical blood loss) and controlling the d istribution o f blood 
flow  (e.g. during exercise). The endothelium secretes vasodilators such as n itric oxide 
(NO), PGI2 and endothelium-derived hyperpolarising factor (EDHF) tha t induce 
relaxation of vascular smooth muscle cells (VSMCs) in the adventitial layer o f blood 
vessels. This relaxation increases luminal diameter, which reduces intravascular 
pressure and increases blood flow  (as a fluid in a high pressure circuit w ill always 
favour the path of least resistance). Conversely, secreted vasoconstrictors such as 
endothelin and angiotensin-converting enzyme (ACE) stimulate contraction o f VSMCs 
and reduce luminal diameter, increasing vascular pressure and reducing blood flow. 
Dysregulation of vasomotor tone caused by endothelial dysfunction impairs the ability 
to  alter local blood flow  in response to  a local stimulus. For example, a sudden increase 
in arterial blood flow  tha t increases blood pressure and shear stress on the 
endothelium would not be addressed by sufficient vasodilation. This can have fu rthe r 
adverse effects on the endothelium, and contribute to  fu rthe r dysfunction as 
described later, a physiological response measurable in the flow-m ediated dilatation 
test.
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The endothelium is semi-permeable to  a plethora of substances tha t can enter or exit 
the blood stream using diffusion or active transport through membrane channels, 
pumps and gap junctions. Ineffective transendothelial solute transport between 
circulating blood and respiring tissues will impede effective clearance of cellular and 
metabolic waste products (e.g. carbon dioxide and potassium) and delivery o f oxygen 
and nutrients. Dysfunction of these mechanisms is thought to  be a precursor fo r 
atherogenesis (Libby, 2006).
Endothelial function can be assessed in vivo using non-invasive techniques such as 
arterial Doppler ultrasonography, laser-Doppler flow m etry (LDF) and strain-gauge 
venous plethysmography, often coupled w ith a provocation stimulus to  test vascular 
reactivity. Invasive alternatives do exist, such as endothelial cell harvesting, which 
involves catheterisation of a vein and collecting endothelial cells directly using a guide- 
wire. Assessment o f endothelial function is particularly relevant to  obstructive sleep 
apnoea patients because endothelial dysfunction in the peripheral vasculature is a key 
early event tha t precedes or accelerates the development o f atherosclerosis (Ross, 
1999). Furthermore, it is thought that early identification of endothelial dysfunction 
could predict fu ture cardiovascular events (Anderson et al., 1995; Perticone et al., 
2001) and provide opportun ity fo r pre-emptive action.
NO is an im portant vascular cell signalling molecule and its bioavailability d irectly 
correlates w ith endothelial function. NO is a heterodiatom ic product o f the conversion 
of L-arginine to  L-citruline in the presence of endothelial nitric oxide synthase (eNOS). 
Therefore, the lim iting factors in NO production are the bioavailability o f the enzyme 
(eNOS) and the substrate (L-arginine). L-arginine can be biosynthesised, or absorbed in 
the diet from  common food groups such as dairy and meat. Expression o f eNOS has 
been measured in OSAS studies before; Jelic et al. (2008) proposed tha t the long term  
oxidative stress in untreated OSAS reduces eNOS enzymatic activity by suppressing 
eNOS phosphorylation (Tanaka et al., 2005). Jelic et al. (2008) provided evidence fo r 
vascular inflammation in OSAS, w ith an upregulation of the endothelial expression of 
cyclo-oxygenase-2 (COX-2) in harvested venous endothelial cells. This research group 
went on to  identify significantly lower concentrations o f eNOS and phosphorylated- 
eNOS (P-eNOS) in normal weight and obese OSAS patients versus BMI-matched OSAS- 
free control groups (screened fo r undiagnosed OSAS) (Jelic et al., 2010).
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Endothelial function has been assessed in OSAS patients before (Ip et al., 2004; 
Trzepizur et al., 2009; Yim-Yeh et al., 2010). B-mode Doppler ultrasonography can be 
used to measure flow-m ediated dilatation (FMD) in conduit arteries after a distal 
arterial occlusion (Celermajer et al., 1992). This technique assesses endothelial 
function in the macrovasculature by measuring the change in brachial artery diameter 
after a period of forearm ischaemia. Conversely, LDF can be used to assess 
microvascular function by measuring changes in skin blood flow  follow ing provocation 
(Turner et al., 2008); which can include a proximal cuff occlusion (that induces a post­
occlusion reactive hyperaemia; PORH), local heating (that induces local therm al 
hyperaemia; LTH) or adm inistration of vasoactive compounds (such as acetylcholine 
(ACh)) which can be delivered intra-venously, intra-arterially (Kato et al., 2000), 
subcutaneously or iontophoretically. FMD, although requiring substantially more 
training, is currently the preferred index of vascular endothelial function because o f its 
specificity, standardised protocol, reproducibility and non-invasive nature. A meta­
analysis (Inaba et al., 2010) estimated tha t fo r every 1% increase in FMD there is a 
concordant 13 [9,17]%  reduction in future risk of cardiovascular events.
PORH index is a sensitive indicator of CVD in high-risk populations (Yamamoto- 
Suganuma & Aso, 2009) and is considered a generalised test o f microvascular function 
as there is conflicting evidence in the literature as to  the role o f NO in the prolonged 
hyperaemic response. Some studies have identified the response as being partially NO- 
mediated (Tagawa et al., 1994), whereas some have noted there is no contribution 
from  NO (Wong et al., 2003), consequently, prudence should be exercised when 
interpreting PORH results. The LTH response has tw o phases: an initial peak, prim arily 
mediated by a local sensory nerve axon reflex (Minson et al., 2001); and, a secondary 
rise and plateau which is primarily NO-mediated (Kellogg et al., 1999; Minson et al., 
2001). Dhindsa et al. (2008) identified a modest-at-best relationship between PORH 
and FMD in measuring vascular reactivity suggesting they involve d ifferent 
mechanisms. Further work should assess the clinical relevance of provocation 
techniques such as PORH and LTH compared to  the validated measurement o f FMD. 
Nieto et al. (2004) suggested tha t vascular endothelial dysfunction could represent a 
premature aging o f the vascular network. Obesity is independently associated w ith 
endothelial dysfunction and can be normalised w ith weight loss (Williams et al., 2005),
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although Hashimoto et al. (1998) proposed OSAS has a stronger association with 
visceral rather than subcutaneous adiposity.
Endothelial-dependent FMD has been shown to  be impaired in OSAS, although some 
researchers have reported no impaired FMD response in large- (Chami et al., 2009) 
and small-scale (Kato et al., 2000) studies. Dysfunction can be reversed w ith successful 
CPAP treatm ent (Ip et al., 2004; Jelic et al., 2008), although nightly therapy is 
im portant because improvements in endothelial function w ith CPAP are reversed after 
w ithdraw ing treatm ent fo r one week (Ip et al., 2004).
Obesity is thought to contribute to  endothelial dysfunction, but some studies have 
identified reduced FMD responses tha t are independent of obesity (Namtvedt et al., 
2013; Jelic et al., 2010) or EDS (Kohler et al., 2008). Resting brachial artery diameter 
has been shown to  be larger than OSA-free controls (Chami et al., 2009; Yim-Yeh et al., 
2010) although others have not (Kato et al., 2000; Oflaz et al., 2006). Larger baseline 
diameter in OSAS could be attributable to Glagov's phenomenon; during the 
development o f atherosclerotic plaque in the arterial wall there is a local 
compensatory dilatation o f the vessel in an a ttem pt to  maintain adequate downstream 
perfusion. Higher baseline diameters in OSAS groups could represent more advanced 
atherosclerotic state.
The extent of the endothelial dysfunction has been shown to be associated w ith  age 
(Yim-Yeh et al., 2010) and OSAS severity (Chung et al., 2008; Jelic et al., 2008); and ODI 
rather than AHI seems to  have a greater association w ith FMD (Chung et al., 2008). 
Oflaz et al. (2006) demonstrated FMD to  be lower in the morning than the evening in 
overweight normotensive adults and overweight OSAS patients alike, suggesting the 
presence of OSAS affects only the absolute values, and not the diurnal variation. This is 
unlikely to  impact practice as the m ajority o f FMD assessments occur in the morning 
after an overnight fast.
2.6 Consequences of obstructive sleep apnoea syndrome
There are several consequences of OSAS tha t m erit discussion. These include 
physiological consequences of repeated nocturnal apnoea, the psychological effects of
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fragmented sleep and the economic impact of OSAS including its direct and indirect 
costs.
2.6.1 Cardiovascular morbidity and mortality
The structure and function of the cardiovascular system is affected by several aspects 
of the repeated obstructive events associated w ith OSAS. OSAS has been linked to a 
variety of cardiovascular complications including hypertension, myocardial infarction 
and stroke and is considered to  be an independent cardiovascular risk factor (Doherty 
et al., 2005; McNicholas et al., 2007). It is d ifficu lt to  independently dissociate the 
contribution o f OSAS to  its associated morbidities from  other (often present) risk 
factors such as obesity, dyslipidaemia, hypertension and physical inactivity. 
Considering the numerous cardiovascular risk factors present in the typical OSAS 
patient, it is perhaps unsurprising tha t certain pathologies are common. Overall, 
untreated OSAS is independently associated w ith cardiovascular m ortality, which can 
be reversed w ith CPAP (Marin et al., 2005). For healthy adults, the risk o f sudden 
cardiovascular events is highest in the late morning, between 6 a.m. and midday 
(Atkinson et al., 2010); in untreated OSAS the period o f highest cardiovascular risk is 
overnight during sleep (Wilcox et al., 1998)
2.6.1.1 Hypertension
Pressure w ith in the circulatory system is dynamic and changes in response to  posture, 
exercise and medication. The normal range fo r systolic blood pressure (SBP; i.e. 
pressure in the arterial tree at the end of the systole phase of the cardiac cycle) is 100 
to  140 mmHg. If resting SBP persistently exceeds 140 mmHg, then blood pressure is 
considered to  be high, and a diagnosis o f hypertension can be made. Hypertension 
increases the risk o f blood vessel rupture, which if it were to  occur in the coronary 
(cardiac tamponade) or cerebral (haemorrhagic stroke) circulations it could have fatal 
consequences.
The association between hypertension and OSAS was firs t introduced by small-scale 
(Fletcher et al., 1985; Nieto et al., 2004) and medium-to-large scale (Bixler et al., 2000) 
cross-sectional studies and ratified in the Wisconsin Sleep Cohort (Peppard et al., 
2000b). Peppard et al. reported a proportional relationship between the severity of
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OSAS and the incidence of hypertension, which was not supported by evidence from 
another prospective cohort study (O'Connor et al., 2009). Peppard et al. (2000b) 
reported tha t moderate-to-severe OSAS is independently associated w ith a 3-fold 
increased risk of developing systemic hypertension. The Sleep Heart Health Study 
assessed the five-year risk of developing hypertension in 2470 normotensive m iddle- 
aged and older adults w ith sleep apnoea at baseline and reported tha t after controlling 
fo r baseline BMI, no significant relationship was found. The causal relationship 
between OSAS and hypertension is fu rther supported by numerous trials reporting 
attenuated blood pressure after treatm ent (Fletcher et al., 1985). Some authors 
hypothesise tha t OSAS could contribute to  the development of drug-resistant 
hypertension (Logan et al., 2001). Purported mechanisms fo r the development of 
hypertension in OSAS include hyperactivity of the sympathetic nervous system 
secondary to  apnoea-induced hypoxaemia, which increases catecholamine secretion 
from  the adrenal glands (Hedner et al., 1995) and vascular smooth muscle tone.
2.6.1.2 Coronary artery disease and stroke
In the developed world, coronary artery disease (CAD) is the leading cause of m orta lity 
and is defined as the presence of atherosclerosis in the coronary arteries tha t can lead 
to  infarction of the myocardium (Bogaert et al., 2005). Atherosclerosis is a chronic 
build-up of fa tty  substances, foam cells and macrophages between the tunica intima 
and tunica media, which steadily increase resulting from  localised endothelial 
dysfunction and mild inflammation (Hansson et al., 2005). The impact o f atheroma 
depends on its size and location as it can cause physiological insult in several ways. The 
presence of atheroma increases turbu lent blood flow  in the artery and coupled w ith 
endothelial dysfunction can increase the risk o f thrombosis. Atheroma increase in size 
steadily and subsequent stenosis can eventually reduce blood flow  enough to  cause 
downstream ischaemia or completely occlude blood flow  causing infarction and acute 
(heart attack) or chronic (angina pectoris) chest pain symptoms. Thrombosis can also 
impede organ perfusion in a similar way. If these events occur in the coronary or 
cerebral circulation they can cause irreparable damage to vital cardiac or neural tissue, 
which can cause debilitating long-term complications or death.
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Observational studies have shown a high proportion of male (Mooe et al., 1996a) and 
female (Mooe et al., 1996b) patients w ith CAD to  have comorbid OSAS. The odds ratio 
was 4.1 [1.7, 9.7] (P<0.01) fo r females, which was higher than fo r hypertension and 
smoking. Chronic in term itten t hypoxia (CIH) has been shown to  induce atherosclerotic 
plaque form ation in the presence of a high cholesterol diet in a murine model 
(Savransky et al., 2007) highlighting the increased risk o f coronary artery disease in 
OSAS and the importance of regulating dietary lipid intake. This paper also identified 
elevated lipid peroxidation markers suggesting additional CIH-induced cellular damage.
2.6.1.3 Other cardiovascular sequelae
Intrathoracic pressure changes can impact on the structure and function o f both 
cardiac ventricles. Stroke volume is transiently impeded during apnoea (Tolle et al., 
1983) and longte rm  hyperactivity o f the sympathetic nervous system could induce left 
ventricular hypertrophy and/or dysfunction (Corea et al., 1983; Alchanatis et al., 2002), 
which can be reversed w ith CPAP (Alchanatis et al., 2002). The incumbent increased 
resistance in the pulmonary circuit (caused by a combination o f sympathetic nervous 
system-induced vasoconstriction and local vasoconstrictor response to  hypoxaemia) 
can result in pulmonary hypertension, or cor pulmonale (Chaouat et al., 1996). Over 
tim e this condition causes right ventricular hypertrophy because the right heart must 
work harder to  pump blood into the hypertensive pulmonary circuit. The hypoxaemic 
episodes in OSAS have been shown to  induce myocardial ischaemia (identified using 
electrocardiography) in patients w ith ischaemic heart disease (Franklin et al., 1995). 
The acute effects o f apnoeic events (especially when in high frequency) can contribute 
to  interruptions of the cardiac rhythm, termed arrhythmia. Intrathoracic pressure 
oscillations can distort the shape of the gross structures o f the heart (Condos Jr et al., 
1987), reduce oxygen supply to  the myocardium (Schafer et al., 1997) and cause 
irregular autonomic nervous system activity. The most common nocturnal arrhythm ia 
observed in OSAS is characterised by bradycardia during apnoea followed abruptly by a 
brie f period of tachycardia, it is termed cyclic variation in heart rate. This arrhythm ia is 
not observed in patients w ith tracheostomy (whom would not experience obstructive 
apnoea; Guilleminault et al., 1983), in patients treated w ith atropine or in patients 
w ith autonomic dysfunction (Guilleminault et al., 1983). A tropine is a
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parasympatholytic which reduces the action o f the parasympathetic nervous system, 
which is upregulated during periods o f rest and lowers heart rate and blood pressure 
(removal o f this parasympathetic "brake" would increase the frequency of sinoatrial 
depolarisations towards the intrinsic rate (approximately 100 times per min). Common 
arrhythmias such as atrial fib rilla tion (AF) are also prevalent in OSAS -  Garni et al. 
(2004) reported a higher incidence of OSAS in AF patients than non-AF patients 
referred to  a cardiology (49% [41, 57]% vs. 32% [27, 37]%; P<0.001). This study used 
the Berlin questionnaire to  identify OSAS instead of objective physiological measures - 
to  address this they subtracted the false positive rate (measured internally using PSG 
in 44 cases) from the OSAS count.
2.6.2 Daytime somnolence
Daytime somnolence is often the presenting intrinsic symptom fo r most patients being 
referred to  sleep clinics. Frequent nocturnal arousals fragm ent sleep and prevent OSAS 
sufferers from  reaching the rapid-eye movement (REM) phase of sleep. Although the 
purpose of REM sleep is not well understood (roles in learning and memory 
consolidation have been proposed), some implications of preventing it have been 
reported (Sutton et al., 2001). The most severe OSAS is associated w ith over a hundred 
microarousals per hour - more than one every m inute on average. This can leave 
patients w ith EDS - the most common symptom o f OSAS. This can cause untreated 
OSAS sufferers to  fall asleep fo r very short periods of tim e (micro-sleeps) during the 
day giving rise to  potentially dangerous consequences, most notably by falling asleep 
while driving (Barbe et al., 1998). In the UK, it is the responsibility o f the driver to  
ensure they drive in accordance w ith the Road Traffic Act (1988) by inform ing the 
Driver Vehicle Licensing Association and the ir respective m otor insurance provider 
about the ir diagnosis and to  remain compliant w ith treatm ent to  prevent daytime 
sleepiness.
Aguillard et al. (1998) suggested tha t the EDS experienced in OSAS could reduce 
inclination fo r patients to start or continue exercise regimens due to  excessive fatigue 
in the ir leisure tim e, and suggested tha t after treatm ent activity levels may increase -  
which could lead to  weight loss and improvement o f OSAS. This has since been refuted 
by West et al. (2009) who reported tha t successful CPAP therapy and alleviation o f
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daytime somnolence does not improve daily activity levels in OSAS. Many obese OSAS 
patients probably have negative attitudes towards physical activity, hence the 
presence of obesity in the first place. Therefore there are underlying psychological 
factors and barriers tha t should be addressed in this population.
2.6.3 Exercise capacity
Exercise capacity can be broadly defined in tw o  ways: the ability to  increase 
cardiopulmonary e ffo rt in response to  incremental exercise; and, the ability to  
maintain a given exercise intensity fo r an extended duration. There is dispute 
concerning the impact o f OSAS on exercise capacity. Some studies have reported 
impaired exercise capacity in OSAS (Lin et al., 2006; Aguillard et al., 1998) and others 
have reported no decrement (Alameri et al., 2010) compared w ith age- and BMI- 
matched control groups. Rizzi et al. (2010) showed no deficit in exercise capacity in 
lean OSAS patients. Because of these uncertainties, the effect o f CPAP (discussed 
fu rthe r in section 2.8.1) on exercise is this population is also unclear (as there may not 
be an exercise capacity deficit to  reverse). As presiding symptoms fo r OSAS include EDS 
and fatigue, Hong and Dimsdale (2003) proposed these as lim iting factors fo r regular 
physical activity levels in this population, and hence to  the detrim ent in exercise 
capacity. It is often suggested tha t if CPAP can reverse the daytime fatigue experienced 
in OSAS tha t patients could find it easier to  introduce lifestyle changes (such as 
improving diet and physical activity levels) tha t could address underpinning causes 
such as obesity. Billings et al. (2013) reported no significant differences in physical 
activity levels between patients w ith high CPAP compliance, low CPAP compliance and 
CPAP intolerant patients.
Alameri et al. (2010) assessed exercise capacity in 55 OSAS patients using the 6-m inute 
walk test and detected no difference in capacity compared to  32 obese controls and 30 
lean controls. Despite no difference in distance walked, there was increased perceived 
dyspnoea in the OSAS group compared to  both control groups, suggesting OSAS is 
associated w ith increased breathlessness. This may have been caused by the narrower- 
than-normal airway often observed in OSAS (Schwab et al., 2003). Alonso-Fernandez et 
al. (2006) published a randomised controlled cross-over tria l tha t identified
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impairments in cardiac output and stroke volume responses to  exercise in untreated 
OSAS were reversed after 3 months of CPAP therapy.
2.6.4 Economic impact
Several studies have tried to  estimate the financial cost o f sleep disorders, not only in 
terms of diagnosis and management, but also in terms of lost working hours and 
tiredness-related accidents. Hillman et al. (2006) estimated tha t undiagnosed sleep 
disorders cost the Australian economy almost $2 billion United States Dollars (USD) 
(~£1.3 billion) in work-related injuries, $800 million USD (~£498 m illion) in private 
m otor vehicle accidents and $1.2 billion USD (~£747 million) in productivity losses. 
Total financial cost was estimated to  be $7.5 billion USD (~£4.8 billion).
Using this estimate from  2004, AIGhanim et al. (2008) extrapolated this figure (based 
on a population of approximately 20 m illion) to  the United States o f America, which 
has an approximate population of 300 m illion. This prediction is approximately $103 
billion USD. AIGhanim and colleagues (2008) also reported the estimated 2002 
economic cost o f chronic obstructive pulmonary disease (COPD) and diabetes as $32 
billion USD (Mannino et al., 2007) and $132 billion USD (American Diabetes 
Association, 2002), respectively. Although AIGhanim et al. (2008) suggested the tota l 
financial burden of OSAS to  be of a similar impact to  diabetes; the reported figures 
would suggest the proportion is approximately 75-80%. Applying this percentage to 
the UK healthcare setting, Hex et al. (2012) reported the tota l economic burden of 
diabetes to be £24 billion in 2010/11, which would put the estimate o f the total 
economic burden of OSAS to  be approximately £20 billion. Further costing studies have 
placed the financial cost o f OSAS-related m otor vehicle accidents at almost $16 billion 
USD (~£10 billion) in the year 2000 (Sassani et al., 2004). The authors also forecast tha t 
treatm ent fo r those involved would cost $3.2 billion USD (~£2 billion) and potentia lly 
save more than $11 billion USD (~£7 billion), and reduce OSAS-related vehicle deaths 
by about 70%.
Although these methods involve a lot o f conjecture and little  certainty can be placed in 
the estimates, what can be ascertained is tha t OSAS is associated w ith enormous direct 
and indirect costs, and considering the steady increase in incidence, these costs are 
only likely to  increase further. These financial implications support the need to
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increase OSAS awareness and investigate alternative treatm ent strategies tha t address 
the underlying causes of OSAS as opposed to  long-term management. The la tter is 
particularly im portant in recognition of the large number o f CPAP-resistant patients.
2.7 Obesity, metabolic syndrome and obstructive sleep apnoea 
syndrome
There is an established and undisputed relationship between the presence of obesity 
and OSAS, however more recently a causative link between OSAS and obesity has been 
proposed. This suggests the relationship between OSAS and obesity is bidirectional and 
more complicated than it firs t appears. Obesity is fundam entally the effect of 
sustained positive energy balance arising from an augmented energy intake, 
diminished energy expenditure, or a combination o f both; however the causes o f this 
energy imbalance are unclear. This promotes energy storage, usually in the form  of 
adipose tissue. Fat distributions differ between sexes which could explain the 
differences in prevalence.
Obesity is associated w ith increased collapsibility o f the airway. Magnetic resonance 
imaging (MRI) studies and computer tom ography have shown decreased intralum inal 
calibre in obese OSAS patients. Excess cervical adiposity increases the structural load 
on the airway and increased peri- and parapharyngeal fa t deposition reduce the 
concentration of structural smooth muscle and overall luminal size (Li et al., 2012). 
These factors, coupled w ith natural nocturnal reduction in airway muscle tone increase 
the collapsibility o f the upper airway during sleep. Additionally, excessive thoracic fa t 
and abdominal fa t are implicated in the pathogenesis o f SDB by impeding respiratory 
dynamics. When supine, surplus weight on the thorax increases the work done by 
inspiratory muscles (principally the diaphragm) to  create the negative intra-thoracic 
pressure required to draw air in. When the diaphragm contracts it moves tow ard the 
abdomen, increasing intra-abdominal pressure. W ith increasing abdominal obesity, 
there is a proportional increase in abdominal resistance and a decrease in lung 
compliance. These contribute to  a reduced lung volume and a tendency towards rapid 
shallow breathing similar to that in chronic restrictive pulmonary disease and obesity 
hypoventilation syndrome. Reduced lung volumes are associated w ith closure of
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smaller distal airways, which creates a ventilation perfusion mismatch (i.e. perfusing 
alveoli downstream of a small airway collapse) and widening of the alveolar-arterial 
P02 difference.
Leptin is an adipocyte-derived hormone which plays a central role in energy balance by 
regulating appetite and metabolism (Bluher & Mantzoros, 2009). Leptin binds to 
receptors in the mediobasal hypothalamus to  inhibit appetite (and in principle, food 
intake). As it is secreted from  adipose cells, circulating leptin increases proportionally 
w ith increasing obesity (Enriori et al., 2006). It has previously been suggested tha t 
sustained hyperleptinaemia could lead to  insensitivity to its effects, appetite 
dysregulation and increased energy intake. Independent of obesity, OSAS has been 
shown to  be associated w ith increased serum leptin (Philips et al., 2000) - supporting a 
contributory link between SDB and obesity. CPAP therapy can reduce serum leptin in 
OSAS patients, suggesting tha t its production is stimulated by the physiological 
consequences of apnoea (Saarelainen et al., 1997; Harsch et al., 2003). 
Hyperleptinaemia and leptin resistance have been implicated in the development of 
CVD (Wallace et al., 2001).
Ghrelin is a hormone tha t works antagonistically to leptin - higher concentrations 
stimulate appetite (Arvat et al., 2001). It is secreted from  the P /D l cells o f the stomach 
fundus and from  epsilon cells in the pancreas. Acylated ghrelin binds centrally to 
receptors in hypothalamus (Bagnasco et al., 2003) and stimulates hunger (usually 
resulting in behaviours tha t increase energy intake). Indeed, circulating ghrelin has 
been shown to  be highest immediately prior to  mealtimes (Pinkey & Williams, 2002). 
The relationship between OSAS and ghrelin is unclear; some have shown it to  be 
increased (Ursavas et al., 2010) and reduced w ith CPAP (Takahashi et al., 2008), while 
others have shown no difference (Ciftci et al., 2004). It is possible tha t changes in the 
production of, or physiological response to, leptin and ghrelin could o ffe r novel 
therapeutic targets fo r obesity and, by association, OSAS.
Insulin is a pancreatic hormone responsible fo r the conversion o f glucose to  glycogen 
(a more efficient storage molecule). It also reduces lipolysis o f adipocytes into serum 
fa tty  acids. It is an essential hormone in the maintenance o f glucose homeostasis. 
Insulin resistance is one aspect of the metabolic syndrome. The association between
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insulin resistance and OSAS is currently unclear (Peled et al., 2007; Ip et al., 2002; 
Young et al., 1993; Gruber et al., 2006) and requires further investigation.
2.8 Treatment paradigms
2.8.1 Continuous positive airway pressure
Continuous positive airway pressure is the standard treatm ent fo r patients w ith 
moderate or worse OSAS (Sullivan et al., 1981). It provides a steady stream of 
pressurised air into the airway via a nasal or facial mask, which increases the 
intrapharyngeal pressure and prevents airway collapse and the ensuing sequelae 
(episodes of hypoxaemia and intrathoracic pressure swings). The air pressure o f the 
CPAP device is determined by titra ting  pressures overnight during simultaneous 
polysomnogram or oximetry. The pressure is usually fractionally higher than the 
pressure required to  prevent an apnoea. A m inority of patients experience residual 
EDS despite adequate CPAP treatm ent, although this is not thought to  be associated 
w ith the increased cardiovascular risk seen in untreated OSAS patients (El-Solh et al., 
2010). Patients are prescribed CPAP therapy to be used at all times during sleep; 
however, patients are variably compliant w ith its use fo r a variety o f physical and social 
reasons (Basner, 2007; Kribbs et al., 1993). Several studies have assessed the 
contributory factors to successful adherence to  CPAP and there is evidence to  suggest 
the main physiological indicator fo r long-term CPAP compliance is the oxygen 
desaturation index (ODI) and not symptoms of EDS (Krieger et al., 1996; Kohler et al., 
2008).
The effectiveness of CPAP therapy in normalising the apnoea frequency during sleep 
has been demonstrated in studies tha t report reduced daytime hypersomnolence after 
a short period o f therapy (Robinson et al., 2006; Jenkinson et al., 1999; Engleman et 
al., 1998). Furthermore, there is strong evidence to  suggest overnight CPAP therapy 
significantly reduces mean nocturnal blood pressure, perhaps unsurprisingly as the 
apnoea it prevents are the primary causes of high blood pressure secondary to  OSAS. 
Robinson et al. (2006) conducted a randomised controlled crossover tria l comparing 
therapeutic CPAP to  sham CPAP. The authors did not identify any significant reductions 
in 24-hour ambulatory blood pressure during sleep or wakefulness in a group o f obese
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non-sleepy patients. The impact o f CPAP on blood pressure in hypertensive patients 
w ith OSAS seems clearer (Becker et al., 2003). Many studies are unclear when 
describing the status o f participants' antihypertensive therapy (whether continued or 
discontinued before and during the tria l, and if discontinued, how long for?) and some 
have used prescription o f antihypertensive medication alone as evidence of 
hypertension. This is perhaps hasty as some General Practitioners may adopt a pre­
emptive approach to  the treatm ent o f ailments more common w ith progressing age 
(e.g. hypercholesterolaemia and hypertension) and may prescribe medication as a 
preventative measure based on borderline clinical measures. Moreover, it is possible 
tha t previous hypertension had since subsided as a result of improved modifiable risk 
factors, such as obesity, and tha t patients were unnecessarily undergoing 
antihypertensive therapy. Thus, the use o f an existing prescription fo r 
antihypertensives as inclusion criteria seems weak. The possible dose-response 
relationship between OSAS severity and incident hypertension is unclear, and 
Dempsey et al. (2010) suggest this may be due to  the use of AHI as the metric o f choice 
fo r disease severity. Indeed, the apnoea frequency does not necessarily represent the 
intensity, duration or frequency of hypoxaemic episodes.
Despite several short-, medium- and long-term studies assessing endothelial 
dysfunction in OSAS patients receiving CPAP versus no treatm ent (Imadojemu et al., 
2002; Lattimore et al., 2006; Bayram et al., 2009; Nguyen et al., 2010), there is lim ited 
evidence tha t quantifies the extent to  which low compliance (i.e. undertaking 
occasional CPAP therapy) attenuates the increased endothelial dysfunction caused by 
the OSAS, compared to  persons tha t are highly compliant (> 80% nightly use, 4 h per 
night). A study by Jelic et al. (2008) showed tha t vascular endothelial dysfunction can 
be significantly reversed w ith four weeks o f effective CPAP treatm ent and tha t 
ineffective treatm ent elicits no marked reversal. These results are ambiguous as the 
researchers grouped persons who refused treatm ent and had low compliance 
together, lim iting interpretation o f the effect o f low compliance on FMD.
Other factors tha t can influence the effect o f CPAP on reversing the negative effects o f 
OSAS include treatm ent compliance, which is not always reported. However, when 
compliance data are presented, they are commonly presented as hours per night or 
percentage of nights > 4 h. This is perhaps inadequate as a patient could be excluded
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fo r using CPAP for 3 Zi hours every night when they only sleep 4 hours per night, and 
another could be included fo r using the ir CPAP for 4 34 hours per night when they sleep 
fo r 9 hours on average (including a m id-afternoon nap w ithout CPAP). Furthermore, a 
patient who uses the ir CPAP for 9 hours on alternate days could still yield an 
"acceptable" compliance level (9 hours x 4 days = 36 hours, divided by 7 days = 5 hours 
per day = compliant?). These confounding circumstances are very d ifficu lt to 
determine, measure and control, however, the ir potential impact on published data 
should be acknowledged. Possibly a more subjective metric o f patient compliance 
could be determined by an experienced healthcare professionals who would utilise 
quantitative data from  the CPAP memory card and qualitative experiences of the 
patient would be more suitable?
2.8.2 OraI appliances
The overarching aim of oral appliance therapy is to modify the architecture o f the oral 
cavity and/or upper pharyngeal airway to  reduce the frequency and duration of 
obstructive events and the negative sequelae tha t fo llow  them. M andibular 
advancement devices (MAD) have been proposed as non-surgical alternatives to  CPAP 
therapy. A MAD sits in the mouth upon the upper and lower teeth. It pushes the 
mandible in an anterior direction which also moves forward the connected anatomy of 
the upper airway, principally the glossus. Evidence suggests tha t MADs are much more 
suited to  the treatm ent o f non-obese OSAS patients as apnoea w ith in  this group tend 
to  arise from  collapse of the anterior wall of the airway. Gotsopoulos and colleagues 
(2004) reported significant reductions in daytime diastolic blood pressure and daytime 
systolic and diastolic blood pressure, albeit modest changes at <4 mmHg.
Tongue stabilising devices (TSD) allow the position o f the tongue to  be controlled to 
reduce the likelihood of airway collapse. Deane et al. (2009) conducted a randomised 
crossover design tha t compared TSD therapy w ith MAD therapy. There was an 
overwhelm ing preference fo r MAD therapy despite both treatm ents having similar 
effects on key outcomes. Tsuiki et al. (2012) described a case study where such a 
device had successfully reduced AHI by 75% in a lean 54 year old female w ith  severe 
OSAS. Such devices are in the ir infancy and research into treatm ent effectiveness and 
cost effectiveness is needed to  assess suitability in the routine management o f OSAS.
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There is increasing demand fo r pragmatic alternatives to the efficacious yet poorly- 
tolerated CPAP machine. The advantages of CPAP include a huge array o f oral, nasal 
and full-face mask interfaces to  suit all face shapes and the reusable nature o f the 
machine and much of its tubing. Unfortunately, oral appliances are not a standard 
provision on the NHS and require self-funding. MADs in particular require moulding to  
the shape of the patient's upper and lower teeth to  ensure effectiveness. This makes 
them bespoke in nature and the assessment o f the ir effectiveness and to le rab ility  on a 
patient-to-patient basis expensive to  discern. It has been suggested tha t oral 
appliances are best suited in the treatm ent of patients who are CPAP-intolerant and 
have m ild-to-m oderate OSAS (Kushida et al., 2006).
2.8.3 Surgical intervention
In certain circumstances surgical intervention may the best treatm ent, and such 
procedures have been reported in the literature fo r as long as CPAP (Fujita et al., 
1981). Caples et al. (2010) reviewed this topic and concluded tha t a lack o f robust 
trials, especially fo r newer techniques, makes it d ifficu lt to  determ ine which patients 
would most likely benefit from  surgical intervention. There are tw o types of surgery 
tha t can be used in the treatm ent of OSAS: surgery to  alter the anatomy o f the airway 
(e.g. by excising soft tissue structures) to reduce propensity fo r obstruction and to  
reduce airway resistance (Fleisher & Krieger, 2007) and surgery to  address obesity by 
facilitating weight loss and reducing the obesity-related airway collapse (Lojander et 
al., 1998). Riley et al. (1993) assessed outcomes o f surgical intervention in OSAS. 
Procedures included uvulopalatopharyngoplasty (UPPP; fo r obstructions involving the 
soft palate) and genioglossus advancement w ith hyoid myotomy-suspension (for 
obstructions at the base of the tongue); these procedures are most often indicated in 
patients w ith especially narrow airways. The overall success rate was determ ined to  be 
77% fo r phase I surgery. As obesity is a major contributory factor fo r the development 
o f OSAS, bariatric surgery can facilitate significant weight loss and the associated 
reduced pressures on the upper airway. General anaesthesia and major surgery carry 
significant peri- and post-operative risks, which need to  be considered in the overall 
clinical picture o f the patient,
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2.8.4 Supplemental oxygen and pharmacological interventions
To address the periods of nocturnal oxyhaemoglobin desaturation, some researchers 
have investigated the effects of supplemental oxygen therapy on several key 
outcomes. Norman et al. (2006) concluded tha t although supplemental oxygen 
improves mean oxyhaemoglobin concentration, it did not improve daytime or n ight­
tim e blood pressure. This finding was supported by Loredo et al. (2006) who also 
reported no improvement in daytime somnolence w ith supplemental oxygen therapy. 
An abundance of pharmacotherapies have been investigated in OSAS including 
oestrogen therapy, medroxyprogesterone acetate (MPA; a progesterone analogue) 
and tum our necrosis factor alpha (TNF-a) antagonists. To address the increased 
incidence of OSAS in post-menopausal women (as described in subsection 2.4) Manber 
et al. (2003) investigated the effects o f oestradiol plus placebo versus oestradiol plus 
progesterone in a single group placebo-controlled design. They observed 
approximately 50% improvement in AHI and non-REM AHI a fter oestradiol-only 
therapy, but not when coupled w ith progesterone. Although promising, these findings 
should be treated as prelim inary because of the small sample size and non-randomised 
design. Polo-Kantola et al. (1999) reported reduced occurrence and frequency of 
nocturnal apnoea in post-menopausal women; however this was based upon only one 
participant tha t was apnoeic at baseline. Volunteers were excluded from  participating 
in this tria l if they had any history of suspected OSAS -  on average the sample was 
overweight (27±3 and 27±5 kg-m’2). It is therefore d ifficu lt to  conclude what effect 
oestrogen therapy could have in improving OSAS. Unfortunately, no prospective study 
has reported a randomised controlled tria l of hormone replacement therapy on AHI in 
post-menopausal women w ith moderate to severe OSAS. The effects o f MPA therapy 
in OSAS are also unclear. Some studies have reported no meaningful improvements in 
OSAS (Block et al., 1981; Cook et al., 1989), however evidence suggests MPA could be 
useful fo r subpopulations such as hypercapnic (Strohl et al., 1981) or alcoholic patients 
(Collop, 1994). Etanercept (a TNF-a antagonist) improved AHI, daytime sleepiness and 
plasma IL-6 levels in a study w ith eight obese participants (Vgontzas et al., 2004). 
Although the findings are encouraging, they cannot be generalised to  the OSAS 
population because of the small sample size. Sibutramine is an oral anorexant and has
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been investigated in OSAS, however due to  potentially fatal side-effects it has since 
been w ithdrawn from  the market.
2.8.5 Other therapies
The implicated role of impaired smooth muscle tonus in the upper airway in the 
development o f OSAS has motivated researchers to  investigate the effects of 
neuromuscular stimulation o f the upper airway muscles on subjective sleepiness and 
disease severity. In 2006 a quite novel intervention was reported in the British Medical 
Journal. Puhan et al. (2006) assessed the impact o f regular didgeridoo playing on 
daytime sleepiness and OSAS severity in non-obese adults w ith moderate disease. 
Their tria l was randomised in nature and elicited significant reductions in ESS (-2.8 [- 
5.4, -0.2]; P=0.04) and AHI (-6.6 [-13.3, -0.1]; P=0.05), after adjusting fo r baseline 
disease severity and changes in body mass during the study period. These data are 
lim ited by the study design which was small scale (n=25) and involved baseline PSG 
data from  up to  a year prior to  enrolm ent. Other devices tha t manipulate the internal 
architecture of the oral cavity and oropharynx have been developed to  o ffe r viable 
alternatives to CPAP therapy and to  reduce the monopoly tha t such devices have in 
the sleep medicine market.
2.9 Adjunct therapies for obstructive sleep apnoea syndrome
Several alternative medical therapies have been proposed and explored fo r the ir 
feasibility and effectiveness at treating d ifferent severities of OSAS. These mostly 
include lifestyle intervention (e.g. modifying dietary intake and/or physical activity to 
promote weight loss) studies, and more uncommon approaches such as psychological 
interventions (e.g. behavioural therapy and hypnotherapy) and respiratory muscle 
training, which could be incorporated into lifestyle intervention or used independently. 
Motivated by the sub-optimal tolerance of CPAP and its ineffectiveness at curing OSAS, 
these studies have often investigated CPAP or non-CPAP patients, but often not both 
in a parallel design.
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2.9.1 Dietary intervention
Suratt et al. (1992) delivered a very low energy diet (VLED) in eight obese patients w ith 
severe OSAS. This study preceded the routine use of CPAP in clinical practice (data 
were collected in the early 1980s) and the intervention produced mixed results for 
weight loss and change in AHI. Patients that improved at the end of the VLED had 
regressed at 2-year follow-up. Lojander et al. (1998) evaluated the impact o f a 
hospital-based nurse-delivered dietary intervention in 24 (96% male) obese newly 
diagnosed OSAS patients. The intervention consisted of a six-week VLED and 
behavioural management (consisting o f group meetings and remote contact). The 
intervention was safe, well-to lerated and caused a 5 kg-m"2 reduction in BMI at the end 
of the VLED phase and >50% improvement in SDB indices, which were maintained at 1 
year follow-up. Furthermore, unlike most studies o f this nature, the authors reported 
the cost-effectiveness of the intervention and compared it w ith the cost of CPAP 
therapy. The cost o f delivering CPAP fo r one year was estimated at $3000 USD, which 
was almost double the cost o f delivering the one-year VLED and behavioural 
management intervention fo r the same period. Although this study was based in 
Finland, the direct costs o f both are unlikely to  d iffer greatly in o ther a ffluent 
countries.
Kajaste et al. (2004) conducted a randomised tria l tha t compared effects o f a 6-week 
VLED (500 kcal per day) followed by 24 months of cognitive-behavioural therapy (CBT) 
w ith and w ithout preceding CPAP therapy fo r six months. The CBT aspect was based on 
guidelines by Brownell (1989) and was bespoke to  each participant and included the 
provision o f counselling on a w eekly/fo rtn ightly basis, which reduced to  m onth ly a fter 
6 months and bim onthly after one year. This reduction in support is intended to  
promote participants' independence and hopefully reflects the reduced requirem ent 
o f regular support. This tapering o f contact is common in counselling-related 
interventions. This study concluded tha t there was no association between an initial 6 
months of CPAP and the uptake of a VLED intervention including CBT. Although 
significant reductions in body mass and ODI were not observed in e ither arm of the 
tria l at six months, they were once the groups were merged. This im provem ent 
steadily worsened over the follow ing 18 months but was still significantly be tte r than
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baseline. This regression is common and represents the major challenge of lifestyle 
intervention. The authors lauded two aspects of the ir intervention. Firstly, the 
individualised counselling approach they used and suggested tha t one-on-one contact 
may offer additional benefits in obese patient populations. Secondly, the flexible 
approach they took to  the tim ing of appointments, which likely improved attendance 
by working around the participants' other commitments.
Johansson et al. (2009) reported a single-centre, randomised, controlled tria l of 63 
obese men (mean BMI: 35 kg-rrf2; mean age: 49 y) w ith OSAS who had been 
undergoing CPAP therapy fo r >6 months. These men were randomised into a VLED 
intervention and a usual diet control group. The intervention consisted of a liquid VLED 
(550 kcal-day1) fo r 7 weeks, w ith gradual introduction of normal food over the 
fo llow ing 2 weeks (to 1500 kcal-day"1). To support the changes in diet fo rtn igh tly  group 
meetings were arranged w ith a research nurse and tw o dieticians. Compared w ith the 
control group, the intervention group improved body mass by 20 kg (-18%) and AHI by 
23 events-h 1. There was a modest relationship between the amount o f weight lost and 
the improvement in AHI, suggesting other mechanisms besides weight loss are 
implicated. 87% o f patients on the intervention improved the ir OSAS severity stratus, 
w ith 46% improving by tw o strata (i.e. severe to  mild or moderate to  OSAS-free). 
Overall, 17% were in complete remission o f OSAS. Improvement in OSAS was 
proportional to  baseline AHI.
The longer term  effects o f this study were reported in a prospective observational 
follow-up study in 2011 (Johansson et al., 2011). The 31 control participants from  the 
previous study were invited to  start the 9-week dietary in tervention. They also 
completed end-point assessment and both groups underwent 4-weekly assessments 
fo r a fu rther 43 weeks. Firstly, the second cohort underwent sim ilar improvements in 
body mass and AHI to the firs t cohort (-20 kg vs. -19 kg; - 21 vs. -25 AHI) and a similar 
relationship in improvement in tha t the largest improvers lost the greater amount o f 
weight, and had the higher AHI at baseline. U ltimately, the improvements in AHI from 
a 9-week VLED were largely maintained after one year (-58% vs. -47%); 48% no longer 
needed CPAP therapy and 10% were in complete remission.
Typically fixed-term  hypoenergetic diets tha t induce an initial rapid weight-loss phase 
and support this w ith education, counselling and recommendations o f how to  maintain
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the weight-loss long term . These hypoenergetic diets are typically between tw o and 
eight weeks in duration and have a prescribed daily energy intake of approximately 
400-800 kcal (VLED) or 800-1200 kcal (LED). In obese individuals, this can induce a daily 
energy deficit of more than 2000 kcal, which can easily induce weight loss in excess of 
15 kg, but unfortunately no high-efficacy strategy currently exists to  avoid weight 
regain in the medium to  long-term (6 months to  5 years post intervention).
2.9.2 Exercise intervention
Exercise has been proposed as both a supplementary therapy and an alternative 
treatm ent modality fo r OSAS. The justification fo r exercise therapy is m ultifactoria l and 
includes improving the impaired exercise capacity reported by some groups (section 
2.6.3), reducing the inherent health risk caused by a sedentary lifestyle and prom oting 
negative energy balance to  facilitate weight loss and perhaps reduce the obesity- 
related collapse of the airway.
Netzer et al. (1997) were the firs t to  report a study investigating the effect o f exercise 
in the management o f OSAS. Their open tria l recruited 11 patients (91% male) w ith 
mild-to-severe disease onto a six-month exercise program involving tw ice-weekly tw o- 
hour sessions delivered by physical therapists. The intervention lasted 6 months w ith 
tw o 2-hour exercise sessions a week, the firs t o f which was sports-based (i.e. jogging, 
games and gymnastics) and the second weights-based (repetitive light weight-lifting). 
This study showed no changes in body mass and significant reductions in RDI, although 
the absolute improvement was minimal and unlikely to  be of clinical benefit. Extended 
results from  the same tria l were reported in Giebelhaus et al. (2000). Participants' BMI 
ranged from  23.6 to  32.8 kg-m'2 including normal-weight, overweight and class I obese 
participants. This was a German community-based study and the main findings were 
tha t this type of intervention was safe, feasible and able to  reduce mean RDI by 28% 
(32.8 to  23.6 events-h'1) w ithout marked changes in body mass or physical fitness. 
These data suggest that exercise could beneficially impact on SDB via alternative 
mechanisms to  weight loss. These findings must certainly be interpreted w ith  caution 
as the low-powered, non-randomised, uncontrolled design was not especially robust. 
The authors reported that funding fo r the six-month intervention came from  public
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health insurance d ifferent to  the NHS currently in place in the UK, so alternative 
funding routes also need to  be explored.
Ueno et al. (2009) conducted a four-arm  prospective exercise intervention study in 
heart failure patients w ith OSAS, CSA and no sleep apnoea, and a group of healthy age- 
matched controls. A fter baseline assessment the heart failure patients underwent four 
months of no exercise, were reassessed, and then four months of exercise training, 
followed by a final reassessment. The exercise intervention involved three 1-hour 
training sessions, including approximately 25-40 min of cycle ergom etry and 10 min of 
strengthening exercises. The main findings o f this study were tha t exercise significantly 
improved MSNA in OSAS (66 to  31 bursts-m in'1; P<0.01) and CSA (62 to  32 bursts-m in'1; 
P<0.01) but not in OSAS-free controls (20 to  20 bursts-min'1; P<0.01) and improved AHI 
by 36% in OSAS (P<0.01) w ith no improvement in the CSA group. As in the Giebelhaus 
et al. (2000) study, the improvements in severity index were independent o f changes 
in body mass. This study again suffered from  a small sample size w ith  less than 10 
participants in each arm of the trial.
Sengul et al. (2011) published a randomised controlled tria l investigating the effects of 
breathing exercises and aerobic training in overweight and obese men w ith non-severe 
OSAS. The intervention involved 12 weeks o f thrice-weekly supervised sessions lasting 
up to  90 min consisting o f breathing exercises (15 to  30 min) and cycle ergom etry (45- 
60 min). The main finding of this study was tha t the intervention reduced AHI by 28% 
(15.19 ± 5.43 to  11.01 ± 5.28 events-h'1; P=0.02) despite no changes in anthropom etric 
variables. This study again included a small sample size, and recruited only m iddle- 
aged men (40 to  65 years), which lim its the generalisability o f the results. Furthermore, 
the study sample did not include patients w ith severe OSAS or many (if any) patients 
w ith extreme obesity (inferred from the BMI characteristics; mean BMI 30 ± 3 kg-m'2). 
Although this study was probably investigating the role o f exercise in non-CPAP treated 
m ild-to-m oderate OSAS, it is unclear whether the patients included were pre-CPAP, 
CPAP-resistant or CPAP compliant.
This ambiguity was not present in a randomised controlled tria l conducted by Ackel- 
d'Elia et al. (2011). This study evaluated the effects o f exercise tra in ing coupled w ith 
CPAP therapy versus CPAP only in patients w ith at least moderate OSAS (AHI>15 
events-h x) up to a BMI o f 35 kg-m 2. In this tria l, exercise involved 1-hour sessions,
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thrice weekly fo r tw o months and consisted of treadm ill walking and running. The 
intensity ranged from  85% of the speed at anaerobic threshold to  40 min above the 
original anaerobic threshold towards the end of the study. The CPAP plus exercise 
group improved several aspects o f quality o f life compared to CPAP-only, perhaps 
unsurprisingly considering the widely reported benefits of exercise. General health 
perception, physical functioning and vita lity  scores using the Short Form-36 tool were 
improved significantly more in the exercise group after treatm ent and also a fter wash­
out. There were improvements in some markers o f physical fitness (+14% maximum 
speed in exercise test; P<0.01) but not others (+10% V02 max; P>0.05), perhaps due to 
the small number of participants (n=12 in intervention). These authors did not report 
any benefits of adjunct exercise therapy on AHI on nights w ith CPAP, on the firs t night 
w ithout CPAP and after a 1-week washout period o ff CPAP, compared to  the CPAP only 
group. Of note, a fter the washout period ESS increased in both groups; the increase in 
the CPAP only group made it similar to pre-CPAP levels, whereas the exercise plus 
CPAP group remained significantly improved. This evidence suggests treadmill-based 
exercise has no impact on OSAS severity or sleep architecture. This study also 
integrated a period of sleep hygiene education before the CPAP delivery, although not 
explicitly discussed it seems tha t the advice-only nature o f the sleep hygiene had no 
beneficial impact on any outcome measures, w ith the exception o f the general health 
perception aspect of the SF36 questionnaire.
Kline et al. (2011) conducted a randomised controlled tria l investigating the effects o f 
aerobic exercise training in overweight and obese patients w ith moderate OSAS. Their 
design incorporated a stratified randomisation process and a placebo control group 
(whom still underwent an intervention, but this was based on static stretching only). 
They reported 38% improvement in AHI (-12 events-h 1; P<0.01) in favour o f the 
exercise group w ith no significant change in body mass (-0.3 kg net change) and slight 
improvement in tota l body fat (-1.4% net change). There was also a modest net 
improvement in maximum inspiratory pressure tha t failed to  reach statistical 
significance but was characterised by a small-to-moderate effect size (+15.9 mmH20; 
P=0.06; g=0.43). This observation suggests tha t exercise can certainly stimulate 
changes in the anatomy and physiology of the respiratory system. The precise 
mechanisms underlying improvements in objective measures of OSAS in the absence
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of meaningful weight loss are unclear. It has been suggested tha t upper airway smooth 
muscle tone, which is largely w ithdrawn during sleep in OSAS, could undergo a training 
effect similar to  the effect o f resistance training on skeletal muscle. This "train ing 
effect" could be stimulated by increased airflow through the airway. The increased 
activation of airway smooth muscle during exercise could increase basal tone, and 
increase nocturnal tone also. Improved tonus increases the structural integrity of the 
airway and reduces its propensity fo r collapse. Another possibility is the rostral fluid 
shift; lower limb exercise or physical activity activates the skeletal muscle pump to aid 
venous return and could reduce or prevent the development of oedematous legs 
during the day - thereby reducing the potential fo r rostral shift. The Kline et al. (2011) 
study also observed excellent participant adherence to the intervention and suggested 
this was because of the careful progression of the intervention. That aside, they 
expected they may have recruited a motivated sample relative to  the population, 
which is d ifficu lt to avoid in exercise-based randomised controlled trials tha t involve 
obtaining w ritten  informed consent and where it is not possible to  blind groups to 
treatm ent allocation. This study also showed tha t exercise can ameliorate deficits in 
daytime functioning such as depressive symptoms and quality o f life. The 
generalisability o f these results is lim ited fo r three key reasons. This sample was fairly 
homogenous fo r severity, w ith principally moderate severity OSAS patients included. 
The relationship between exercise and severity o f OSAS is bidirectional (Giebelhaus et 
al., 2000; Peppard & Young, 2004) and probably reversible.
2.9.3 Combined dietary and exercise intervention
Dietary intake and physical activity are the principal governors o f energy intake and 
energy expenditure, and consequently energy balance. Common sense would suggest 
tha t addressing both in tandem should exert greater influence on the energy balance 
equation and avoid compensatory shifts in energy intake and physical activ ity to 
maintain energy homeostasis. This has been shown to  be the case in obesity (Shaw et 
al., 2006). Peppard et al. (2000a) showed tha t reducing body mass by 10% was 
predictive of a 26% reduction in the severity o f OSAS. Several studies have 
incorporated such approaches in OSAS w ith mixed results.
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Norman et al. (2000) built on the study by Netzer et al. (1997) by conducting a similar 
tria l incorporating dietary counselling. Eleven obese patients w ith mild-to-severe OSAS 
were recruited, o f which 9 completed (89% male) the study and were included in the 
analyses. This included patients tha t were [n=5) and were not (/i=4) undergoing nasal 
CPAP therapy. The main findings were significant reductions in body mass (110.9 to 
104.7 kg; P=0.001), neck (A -1.8 cm; P=0.002), waist (A -4.7 cm; P=0.004) and hip 
circumferences (A -2.9 cm; P=0.016), systolic (A -8.8 mmHg; P=0.016) and diastolic (A -
8.1 mmHg; P=0.001) blood pressure and AHI (21.7 ± 9.0 to  11.8 ± 6.8 events-h'1; 
P=0.002). The authors did not identify any correlation between amount o f weight lost 
and reductions in AHI (r=0.35; P=0.35), strengthening the hypothesis tha t exercise can 
independently improve OSAS. They also split the ir group up into CPAP and non-CPAP 
users to  detect any treatm ent effect on key outcomes, but none were noted.
Barnes et al. (2009) conducted a cohort study investigating the effects o f a 16-week 
VLED and structured exercise in 12 obese, middle-aged adults. The VLED component 
was steadily w ithdrawn over the course of the intervention (from three study meals 
per day to  two, then to  one) as was the supervised exercise component (from three 
per week to  one-to-three per week. Participants were asked to  maintain a fixed 
frequency of five training sessions per week consisting of hospital-based sessions and 
independent home-based sessions. The exercise was 100% resistance training-based 
fo r the first four weeks to  lim it muscle atrophy during the rapid weight loss phase, 
after which an aerobic component was added. The cohort reduced body mass by 12.7 
± 9.6 kg at 16 weeks, however all participants suffered weight regain at 12-month 
follow-up which reduced weight loss from  baseline to 8.3 ± 7.7 kg. The weight 
reduction at 16-weeks corresponded to  an approximate 25% im provem ent in mean 
AHI (24.6 ± 12 to  18.3 ± 11.9 events-h1). This improvement was not statistically 
significant (P=0.19) perhaps because three of the twelve participants' AHI increased by 
>5 events-h'1. In this study, the intervention reduced daytime sleepiness, daytime 
blood pressure, 24-hour blood pressure, to ta l cholesterol, LDL, triglycerides, CRP, 
Insulin and gamma-GT (all P<0.05) at 12 weeks.
Tuomilehto et al. (2009) conducted a randomised controlled tria l to  examine the 
effects o f a VLED, nutritionist-delivered counselling and advice to  increase physical 
activity on body mass and OSAS severity in 81 patients w ith mild OSAS. At the one year
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fo llow -up there were significant improvements in body mass, waist circumference, 
plasma insulin concentration and AHI, compared to the advice only group. This study 
also identified strong correlations between weight loss and im provem ent in OSAS. 
Longer-term follow-up of this cohort was conducted 2 years after enrolm ent 
(Tuomilehto et al., 2010). The intervention group improved AHI fu rthe r (A -4.1 [-7.6, - 
0.7] events-h'1; P=0.049) despite having regained 50% of the weight in itia lly lost during 
the intervention, which promotes the hypothesis o f exercise-induced improvements in 
OSAS independent of weight change. Furthermore, 26 [3, 48]% of those in the 
intervention group were clinically cured of OSAS; an outcome not associated w ith 
CPAP intervention. It is worth reiterating tha t this study did only include those w ith 
mild OSAS. Recently, Tuomilehto et al. (2013) published impressive five-year fo llow -up 
data fo r this cohort. Weight loss from baseline was still marked in the intervention 
group (A -5.5 kg) compared w ith the control group (A 0.6 kg). Changes in AHI from  
enrolm ent were 5.0 [0.8, 9.2] and -0.8 [-3.3, 0.8] events-h"1, which was still significantly 
d ifferent (P=0.04).
In 2009, Foster et al. (2009) reported a prospective cohort study as part o f the Look 
AHEAD (Action fo r Health in Diabetes) study; the Sleep AHEAD study. To date, this is 
the largest randomised tria l assessing weight loss in OSAS. The study recruited 264 
participants w ith type 2 diabetes and compared the effects o f tw o interventions; 
diabetes support and education and intensive lifestyle intervention. The form er 
involved thrice-yearly group sessions aimed at promoting behaviours to  effectively 
manage diabetes, and the la tter was a behavioural weight loss program involving 
prescribed LED and 175 min of moderate exercise per week. The provision o f LED 
prepared meals was reduced after four months. The sample included good 
representation o f d ifferent severities o f OSAS (approximately 40% mild, 35% moderate 
and 25% severe) and included only 5% CPAP users at follow-up. A fte r one year, the 
intervention group showed improved body mass (-10.8 ± 0.7 kg) compared w ith  the 
support and education (-0.6 ± 0.7 kg) group (P<0.001), while AHI reduced by 5.4 ± 1.5 
in the intervention group and increased by a similar amount in the support and 
education group (P<0.001). It is likely tha t these improvements were more profound 
after four months however these data were not collected. It is therefore d ifficu lt to 
assess the weight regain pattern and its association w ith improvements in AHI.
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Alarmingly there was a significant increase in AHI fo r the support and education arm of 
the tria l (+4.2 ± 1.2 events-h"1), despite no increase in body mass (-0.6 ± 0.7 kg; 
P<0.05). The authors proposed this could be due to a rapid natural progression of 
OSAS in older adults, although other contributing factors to  apnoea were not assessed 
(e.g. alcohol/sedative use). There is lim ited evidence fo r or against this hypothesis and 
it w ill be interesting to see how this trend continues in the four-year fo llow -up due 
w ith in the next 12 months. The authors reported tha t the major findings o f the study 
were unchanged after reanalysis excluding CPAP users.
Papandreou et al. (2012) conducted a randomised tria l assessing the impact o f CPAP 
therapy, unsupervised encouragement to  increase physical activity, and e ither a 
Mediterranean diet (high in fish, vegetables and non-refined cereals) or a prudent diet 
(high in red meat and poultry) in 21 obese apnoeics. A fter six months the intervention 
group had reduced body mass by 10.8 ± 3.8 kg, along w ith proportional reductions in 
BMI, waist circumference and body fa t percentage. The study reported significant 
reductions in a lipid peroxidation marker (th iobarbituric acid) suggesting tha t both 
diets beneficially improved oxidative stress. Reductions in AHI were only significant in 
the Mediterranean diet group, although the magnitude of improvement was similar in 
both groups (Mediterranean: 47 ± 34 to 35 ± 32; prudent: 46 ± 32 to  37 ± 29 events-h"1; 
P< 0.05).
EDS is a hallmark characteristic of OSA, and Basta et al. (2008) showed tha t a lack o f 
regular exercise is a significant predictor fo r degree of EDS in men. Exercise tra in ing 
has been shown to  benefit many medical conditions and often offers an economically 
viable alternative which addresses not only the conditions at hand but also offers a 
protective effect against a wide range of other health problems. Exercise can increase 
NO bioavailability and decrease the inflam m atory response; however the mechanism 
of action has not yet been identified (De Meirelles et al., 2009). Rizzi et al. (2010) 
reported tha t functional capacity was not impaired in lean OSAS patients suggesting 
tha t the impaired exercise capacity o f obese OSAS patients is independently obesity- 
related. Currently there are routine rehabilitation clinics fo r patients w ith COPD and 
post-myocardial infarction patients, and are intended to improve functional capacity 
and long-term outcomes. Other less specific referral schemes exist fo r patients 
referred from  the ir GP are available in some parts of the UK.
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2.9.4 Summary
There is considerable evidence to  support the role o f lifestyle management in the 
overall management of OSAS, especially because a significant proportion of OSAS 
patients are in tolerant to  CPAP therapy. However w ith evidence coming from  
interventions of varying duration and design (e.g. combined VLED and exercise or LED 
and behaviour change counselling), and from  specific subsets o f the OSAS population, 
fo r example those w ith a specific disease severity (i.e. mild, moderate or severe) or a 
comorbid condition (e.g. heart failure or diabetes) it is d ifficu lt to generalise these 
findings to  the OSAS population. The ways in which weight loss can improve OSAS 
seem to  be clear; increased airway calibre and decreased load-induced collapse. The 
precise mechanisms implicated in the exercise-induced im provem ent in OSAS 
(independently o f changes in body mass) are unclear. Improved airway smooth muscle 
and reduced rostral flu id shift could be responsible.
2.10 Assessing the impact of clinical trials
Empirical data in scientific research are most often quantitative and scalar in nature. 
This can make the determ ination of not only the magnitude, but the simple presence 
o f a significant change difficult. Karl Raimund Popper (b. 1902) was a 20th Century 
philosopher responsible fo r promoting the concept o f falsifiability; where an 
experiment is characterised by a testable hypothesis. In fact, Ronald Fisher (1935) 
suggested tha t the only hypothesis tha t should be scrutinised is the null hypothesis, 
which states tha t there is no effect. This inferential method provides a probability, or P 
value, tha t the observed difference was due to  chance. Rather arbitrarily, the 
threshold probability is almost universally considered to  be 1 in 20, or 5%. Probabilities 
lower than this are considered to  be significant (e.g. a change w ith P=0.024 is 
significant and not attributable to  chance alone). A single P value is usually produced 
from  a statistical test when comparing d ifferent sets o f data and it can be generated 
from  a number o f statistical tests. These tests, or more correctly the ir selection, are 
much more fallible than ideal, w ith subjective assessments o f the characteristics of the 
data (e.g. does it f it  a Gaussian distribution?) as key decisions on the path to  test 
selection. The underpinning mathematics of many methods, such as analysis o f
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variance (ANOVA), are robust to m inor violations in key assumptions but quantifying 
the amount o f violation tha t makes a test unsuitable has not yet been proposed. 
Although hypothesis testing, and the sacred P value, provide a quantifiable likelihood 
of an observed effect being attributed to  chance, there is no inform ation about the 
direction or magnitude of this effect (Bland & Peacock, 2002). Jacob Cohen proposed 
using an effect size, d, to  quantify the magnitude of the effect (or difference) (Cohen, 
1992). This is calculated by dividing the difference between means by the pooled 
standard deviation. Thresholds o f 0.2, 0.5 and 0.8 are considered to  be small, 
moderate and large effects, respectively. A caveat, this approach is suitable only for 
parametric data; alternative statistics such as C liffs 6 and Hedge's g should be 
calculated fo r datasets tha t profoundly violate normality.
More recently, confidence intervals around the difference (between groups, overtim e , 
or between groups over time) have been endorsed as an estimate o f the effect and its 
error. Confidence intervals provide a range of values tha t are 90, 95 or 99% likely to 
include the true population parameter o f interest. Both significance testing and 
confidence intervals are heavily influenced by the number [n) o f cases included. As n 
increases the standard error o f the mean (SEM; equal to  the standard deviation 
divided by the square-root o f n) decreases - this reduces the breadth o f confidence 
interval. Similarly, as n increases, the probability tha t the observed difference is 
a ttributable to  chance alone decreases, because as more cases are included a higher 
proportion of the population is included in the sample and more confidence can be 
placed in the test statistic. This phenomenon can contribute towards making seemingly 
small changes statistically significant.
Most clinical trials report results that are statistically significant w ith no e ffo rt to 
ascertain the clinical meaningfulness o f the results. The minimum clinically im portant 
difference (MCID) is an a p rio ri threshold specified by the researcher tha t is clinically 
meaningful; a change from baseline - or difference between groups - of greater than 
the beneficial MCID (positive or negative, depending on the variable) can be inferred 
to  affect the clinical status o f the sample (and possibly the population). MClDs are 
population- and disease-specific; fo r example a reduction in serum cholesterol o f 1 
mmol-L'1 is probably o f clinical benefit to group whose baseline was 5 mmol-L'1, but 
not to  a hypercholesterolaemic group whose baseline was 10 m m ol-'1. The MCID can
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be calculated using anchor-based (i.e. pilot data) or distribution-based (i.e. a pre­
determined effect size or d istribution proportion) methods. The latter is often 
calculated as a proportion of the standard deviation at baseline (e.g. one fifth , one 
quarter or one third) and is therefore dependent on baseline characteristics. For 
example, if by chance (or design) all participants on a diabetes study are between 120 
and 130 kg, the standard deviation may be as low as 2 kg, w ith  one quarter of tha t as 
500 g -  this proposed MCID could be feasibly observed before and after a single trip  to  
the to ile t, and is unlikely to  be of clinical benefit to  patients. Distribution-based 
methods are not founded w ith any clinical metric (such as answers to  "Do you feel 
better?") so it is perhaps more prudent to  refer to  these values as minimal im portant 
differences (MIDs) instead.
Batterham and Hopkins (2006) proposed a trichotom ous scale to  compare confidence 
intervals fo r the difference between groups over tim e. These three regions describe 
effects as harmful, triv ia l or beneficial. The thresholds between harmful and trivia l, and 
triv ia l and beneficial were defined as one MCID (or MID) either side of 0. The authors 
also recommended reducing the confidence interval to  90% as they considered 95% to  
be too conservative -  this allows each tail o f the interval to  be equal to  alpha (usually 
0.05). Moreover, Sterne & Davey-Smith (2001) also promote the use of 90% 
confidence intervals, but the ir justification was to  increase distinction between 
confidence intervals and alpha thresholds to minimise m isinterpretation. Depending 
on the proportion o f the 90% confidence interval tha t sits w ith in  each domain, the 
effect can be attributed a simple, plain-language inference based on ratios previously 
published (Hopkins, 2002). The particular usefulness of a confidence interval and its 
meaningfulness is apparent in health economics.
2.11 Rationale
W ith a strong epidemiological link between obesity and OSAS, and the obesity 
epidemic rife in the developed world, there is likely to  be a marked increase in 
diagnoses of OSAS over the next decade. Although CPAP has formed the bedrock o f 
OSAS treatm ent fo r tw o  decades, patient compliance to  its use is sub-optimal and 
hence identifies a need for alternative therapeutic approaches to  be investigated w ith
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robust randomised controlled trials, and for the effects of low compliance with CPAP 
on key health outcomes to be better understood.
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Section 2 -  Lifestyle intervention in obstructive sleep apnoea 
syndrome -  a randomised controlled feasibility study
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Chapter 3 -  Introduction
Despite the effectiveness of nightly CPAP therapy, it simply manages OSAS (by 
increasing intra-pharyngeal pressure and reducing airway collapsibility) and does not 
itse lf offer hope of a cure. Especially fo r those diagnosed in the ir early adult life, it can 
be a quite daunting prospect to  know they may sleep w ith a facemask fo r the 
remainder o f the ir life. This can be especially complicated fo r those who travel 
regularly, spend tim e away from  electricity or are starting a new relationship. 
Consequently, intervention must take place fo r there to be any chance of reducing 
syndrome severity significantly enough tha t CPAP is no longer necessary. This can 
probably act as a reliable motivator.
Therapies delivered in parallel to  CPAP can induce marked reductions in body mass 
tha t have been shown to  improve OSAS. These can be broadly grouped into dietary 
interventions, exercise interventions, surgical interventions, pharmacological 
interventions and hypnotherapeutic interventions. Indeed, diet and exercise are 
commonly addressed in tandem (as they both contribute to  energy balance) and hence 
term ed lifestyle-based interventions. Also, they can be supplemented w ith other 
approaches such as behaviour change counselling or Orlistat therapy. Such strategies 
could provide efficacious and cost-effective options fo r the holistic management of 
OSAS. Reductions in obesity and improvements in cardiopulmonary fitness can provide 
significant health benefits and although there are substantial recommendations in the 
public domain to  make such improvements self-directed uptake appears to  be poor. 
Furthermore, NHS-supported programmes are lim ited to  cardiac and pulmonary 
rehabilitation services.
W ith continuous treatm ent likely unless significant changes in the underlying aetiology 
are achieved, it is obvious tha t strategies to  address causation are required. Exercise 
plays a role in the management o f many chronic conditions and has been proposed in 
OSAS to  not only stimulate weight loss, but to address the greater risk inactiv ity is 
thought to  play in the development o f cardiovascular disease (Blair, 2009). Previous 
exercise-based interventions have been poorly designed w ith small sample sizes (Ueno 
et al., 2009; Sengul et al., 2011), uncontrolled designs (Norman et al., 2000; Giebelhaus
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et al., 2000; Barnes et al., 2009) and homogenous samples (Ueno et al., 2009). There is 
a need fo r robust randomised controlled trials investigating the effects o f pragmatic 
lifestyle interventions in obstructive sleep apnoea.
This longitudinal study aimed to investigate the feasibility of a pragmatic lifestyle 
intervention incorporating exercise, dietary advice and behaviour change counselling 
delivered to obese obstructive sleep apnoea patients in Sheffield whom were 
compliant w ith CPAP therapy. The underlying reason fo r recruiting highly-compliant 
CPAP patients is two-fo ld: because this group constitutes the most common sub-group 
of treated OSAS patients; and, CPAP-compliant patients are likely to  be compliant w ith 
adjunct lifestyle intervention. To our knowledge this is the first UK-based tria l o f its 
kind. The objectives of this study are to design and conduct a combined lifestyle 
intervention tha t could be deliverable in a healthcare setting and to  collect provisional 
data to  evaluate its feasibility and its effects on im portant health outcomes.
The research questions are:
•  Is a pragmatic lifestyle intervention feasible in CPAP-compliant OSAS patients?
• Can a lifestyle intervention improve body mass and composition, cardiovascular 
risk profile, health-related quality o f life and exercise capacity?
The original hypotheses are:
• The lifestyle intervention w ill be acceptable to patients which will be reflected 
in a favourable recruitm ent rate o f at least 10% (in line w ith other studies from  
our centre)
•  The lifestyle intervention will improve key health outcomes including body 
mass, serum cholesterol and exercise capacity
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Chapter 4 -  Methods
4.1 Study design
This was a non-blinded, parallel group, randomised controlled feasibility study. The 
terms feasibility and pilot in reference to  tria l design are often used interchangeably 
and the difference between the can be d ifficu lt to  discern. Arain et ol. (2010) discussed 
the key differences between the tw o and advocated the use of National Health Service 
Evaluation, Trials and Studies Coordinating Centre (www.netscc.ac.uk/glossary) 
definitions. A feasibility study investigates the viability o f a study design/methods, such 
as key participation rates (such as recruitment, retention and compliance), the 
practicality/design of study commitments, provisional data on principal outcome 
measures and the overall practicality and value of recreating the study on a larger 
scale. Feasibility studies w ill often identify areas of weakness in the design of a study 
which should be addressed before proceeding to  a larger tria l. A p ilo t study is a small 
version of an intended larger study tha t is conducted to  ensure the main processes of 
the main study, such as recruitment, randomisation and the intervention are 
appropriate and integrate effectively. If the pilot study is successful the collected data 
could be used in the larger study, hence becoming an internal pilot.
Regardless o f the ir "classification" these small-scale studies tend not to  be reported, 
despite the ir value in contributing towards study design fo r researchers in similar fields 
(Lancaster et a!., 2004; Arain et al., 2010). Preliminary studies are usually conducted to 
refine study design and are often developed into randomised controlled tria ls (RCTs). 
An RCT is the gold-standard design in health research and allocates a sample randomly 
to  either a treatm ent group or a control group. The treatm ent could be a new drug, 
behaviour, device or procedure and the control is usually e ither the current preferred 
treatm ent or no treatm ent at all. In this study, our treatm ent was a lifestyle 
intervention, and our control was basic lifestyle advice.
Pilot work is im portant to ensure subsequent tria ls are feasible in design and to 
provide provisional clinical evidence on treatm ent efficacy. Data yielded from  pilo t 
work can contribute to  a sample size calculation fo r a definitive tria l, providing specific
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aspects of the design remain unchanged. This study was sponsored by Sheffield 
Teaching Hospitals NHS Foundation Trust (STH-15488) and jo in tly  funded by Sheffield 
Hospitals Charitable Trust and the Sleep Apnoea Trust Association. This research was 
carried out in accordance w ith the Declaration o f Helsinki of the W orld Medical 
Association and ethics approval was provided by South Yorkshire Research Ethics 
Committee (09/H1310/74). This study was registered on an international database 
(h ttp ://w w w .clin ica ltria ls.gov; NCT01546792)
4.2 Recruitment
4.2.1 Strategy
Participants were recruited from  sleep clinics at the Royal Hallamshire Hospital, 
Sheffield, and the Northern General Hospital, Sheffield. Potentially eligible participants 
were identified at firs t pass using three basic criteria:
•  at last check were using CPAP fo r >4 hours on >65% nights over at least a 6 
month period
• body mass index (BMI) >28 kg-m'2
• no obvious contraindications to  any study procedures
• no obvious exclusion criteria
This criteria were intentionally more inclusive than the inclusion and exclusion criteria 
because physiological parameters tha t could exclude someone (e.g. BMI=29 kg-irf2) 
who had since put weight on and was now eligible. Potentially eligible participants 
were sent a recruitm ent pack tha t contained a recruitm ent le tte r (appendix 1), 
participant inform ation sheet (appendix 2), response slip and an addressed prepaid 
envelope (to return the ir response slip). W hether interested or not, patients were 
asked either to  call the study researcher (and leave a message if unable to get through) 
or return the reply slip (that included space fo r the ir name, phone number and tw o 
check boxes to  indicate interest or disinterest). A fter four weeks, those who did not 
provide a response were presumed to  have not received the recru itm ent le tte r and to 
ensure equal opportunity were followed up w ith a telephone call.
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4.2.2 Familiarisation
Participants tha t responded w ith interest were invited to our laboratory at Sheffield 
Hallam University to meet a member o f the research team. The researcher briefly 
outlined the activities tha t the Centre fo r Sport and Exercise Science undertakes gave a 
tour of our laboratories. A thorough medical history (appendix 3) was taken and 
compared w ith a detailed list of inclusion and exclusion criteria (section 4.3 and 4.4). 
Patients' compliance to  CPAP therapy was also discussed. Ineligible patients were 
informed of the ir unsuitability at this point and thanked fo r showing an interest in the 
study. Patients considered potentially elig ib ility were referred to  Dr Stephen Bianchi 
(Consultant Physician in Respiratory Medicine, Northern General Hospital, Sheffield, 
UK) fo r final approval.
The researcher then explained in detail the purpose of the study, the procedures 
involved in assessments, the randomisation process and the potential benefits and 
risks o f participation. The difference between the tw o groups in the study and the 
d ifferent requirements these groups had was also discussed. The difference in tim e 
com m itm ent was emphasised and patients were encouraged to  enrol only if they 
intended to fu lfil the requirements o f whichever group they were randomised. At this 
point a demonstration of the principal equipment and procedures involved w ith  the 
study was given. The patient was then encouraged to ask any questions and express 
any concerns they may have had. Once questions had been answered to  the 
satisfaction of the patients they were asked if they would like to  enrol on the study. 
Those wishing to  enrol provided w ritten  informed consent (appendix 4). The medical 
history taken at this stage was compared w ith a more extensive list o f inclusion and 
exclusion criteria.
4.3 Inclusion criteria
•  Obstructive sleep apnoea confirmed w ith single-/m ulti-channel 
polysomnography or overnight pulse oximetry. OSA was defined as an AHI o f 
>10 events-h1 or an ODI o f >10 desaturations-h1
• BMI >30 kg-m'2
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• Compliant to  CPAP therapy (>4 hours per night and >75% of nights) fo r six 
months prior to  enrolm ent
•  Men and women aged 18 to  85 years
4.4 Exclusion criteria
• Current participation in regular purposeful physical activity (>30 minutes on >3
days per week fo r six months prior to  enrolm ent); based on self-report
•  Contraindications to  exercise testing and training, such as unstable angina,
uncontrolled hypertension
•  Individuals unable to  provide w ritten informed consent
•  Patients unable to  travel to the testing facility at Sheffield Hallam University
•  Recent participation in medical research (<6 months)
4.5 Lifestyle intervention
4.5.1 Overview
The lifestyle intervention involved 24 supervised sessions delivered w ith decreasing 
frequency over 12 consecutive weeks tha t took place w ith in a dedicated exercise 
facility at Sheffield Hallam University, Sheffield, UK. The sessions were based on 
supervised exercise and included components o f dietary advice and behaviour change 
counselling. As the study was designed as a pilot, the overall objective was to  collect 
data tha t could inform the design o f a larger definitive tria l (outcomes described 
fu rthe r in section 4.6). Consequently, the intensity and duration o f the intervention 
were designed w ith both efficacy and pragmatism in mind. We were conscious not to 
over-burden participants w ith a high-intensity intervention w ith which they were likely 
to  struggle, but to  have it intensive enough to  elicit clinically meaningful changes in 
secondary outcome measures. The intervention was designed so that it could be 
integrated into NHS practice, w ith sessions lasting approximately an hour (sim ilar to 
most hospital appointments) and arranged at a tim e mutually convenient fo r s taff and 
participants (as is the practice in the sleep clinics from  which we were recruiting from).
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4.5.2 Role of supervision
The role o f the supervisor in the exercise sessions was three-fo ld: instructor, educator, 
and counsellor. Participants were coached on the safe and correct way to  use the 
exercise machines involved in the exercise sessions (instruction). They were given full 
tu ition  on the correct technique fo r free-weight dumb-bell exercises and Swiss ball 
exercises selected to strengthen the major muscle groups of the body. Participants 
were taught in simple terms the benefits of exercise as understood in current scientific 
literature (education). This helped to  address any misconceptions participants may 
have had from  the ir own education and experiences over the decades previous. The 
researcher discussed w ith participants the ir habits and behaviours and encouraged 
them to make improvements wherever possible (counselling). This aspect o f the study 
is discussed fu rther in section 4.5.5.
4.5.3 Exercise
4.5.3.1 Safety and considerations
Recruiting to exercise trials from  clinical populations brings w ith it an increased level of 
risk. These risks are especially present when obese adults are involved as obesity is 
associated, amongst other things, w ith an increased load on the heart during rest, and 
during exercise. This can be caused by increased intrapericardial fa t and increased 
peripheral blood vessel resistance.
Comparing our inclusion criteria w ith the ACSM risk stratification (Armstrong, 2006), all 
participants recruited onto this study were of at least moderate risk (because of the 
presence of obesity and physical inactivity) and consequently, all exercise tra in ing  and 
testing were conducted by individuals w ith at least Immediate Life Support training, 
access to  life support equipment such as a defibrillator/oxygen and knowledge o f the 
current departmental standard operating procedures fo r dealing w ith serious adverse 
events (such as cardiac arrest). Sessions involving exercise to volitional exhaustion 
were likely to  involve the highest risk and were conducted in the presence of tw o  
qualified individuals.
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4.5.3.2 Principles of exercise prescription
The exercise sessions were bespoke in design fo r each participant depending on co­
morbidities, physical ability and patients' preference. Exercise can be defined by the 
acronym FITT; frequency, intensity, time, type.
Frequency: How often the exercise occurs.
Intensity: How hard the exercise is perceived.
Time: How long the exercise lasts.
Type: How the exercise is delivered.
This intervention involved a fixed frequency o f three exercise sessions per week. This 
allowed fo r alternate tra in ing days and resting days through the working week 
(supervised sessions took place during working hours to comply w ith health and safety 
protocols and reflect the circumstances w ith which it could be delivered in a 
healthcare setting). A fter 4 weeks the number o f weekly supervised sessions was 
reduced to  2 w ith the th ird  weekly session being completed unsupervised at a remote 
location. The structure o f this session was planned in advance on a home exercise 
sheet (appendix 5), which also left space to  put the achieved exercise. At week nine 
the number o f unsupervised sessions increased to  two per week, w ith one still 
supervised at Sheffield Hallam University. The intensity o f prescribed exercise was 
controlled using the Borg rating of perceived exertion 6-20 scale (RPE; Borg, 1982) and 
heart rate. The RPE scale is a subjective measure o f exercise intensity from  the 
participant's point o f view. The researcher carefully explained this tool at the start o f 
the intervention using a pre-defined explanation. Heart rate (HR) was also used to  
control the intensity o f exercise -  this is an objective physiological measure free from  
conscious bias (unlike RPE). Heart rate was assessed using a chest-mounted heart rate 
m onitor (F4, Polar Electro, Finland) and a wristwatch receiver (Polar Electro, Finland). 
Heart rate reserve (HRR) was calculated fo r each participant using estimated maximum 
heart rate (H R Max = 2 2 0  - age) and resting heart rate (H R RESt ; measured after 2 0  minutes 
in a supine position during the baseline assessment) using a standardised equation 
(HRmax -  H R rest). Percentage of HRR (%HRR) was determined (decimalised proportion x  
HRR + H R rest). The use of HRR fo r exercise prescription was used only in patients not 
taking medication tha t can affect heart rate (such as |3-blockers).
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Exercise sessions started w ith a light 5-min warm-up (i.e. RPE 9/10; light) and 
concluded w ith a 5-min cool-down (i.e. RPE 9/10) in accordance with ACSM guidelines 
(Armstrong, 2006). The intensity was initia lly set low (equivalent 50% HRR, RPE<12; 
moderate) to  allow participants to  become accustomed to  any unfamiliar equipment 
and techniques. After one week, once participants were comfortable, the intensity was 
increased to 60-80% HRR and RPE 13-15. Over the course of the intervention the 
intensity was increased in accordance w ith decreased heart rate and RPE (indicative of 
improved exercise tolerance). The tim e spent on each piece of equipment was in itia lly 
between 8 and 12 minutes and also increased as the programme progressed. Sessions 
in itia lly targeted 30 minutes o f aerobic exercise and steadily increased to  45 minutes. 
The types of aerobic exercise include treadm ill walking, cycle ergometry, rowing 
ergom etry and elliptical-training. An example o f a participant in a tra in ing session is 
depicted in Figure 4.1.
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Figure 4.1 Participant exercising during a training session.
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Interval training was commonly used in the delivery of aerobic exercise (i.e. 2 min 
cycling at 80 W / l  min cycling at 110 W) because it has greater health benefits than 
m oderate-intensity exercise (Tj0nna et al., 2008)). Also, alternating hard and light 
intervals allowed participants to  be interactive w ith the ir exercise sessions, possibly 
reduced repetitiveness and boredom and provided opportunity fo r discussion and 
counselling w ith the ir supervisor (during the light intervals). Participants who could not 
exercise at intensities equivalent to  hard intervals performed continuous exercise at 
the ir highest capacity. There was also dedicated tim e spent on flexib ility  (dynamic and 
static stretching) and resistance training. Resistance training consisted o f 2-3 sets of 8- 
12 repetitions using free-weights tha t were challenging, yet achievable (correctly 
selected weights would be very challenging towards the end of the final set). Target 
muscle groups included biceps brochii, triceps brochii, deltoids, pectoralis major, rectus 
abdominus, quadriceps femoris and rectus femoris.
4.5.4 Dietary advice
Unlike the aforementioned VLED interventions, the dietary aspect o f our study was 
designed to be direct, pragmatic and deliverable in a healthcare setting. Advice was 
basic, delivered by an exercise scientist and integrated into the supervised exercise 
sessions (either before the session, during light exercise, during recovery periods or 
a fter the session). The dietary advice was delivered using three key points based on 
addressing the quality (dietary imbalance and food labelling) and quantity (portion 
sizing) o f food consumed:
Dietary balance: using the Eat-well Plate - a pictorial representation o f the five major 
food groups in a pie chart form at (Food Standards Agency, www .eatwell.gov; Figure 
4.2) - w ith size o f each segment relative to  the proportion of a healthy diet tha t food 
group represents. Particular emphasis was placed on the "fru it and vegetables" slice 
and the concept o f 5-a-day (five portions of fru it and vegetables per day). This too l has 
been incorporated into interventions previously (Ford et al., 2010).
Food labelling : although tra ffic-ligh t labelling is mandatory fo r pre-packaged foods in 
the UK on packaged food, manufacturers are keen to  present the ir product in the best
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light to  improve sales. As a result, the perceived "healthiness" o f products is easily 
overestimated. A systematic review by Campos et al. (2011) suggested regular use and 
understanding of food labels is sub-optimal. Participants were taught how to  read and 
understand food labels to  facilitate the ir ability to  make informed choices.
Portion sizing: participants were advised about the concept of energy balance and the 
role o f portion sizing in regulating daily energy intake. Plate choice, the amount o f food 
prepared during mealtimes and snacking habits were also discussed.
To support these ideas, participants kept a three-day diet diary (appendix 6) during the 
firs t week to assess baseline eating habits. This facilitated the identification of dietary 
imbalance and overeating. The diet diary was used in the setting of short- and long­
term  goals to  support the concurrent behaviour change. A British Heart Foundation 
resource "So... you want to  lose weight fo r good" was used as a take home resource. 
The study researcher discussed the contents w ith participants w ith particular emphasis 
on key topics such as planning mealtimes ahead of tim e (e.g. making a shopping list 
and sticking to  it) and identifying eating patterns and triggers fo r unhealthy choices.
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Fruit and 
vegetables
IMeat, fish, 
eggs, beans
and other non dairy 
sources of protein
Bread, rice, 
potatoes, pasta
and other starchy foods
Food and drinks 
high in fat and/or sugar
Milk and 
dairy foods
Figure 4.2 The EatWell Plate. A basic pictorial representation of the main food groups and they 
proportion of a balanced diet each should occupy. Food Standards Agency, www.eatwell.gov
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4.5.5 Behaviour change
Behaviour change counselling aimed at promoting regular physical activity and healthy 
eating (referred to  hereafter as lifestyle change) was integrated into the supervised 
exercise sessions. The intention was to  provide participants assigned to the lifestyle 
intervention group w ith  the necessary knowledge and the psychological skills and tools 
to  sustain changes in the ir exercise and dietary behaviours. This tria l used the Trans- 
Theoretical Model (TTM; Prochaska & Norcross, 1999) as the guiding model of 
behaviour change.
Information elicited from  health screening and during the firs t couple o f sessions 
helped the researcher to  assess which stage of change participants were at (pre­
contemplation, individuals w ith no intention of lifestyle change; contemplation, 
individuals intending to  change the ir lifestyle; preparation, individuals who have made 
steps towards lifestyle change w ithout regularity). Individuals in the action (have 
sustained lifestyle change fo r six months) and maintenance (have sustained lifestyle 
change fo r more than six months) stages of change had already been screened out at 
the fam iliarisation stage and were not enrolled on the study. In line w ith  TTM, weeks 
1-4  focussed on cognitively based intervention strategies such as cognitive reappraisal 
and consciousness-raising.
During weeks 5-8, more behaviourally-based interventions were introduced, for 
example, goal-setting, self-m onitoring and finding social support. Participants followed 
a broad, structured curriculum of topics over the course o f the intervention. Detailed 
descriptions o f the strategies and techniques used are outlined in appendix 7. Such an 
approach has demonstrated efficacy in other clinical populations (Daley et al., 2004). 
This aspect of the intervention was delivered by an exercise physiologist (James Moss) 
and supervised by a Chartered Psychologist (Dr Robert Copeland).
4.6 Primary outcome measures - feasibility
Feasibility trials assess study design and identify changes tha t should be made before 
reproducing the study on a larger scale. This should safeguard against major wastage 
of resources, tim e and effort. Despite the ir importance, p ilot trials are under­
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represented in leading medical journals (Arain et al., 2010). Thabane et al. (2010)) 
suggested tha t p ilot studies address four key aspects o f research design:
Process:
•  Recruitment: how willing will participants be to  volunteer fo r the research?
W hat factors lim it recruitm ent (i.e. childcare, work commitments, transport
difficulties?)
• Retention: how many participants will w ithdraw  from the study? Why have 
participants w ithdrawn?
• Compliance: how compliant will participants be w ith the commitments o f the 
study? Will compliance to study activities dwindle as tim e goes on?
• Eligibility: are the elig ibility criteria appropriate? Are they too inclusive 
(confounding results) or exclusive (lim iting recruitment)?
Resources:
• Capacity: how many participants can the study handle at any one time? What 
changes could be made to increase participant throughput?
• Equipment: is the equipment valid, does it promote reproducible measures and
does it measure the desired variable?
Management:
•  Financial management: was the projected budget accurate? Were there and 
unexpected costs?
• Data collection: can assessments be completed on time?
• Data management: can the data stored safely and backed up regularly? Was 
any data lost?
•  Variability o f outcome measures: how variable were the outcome measures of 
interest?
Scientific
• Safety: were there any adverse or serious adverse events? How can they be 
avoided in the future?
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• Treatment intensity: was the intensity o f the intervention appropriate?
• Estimate of the treatm ent effect: were any changes of the direction and 
magnitude anticipated?
• Variability of the treatm ent effect: how variable was the treatm ent effect?
4.6.1 Recruitment
Two recruitm ent rates were calculated as screening occurred at tw o points during the 
recruitm ent process. Some participants were obviously unsuitable and not sent a 
recruitm ent pack (screened out at first-pass). Some patients were then ineligible upon 
a more in depth screening after showing an interest in participating (second-pass).
The overall recruitm ent rate was determined by dividing the number o f patients 
recruited by the number o f patients invited to participate (m ultiplied by one hundred 
to  yield a percentage). The expected recruitm ent rate was calculated by inferring the 
rate of inelig ibility in the interested patients existed in the original sample (once those 
who had already been identified as ineligible were accounted for). This produced a 
smaller denominator and a higher recruitm ent rate. The reasons participants were not 
interested in participating were recorded, if offered, to  identify potential factors tha t 
lim ited recruitment.
4.6.2 Retention
Participant retention rate was calculated by dividing the number o f patients 
completing the study by the number o f patients tha t enrolled (expressed as a 
percentage). The reasons fo r participants w ithdraw ing from  the study were recorded, 
if offered, to  identify factors tha t were influencing participant drop-out.
4.6.3 Compliance
Compliance was calculated fo r the assessment sessions (for participants in all arms of 
the tria l), fo r exercise sessions (for the intervention group only) and fo r all study visits 
(including fam iliarisation, assessments and exercise sessions (if applicable)). 
Compliance w ith assessments was calculated by dividing the number o f completed 
assessments by the total number o f possible assessments (m ultip lied by one hundred 
to  yield a percentage). Exercise sessions compliance was calculated by dividing the
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number of attended exercise sessions by the tota l number of possible exercise sessions 
(m ultiplied by one hundred to  yield a percentage). Total study compliance was 
calculated by dividing the number of attended study sessions by the number of 
scheduled visits. All compliance rates were calculated post-hoc using attendance data 
from  participants who completed the study only.
4.6.4 Safety
Any adverse events (AEs) or serious adverse events (SAEs) were recorded in the study 
site file and reported in accordance w ith Sheffield Teaching Hospitals NHS Foundation 
Trust procedure. The nature of the event, how it was managed, and what action was to 
be taken in the future to  avoid it was included.
4.7 Secondary outcome measures - efficacy
Assessment sessions took place at varying times of the working day (8 a.m. to  6 p.m.) 
depending on convenience principally fo r participants but also researchers. 
Subsequent assessments took place at the same tim e of day as the baseline 
assessment. For shift workers subsequent assessments occurred at the same stage of 
the ir shift pattern (e.g. tw o days after finishing night shifts). For pre-menopausal 
female participants subsequent assessments occurred at the same stage of the ir 
menstrual cycle.
Participants were asked to  abstain from  exercise fo r 48 hours, from  smoking fo r 12 
hours, from  caffeine fo r 12 hours and from food fo r 4 hours before all assessments. 
Ideally, all assessments would take place in the morning after a 12-hour overnight fast, 
however we were concerned this would have an adverse effect on those in fu ll-tim e  
work and consequently the ir willingness to  participate.
4.7.1 Anthropometry
Stature was measured (in cm to 1 decimal place) using a fixed stadiom eter 
(Harpenden, Holtain Ltd, Crymmych, Wales). Participants were asked to  align the 
posterior aspect o f the ir scapulae to  a backboard, w ith the posterior aspect o f the ir 
heels to  a heel board. The head was positioned so tha t the Frankfort plane was parallel
69
to  the floor. Participants were asked to  inhale deeply while adhering to the 
aforementioned criteria. Body mass was measured (in kg to 2 decimal places) on a 
calibrated balance beam scale (model 424; Weylux; Hallamshire Scales Ltd, Sheffield, 
UK). M inim ally dressed participants were asked to stand upright while the researcher 
used sliding weights to counter balance the ir mass. Once an equilibrium  was met the 
position was held fo r >10 s to  ensure accuracy. Body fat percentage was assessed using 
bioelectrical impedance (Bodystat® Quadscan 4000, Bodystat ltd., IM99 1DQ). 
Participants were asked to  lay supine w ith tw o  adhesive cathodes attached to  the volar 
aspect o f the wrists and anterior aspect o f the ankles on the right hand side of the ir 
body. Anodes were placed 3 cm distal to  the cathode. Neck, waist and hip 
circumference were measured using an inelastic anthropom etric tape. The locations 
fo r measurement were covered w ith as little  clothing as possible. Neck circumference 
was defined as the smallest measureable circumference between the clavicle and the 
mandible on the anterior aspect, and the firs t and seventh cervical vertebrae on the 
posterior aspect. Abdominal circumference was defined as the circumference of the 
abdomen at the level o f the omphalion, parallel to  the floor (Eston & Reilly, 2009). Hip 
circumference was defined as the circumference of the pelvis at the point o f greatest 
posterior protuberance, parallel to  the floor (Eston & Reilly, 2009). The mean of three 
measurements was used at each site.
4.7.2 Blood-borne biomarkers
Participants were asked to  fast fo r at least six hours prior to  the ir visit. Blood was 
drawn using the BD VacuTainer® system from  a vein in the antecubital fossa using 
aseptic techniques. Blood was collected into gel serum-separator tubes lined w ith a 
clot-activator compound. The tubes were inverted and reverted six times to  allow 
thorough mixture o f the blood and preservatives and given 30 minutes to  clot. The 
clotted samples were then centrifuged at 3000RCF (Heraeus Labofuge 400R, Germany) 
fo r 9 minutes. Once separated, 4 mL of serum were extracted using a 1000 piL Gilson 
p ipette and stored in 1 mL Eppendorf tubes. These Eppendorf tubes were im m ediately 
placed in a -80 °C freezer. Time between venepuncture and freezing was <1 hour 
(which lim its ex-vivo glycolysis and subsequent inaccurate measurement o f serum 
glucose; Fernandez et al., 2012). Once the study was complete, samples were
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transported to  the Blood Sciences laboratory at Leeds General Infirmary (Old Medical 
School, Leeds, LSI 3EX) in a polystyrene container w ith dry ice. Once there, they were 
transferred to  another freezer. Samples were thoroughly defrosted at room 
tem perature and analysed in tw o  batches on consecutive days in January 2012. Full 
lipid profile, glucose and high-sensitivity CRP were assessed using an ADVIA 2400 and 
insulin concentrations on an ADVIA Centaur® XP (Siemens, 511 Benedict Ave, 
Tarrytown, NY 10591). The CRP concentrations tha t exceeded 10 m g-L1 were 
considered indicative of an acute in fection/inflam m atory response (Ridker et al., 2003) 
and all blood results fo r tha t participant at all tim e-points were discarded.
4.7.3 Micro vascular function
Microvascular function was assessed by measuring changes in skin blood flow  in 
response to  iontophoresis o f vasoactive compounds. Skin blood flow  was assessed 
non-invasively using laser Doppler flow m etry (LDF; PF 5010 laser Doppler perfusion 
m onitoring system, Perimed AB, Jarfalla, Sweden). This technique uses a low-energy 
laser beam (780 nM) transm itted from  one or more probes positioned on the surface 
of the skin. The beam penetrated the skin to  a depth of approximately 1 mm and was 
deflected back to a photosensor built into the probe. Some returned light underwent 
a wavelength shift (caused by the Doppler effect) proportional to  the num ber and 
velocity o f erythrocytes in the penetrative field. Unfortunately, LDF cannot measure 
actual blood flow  in traditional units (volume per tim e) as there is no way to  determ ine 
microvessel diameter (and consequently volume) -  flux is calculated as an index of 
erythrocyte concentration and velocity and is expressed in arbitrary values. LDF has 
been used to  investigate microvascular function in OSAS. (Yim-Yeh et al., 2010; 
Trzepizur et al., 2009; Kheirandish-Gozal et al., 2010). We used a therm ostatic 
iontophoresis probe (PF 481-1, Perimed AB) to  make skin blood flux measurements 
(Figure 4.3). This probe consisted of a single-fibre laser surrounded by a copper heating 
disc tha t was connected to  the PF 5010 unit and a heating unit (PF 5020, Perimed AB).
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Iontophoresis well 
Laser fibre 
Heating unit
Transparent window 
Sponge 
Adhesive backing
Powered by an 
internal 9V battery
Circuit clips 
-Cathode (RED) 
-Anode (BLACK)
Clip to power pack Time knob Current knob
Figure 4.3 Equipment used in iontophoresis. Top left: Perimed pf 481-1 iontophoresis 
probe; right: Perilont power supply; bottom left; PF 383 iontophoresis electrode
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The iontophoresis probe was affixed to a drug delivery electrode (PF 383, Perimed AB) 
to  allow simultaneous iontophoresis and skin blood measurement. Iontophoresis is the 
non-invasive transcutaneous delivery o f ionic compounds using an appropriately 
charged electrical current (i.e. a positively charged current w ill cause delivery of a 
positively charged compound; Figure 4.4).
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Figure 4.4 Iontophoresis of a positively charged molecule
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The iontophoresis electrode consists o f a transparent w indow (for the LDF laser beam), 
surrounded by a small sponge in a well, which can be soaked in an ionic compound to 
be delivered (Figure 4.3). Behind this sponge is a copper disc tha t extends from  the 
back o f the electrode in an insulated arm. A device capable o f providing a tim e- 
measured current (PF 382b Perilont power supply, Perimed AB; Figure 4.3) was 
attached to  the drug delivery electrode and a dispersive electrode (PF 384, Perimed 
AB) placed 10-15 cm away. The tota l charge (current x tim e) was minimised in favour 
o f an extended duration to  prevent any non-specific (charge-related) vasodilation. The 
electrode has a large adhesive surface to facilitate secure placement of the probe (and 
to  ensure the sponge makes contact w ith the skin (and complete the circuit)).
All vascular assessments were performed in a tem perature-controlled room (22-24 °C) 
w ith participants supine and the ir experimental arm (usually left) extended laterally at 
the level o f the heart. Heart rate and blood pressure (Dinamap Dash 2500, GE 
Healthcare, USA) were measured on the contralateral arm to  avoid occlusion-related 
alterations in blood flow  in the experimental arm. Participants rested fo r at least 15 
min before starting data acquisition during which the probe was calibrated using the 
manufacturer's m otility  standard. During this tim e a suitable site fo r the LDF 
iontophoresis probe was identified using the follow ing criteria:
•  hypopigmented glabrous skin
•  no visible superficial blood vessels
• no dermal damage (e.g. burns, dermatitis, psoriasis)
• stable, resting perfusion of 2-8 APU
• stable skin tem perature (set at 32 °C)
• stable tota l backscatter reading
Once identified, the site was cleaned using a disposable alcohol wipe to  remove any 
latent skin cells and natural skin oils which could d istort the signal or compromise the 
electrode adhesion. As appropriate, excessive arm hair was gently shaved at the 
earliest opportun ity to  allow any microtrauma-related hyperaemia to  subside.
Skin blood flow  data were recorded using PeriSoft fo r W indows 2.5 (PSW 2.5; Perimed 
AB) software. Data capture commenced once the participant was at rest and all
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experimental conditions had been met. A 5-m inute recording of resting skin blood flow  
was taken; if this was stable the firs t iontophoresis dose was usually delivered at 5 
minutes.
4.7.3.3 Endothelium-dependent vasodilation
Twenty mg of acetylcholine chloride (ACh; Miochol-E, Novartis, Stein, Switzerland) 
were dissolved in 2 mL of Ringer's solution to  produce a 1% solution. One hundred pL 
of this solution were then soaked into the circular sponge on the drug-delivery 
electrode. ACh is an anionic neurotransm itter and was delivered in seven 30-second 
doses, 30 seconds apart, using a delivery current o f 0.1 mA-s'1 (Morris & Shore, 1996). 
Blood pressure was measured during each dose on the upper part of the contralateral 
arm. The experimental set-up is depicted in Figure 4.5.
The ACh delivery increased the activity o f endothelial nitric oxide synthase (eNOS) tha t 
in turn increased nitric oxide NO production. NO is a potent vasodilator tha t activates 
cyclic guanosine monophosphate (cGMP), which opens calcium-dependent potassium 
channels (KCa). Potassium effluxes the cell, hyperpolarizing the cell membrane, closing 
voltage-gated calcium channels, inducing smooth muscle relaxation, vasodilation and 
increasing blood flow. ACh-dependent vasodilation is endothelium -dependent as it 
relies on the presence of eNOS to  convert L-arginine to  NO. This is supported by 
evidence tha t ACh will only stimulate vasodilation in the presence of the vascular 
endothelium (Furchgott, 1980).
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Figure 4.5 Experimental set-up (study 1)
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4.7.3.4 Endothelium-independent vasodilation
Endothelium-independent vasodilation can be assessed by iontophoresing sodium 
nitroprusside (SNP; Nitroprussiat Fides, Reig Jofre Group, Barcelona, Spain). Fifty mg 
of SNP were dissolved in 5 mL of Ringer's solution to produce a 1% SNP solution. Once 
again, 100 pL of this solution were then soaked into the circular sponge on the 
iontophoresis electrode. SNP is a NO-donor, which causes vasodilation w ithout 
involvement o f the vascular endothelium. SNP is cationic and was delivered in four 30- 
second doses, 150 seconds apart, using a current of 0.2 mA-s'1 (Morris & Shore, 1996). 
Blood pressure was measured during each dose on the upper part of the contralateral 
arm.
4 .7.3.5 Offline analysis o f laser Doppler flowmetry scans
Raw LDF recordings were analysed offline using PeriSoft (PeriMed AB, Sweden) after all 
study data had been collected. Areas o f interest were highlighted on each trace and 
averaged using software-based algorithms. Any artefacts assumed to  be caused by 
movement of the participant during data collection were interpolated to  ensure data 
reflected changes in skin blood flow  only.
The ACh traces had eight areas o f interest; one area represented resting skin blood 
flow  and seven "dose" areas followed each iontophoresis dose (indicated by vertical 
event markers on the trace; Figure 4.6). The SNP traces had five areas o f interest; the 
firs t represented resting skin blood flow  and remaining four areas represented peak 
blood flow  after each dose. Resting skin blood flow  was defined as a period >2 min 
before iontophoresis during which blood flow, tota l backscatter and tem perature were 
stable and w ith in range (each dose area was defined as the 30 seconds o f continuous 
recording during each dose/rest cycle, which showed the highest mean blood flow). 
Once each trace was marked up, a report was generated to  calculate mean values for 
each o f the highlighted areas o f interest. Mean values were divided by the mean 
arterial pressure recorded during tha t period to  transform  data into cutaneous 
vascular conductance (CVC) (mV/mmHg).
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Figure 4.6 Example laser Doppler flowmetry recording. Highlighted areas are averaged 
to provide peak perfusion values for each region o f interest for acetylcholine chloride (top) and 
sodium nitoprusside (bottom) iontophoresis. The top trace represents skin blood flow  (in PUs); the 
middle trace shows the tota l backscatter (TB); and, the bottom  trace shows tem perature (°C)
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4.7.4 Quality of life
The EuroQol-5D-3L quality o f life assessment tool assessed health-related quality of life 
(appendix 8). The questionnaire consists of five questions pertaining to m obility, self- 
care, usual activities, pain/discom fort and anxiety/depression. Each question has a 
three-level response indicating no presence, some presence and high presence of 
disability. There is also a visual analogue scale which represents participants' self- 
reported health. It involve interception a 0-100 scale at the appropriate level, w ith 0 
representing worst health state imaginable, and 100 being best health state 
imaginable. Participants were not given any advice about interpreting and completing 
the questionnaire additional to  that included in the official version. On recurring 
assessments, investigators and participants were blinded to  previous responses. This 
tool was registered online w ith EuroQol.
4.7.5 Exercise capacity
Choosing appropriate assessment tools fo r exercise capacity in clinical populations is 
often d ifficu lt because of the m ulti-factorial nature o f disease. Typically, an 
incremental protocol is used tha t starts o ff at a very light intensity and gradually 
increases allowing a large measurable range fo r the test tha t should - if appropriate - 
include the best and worst perform er in the sample.
In a surgical setting, a pre-operative cardiopulmonary exercise test (CPET) is 
increasingly being used to  assess functional capacity in high-risk patient groups. CPET 
performance strongly correlates w ith peri- and post-operative outcomes (Simpson et 
ol., 2009) as exercise increases cardiopulmonary demand in a similar fashion to  major 
surgery. The CPET involves assessment o f expired gas volumes and gas fractions to 
determine the volume of oxygen and carbon dioxide being utilised and produced, 
respectively. These measurements are typically made on a breath-by-breath basis 
during an incremental test on a treadm ill or cycle ergometer. Maximal oxygen uptake 
(^02 m ax ) can be measured if a CPET test is performed to  patient exhaustion, otherwise 
peak oxygen uptake is recorded (\Z02peak)- It is common to  perform maximal tests on a 
cycle ergometer to  reduce the risk of a falling injury or to  wear a harness connected to 
a "dead man's switch" (a pressure sensor tha t instantly stops the treadm ill belt if a 
threshold force is applied to  it - typically if a participant was to lose balance and fall).
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W ith the equipment and expertise required, CPET can be an expensive way to  assess 
functional capacity and simpler tests have been devised.
The Bruce protocol is an incremental treadm ill test devised by Robert A. Bruce (Bruce 
et al., 1963). This protocol was designed to  address the lack o f standardised test to 
investigate cardiopulmonary function in exercising patients. The Modified Bruce 
protocol introduces tw o easier stages before the original firs t stage to  allow even the 
most immobile patients to  safely undertake the test.
The six-minute walk test (6MWT; Balke et al., 1963) utilises a 10-, 20- or 30-metre 
shuttle course which patients are asked to  walk as far as possible at a self-selected 
pace in the allotted six minutes. This is a useful test fo r patients w ith moderate to 
severe physical im pairm ent and requires no specialised equipment or venue. 6MWT 
distances (6MWD) have a moderate-to-high correlation w ith VO2 p e a k  in heart failure 
patients (Faggiano et al., 1997)). Its specificity and u tility  as a clinical tria l endpoint in 
some populations has been questioned (Schoindre et al., 2009).
In this study, exercise capacity was assessed using the incremental shuttle walking test 
(ISWT; Singh et al., 1992). This test involved completing circuits o f a 10 metre shuttle 
course. Shuttle tim ing was dictated by an audio signal broadcast through wall mounted 
speakers. Participants wore a chest-mounted heart rate m onitor (F4, Polar Electro, 
Finland) allowing fo r continuous monitoring during the test. The ISWT was term inated 
under the follow ing conditions:
•  The participant completed the test (102 shuttles, 1020 metres)
•  The participant fell more than 1 metre behind the audio signal fo r tw o 
consecutive shuttles)
•  The participant electively discontinued the test fo r symptoms such as 
breathlessness, fatigue or pain
• The researcher considered the participant to  be having an adverse reaction to 
the exercise stimulus
Participants were asked to  continue to the test fo r as long as possible and encouraged 
to  continue during the la tter stages. The ISWT is more commonly used in COPD 
populations, but has recently been validated in obese OSA patients (Billings et al., 
2013). An alternative test would have been the 20-metre shuttle running test (Leger,
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1982), however this protocol starts at 8 km-h 1 and probably would have exceeded the 
capacity o f the most lim ited participants. Participants were told to use any type of 
locomotion they wished to  maintain pace with the audio signal fo r as long as possible, 
including running. Immediately after the test, heart rate, blood pressure, RPE and the 
primary reason fo r not completing additional stages of the test.
4.8 Statistical analyses
Reseland et al. (2001) reported a significant reduction in body mass index between 
groups over tim e (A -2.1 kg-m'2; P<0.001) using a similar intervention (supervised 
exercise and dietary advice). Using these data a sample size estimate was calculated 
using nQuery; at least 25 participants in each group were required (a= 0.1; (3=80%). As 
we were unsure o f potential dropout rates and the variability of our outcome 
measures we included an additional 20% and aimed to  recruit 60 patients (30 per 
group). A sample size of 60 is fu rther supported by the general rule o f "a t least 30 
participants could be used to  estimate a parameter from  pilot tria ls" referred to in 
Browne (1995) and Lancaster et al. (2004). The sample size calculation in Johansson et 
al. (Johansson et al., 2009) aimed for 30 patients per group, to  detect an im provem ent 
in AHI of 15 events-h'1; although the current study did not assess AHI, we have 
recruited a sample large enough to detect a meaningful improvement. The principal 
reasons for not using AHI as an outcome in the current study was because o f financial 
constraints (the monetary cost of acquiring the necessary equipm ent and 
consumables) and the added inconvenience fo r participants to  make additional, albeit 
brief, visits to  the study centre.
Mean and SD values described continuous variables at all tim e-points. Changes 
between groups over tim e were assessed using ANCOVA using change scores from  
baseline as the dependent variable and group and baseline values as independent 
variables. This model produced an adjusted mean difference tha t accounted fo r the 
impact of variation at baseline. The mean difference in change between groups was 
used as the main treatm ent effect w ith 90% confidence intervals and effect sizes using 
an adapted Cohen's d method (Morris, 2008) were calculated. These confidence 
intervals were compared w ith the estimated minimal im portant difference (MID)
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which was defined as one th ird  o f the pooled standard deviation at baseline (Yost & 
Eton, 2005). Effect sizes >0.33 were considered clinically meaningful. These 
comparisons were attributed qualitative inferences to  facilitate interpretation 
(Batterham & Hopkins, 2006). Key relationships were explored using Spearman's 
correlations; strong relationships were explored fu rther using repeated measures 
within-subjects modelling (Bland & Altman, 1995).
Statistical significance was set at P<0.05. All analyses were done on an in tention-to- 
trea t basis w ith previous observations carried forward where necessary. A per- 
protocol analysis was also done fo r exploratory purposes. Data were analysed using 
the SPSS 21.0 statistical package (SPSS, IBM Corporation, Armonk, NY, USA).
4.9 Reliability of methods
4.9.1 Analysis outline
It is im portant to  assess the reliability o f experimental techniques. This requires 
assessment of both the skill of the investigator in perform ing the measurement and 
the technique itself. The reliability of a technique includes its valid ity (does it measure 
the required variable w ith adequate precision?) and reproducibility (are repeated 
measurements consistent?). Inter-day reproducibility can be assessed. Validity is 
critical fo r novel techniques and measurements will usually be compared to  the 
current state-of-the-art method. Reproducibility can be measured on an inter-day 
intra-observer or inter-observer basis. Both examine the skill of the investigator and 
the form er also assesses the stability o f the measurement, which is especially useful 
fo r measuring biological variables (e.g. cholesterol).
Statistical methods exist to scrutinize re liability using the test-retest method. Intraclass 
correlation coefficient (ICC), coefficient of variation (CV) and technical error o f 
measurement (TEM) were be used to  assess inter-day reproducibility in this thesis.
4.9.2 Results
The reproducibility o f methods used in study one is outlined in Table 4.1. Nine 
participants were tested tw ice at the same tim e o f day approximately seven days 
apart. The reproducibility o f the blood-borne biomarkers investigated in this study was
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not assessed. This was deemed an unnecessary cost because the equipm ent used to 
perform the analysis was in a working hospital laboratory and under goes quality 
control and assurance at m ultip le points through the day. Furthermore, om itting 
repeat blood samples reduced risk to  participants.
Table 4.1 Inter-day intra-observer reproducibility of secondary outcome measures
CV (%) ICC TEM (%)
Body mass (kg) 0.27 1.00 0.4
Stature (cm) 0.07 1.00 0.1
Body fa t percentage (%) 1.85 0.99 2.2
Neck circumference (cm) 0.45 0.99 0.7
Waist circumference (cm) 0.67 0.99 0.9
Hip circumference (cm) 0.65 1.00 0.7
Resting heart rate (b e a tsm in 1) 3.95 0.82 4.6
Systolic BP (mmHg) 1.83 0.89 2.6
Diastolic BP (mmHg) 2.91 0.84 3.8
Post-ex RPE 5.78 0.60 8.2
Post-ex heart rate (beats m in 1) 3.22 0.95 4.2
Post-ex systolic BP (mmHg) 3.92 0.83 7.1
Post-ex diastolic BP (mmHg) 7.57 0.59 9.2
ISWD (m) 4.38 0.97 4.9
CVCREst (ACh; mV/mmHg) 17.8 0.69 17.9
CVCMAX (ACh; mV/mmHg) 25.3 0.33 30.4
CVCREst (SNP; mV/mmHg) 14.5 0.54 17.1
CVCMAX (SNP; mV/mmHg) 26.0 0.61 33.3
BP: blood pressure; ex: exercise; RPE: rating of perceived exertion; ISWD: incremental shuttle 
walk distance; CVC: cutaneous vascular conductance; ACh: acetylcholine; SNP: sodium 
nitroprusside.
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Chapter 5 -  Results
5.1 Baseline characteristics
Sixty patients w ith CPAP-controlled OSAS were recruited from local sleep clinics and 
randomised equally into the intervention group and the control group. Baseline 
characteristics are described in Table 5.1. The intervention group were 56 ± 12 years 
old, 73% male, normotensive (systolic: 127 ± 11; diastolic: 72 ± 8 mmHg) and had a 
BMI o f 40 ± 7 kg-m'2. Similarly, the control group were 55 ± 10 years old, 80% male, 
normotensive (systolic: 132 ± 15; diastolic: 75 ± 9 mmHg) and had a BMI o f 39 ± 7 
kg-m'2.
Despite randomisation there was higher prevalence of coronary artery disease (16 vs. 
3%), ACE-inhibitor usage (23 vs. 13%) and beta-blocker usage (23 vs. 3%) in the control 
group compared w ith the intervention group. Other key comorbidities identified 
during history taking were similar including hypertension (40 vs. 50%), type 2 diabetes 
mellitus (20 vs. 16%) and smoking status (current: 6 vs. 10%; previous: 43 vs. 50%). 
Furthermore, other key medications were also similar (calcium channel antagonists: 20 
vs. 13%; diuretics: 30 vs. 23%; statins: 36 vs. 33%; and, platelet inhibitors: 16 vs. 20%). 
Post-hoc verification of CPAP compliance from  three months prior to  study enrolm ent 
to  the completion of the follow -up assessment was assessed using data from  the CPAP 
machine memory card tha t was downloaded routinely w ith in a year o f the ir 
participation. These data showed tha t although median compliance was excellent 
there were 13 of 60 participants (22%) across both groups who were unexpectedly 
below the compliance threshold despite reporting regular usage (>4 hours per night on 
>75% nights) to  the research team during the screening process (Control: 95 [65, 98]%; 
intervention: 95 [81, 99]% nights>4 hours-night'1).
85
Table 5.1. Baseline characteristics
Control Intervention
Characteristics
Participants (n) 30 30
Age (years) 56 ± 12 55 ± 10
Sex (male/female) 2 2 /8 2 4 /6
Body mass (kg) 118 ± 22 117 ± 24
Stature (cm) 172 ± 8 174 ± 9
Body mass index (kg-rrT2) 40 ± 7 39 ± 7
Resting heart rate (beats-min-1) 65 ± 14 67 ± 11
Systolic blood pressure (mmHg) 127 ± 11 132 ± 15
Diastolic blood pressure (mmHg) 72 ± 8 75 ± 9
CPAP usage (% nights >4h) 95 [65, 98] 95 [81, 99]
Serum cholesterol (m m ol-L1) 4.6 ± 0.9 5.0 ± 1.3
Serum HDL (m m ol-L1) 1.2 ±0.2 1.3 ±0.3
Serum triglycerides (m m ol-L1) 1.8 ±0.7 2.1 ±0.9
Serum LDL (m m ol-L1) 2.7 ±0.7 2.9 ± 1.1
Serum C-reactive protein (mg-L-1) 3.0 ± 2.3 2.9 ± 2.5
Serum glucose (m m ol-L1) 5.7 ± 1.6 5.0 ± 1.1
Serum insulin (mU L 1) 39 ± 39 31 ±30
ISWT distance walked (m) 4 1 4 ± 162 58 8 ± 157
Co-morbidities
Coronary artery disease 5(16) 1(3)
Hypertension 12 (40) 15 (50)
Diabetes 6(20) 5(16)
Current smoker 2(6) 3(10)
Ex-smoker 13 (43) 15 (50)
Medication
Beta-blocker 7(23) 1(3)
ACE inhibitor 7(23) 4(13)
Calcium channel antagonist 6(20) 4(13)
Diuretic 9 (30) 7(23)
Statin 11 (36) 10(33)
Platelet inhibitor 5(16) 6(20)
CPAP: continuous positive airway pressure; HDL: high-density lipoprotein; LDL: low-density 
lipoprotein; ISWT: incremental shuttle walk test; ACE: angiotensin-converting enzyme. Data are 
presented as mean ± SD, median [IQR], or frequency (%)
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5.2 Primary outcome measures - feasibility
5.2.1 Recruitment
In accordance w ith the Consolidated Standards of Reporting Trials (CONSORT) a flow  
chart depicting the flow  of participants through the study is shown in Figure 5.1. Of 
550 patients considered, 69 (12.5%) were overtly unsuitable either not meeting 
inclusion criteria such as BMI (26; 4.7%) or CPAP usage at the last compliance check 
(18; 3.2%), or having comorbid medical conditions tha t compromised participant safety 
or the fide lity  o f results (9; 1.6%). These data were gleaned from  patient files w ith in 
the sleep clinics, including consultation notes and referral letters.
The remaining 481 provisionally eligible patients were form ally invited to  participate. 
123 (25.6%) responded w ith interest. Of these, 35 (28.5%) were ineligible upon further 
screening; including 11 (8.9%) who did not meet the inclusion criteria and 24 (19.5%) 
who met at least one exclusion criterion. Assuming all patients contacted were eligible 
to  participate, our recruitm ent rate was 12.5%. However, pre-enrolm ent medical 
screening during fam iliarisation identified an ineligibility rate o f 28.5%. Inferring this 
rate to  the whole sample, 157 of the 550 patients in itia lly considered would have been 
ineligible. This number of remaining patients inferred to  be eligible (397) used as the 
denom inator to  calculate recruitm ent rate gives an inferred rate o f 15.3%.
Of those interested, 88 (71.5%) were eligible to participate. Twenty patients were 
unable to integrate the demands o f the study into the ir current commitments (e.g. 
employm ent and childcare) and 8 patients became unreachable by the research team. 
The remaining 60 enrolled giving a recruitm ent rate of 15.3%. Recruitment was 
completed w ith in the proposed tim efram e of 18 months.
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Eligible (n=88)
Randomised (n=60)
No response (n=131)
Lifestyle intervention (n=30)
End-point assessment (n=26)
Follow-up assessment (n=27)
Responded w ith interest (n=123)
Usual care (n=30)
End-point assessment (n=24)
Follow-up assessment (n=27)
Sent a recruitment le tter & PIS (n=481)
Responded w ith disinterest (n=227)
Provisionally assessed fo r eligibility (n=550)
W ithdrew from study (n=3) 
Missed assessment w indow (n=3)
W ithdrew from study (n=3) 
Missed assessment w indow (n= l)
Did not enrol (n=28)
Unable to  make time com m itm ent (n=20) 
Became unreachable (n=8)
Ineligible at first pass (n=69)
BMI <30 kg-m (n=42)
Sub-therapeutic CPAP adherence (n=18) 
Co-morbidities (n=9)
Ineligible at second pass (n=35)
BMI < 30 kg-m 2 (n=3)
Sub-therapeutic CPAP adherence (n=8) 
Co-morbidities (n=24)
Figure 5.1. CONSORT flowchart showing the flow  of participants through the study. BMI: body 
mass index; CPAP: continuous positive airway pressure; PIS: participant inform ation sheet
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5.2.2 Retention
Six participants w ithdrew  from  the study (10%) and 54 (90%) completed the follow-up 
assessment (90%). W ithdrawals were evenly split between groups (intervention: 3 vs. 
control: 3). Two participants cited a change in the ir health unrelated to  the ir 
involvement in the study (one participant had recurrence of a previous chronic back 
problem ; brought about by a fall during a weekend and another had acute 
exacerbation of COPD and although these participants wished to  continue they were 
excluded by the research team for safety reasons). Indeed; this made the elective 
dropout rate from  the intervention group one in th irty  (3%). Two participants 
w ithdrew  because of a change in the ir professional commitments (one participant was 
relocated by his employer to  elsewhere in the UK and the other was given an 
alternative position at a d ifferent site making travelling to  the University unfeasible). 
Both participants reported they would not have enrolled had known about the 
impending changes in the ir circumstances. Two participants declined to  provide a 
reason fo r discontinuing the ir participation although they expressed mild 
dissatisfaction at the ir group allocation.
5.2.3 Compliance
Participants in the intervention group who completed the study (n=27) attended 98% 
(79 of 81) o f assessment sessions compared w ith 96% (78 of 81) in the control group 
(n=27). Reasons fo r missing an assessment session included work commitments (n=3) 
and ill health (n=3). The last observed value, when available, was carried forward fo r 
missing data points. The intervention group attended 620 of 648 (96%) University- 
based exercise sessions and completed 312 of 324 (96%) independent exercise 
sessions. Overall compliance w ith scheduled sessions was 96% (777 o f 810).
5.2.4 Safety
In over 650 hours o f supervised exercise and 300 hours o f independent exercise there 
were no reported AEs or SAEs. Participants in the intervention arm occasionally 
reported muscle soreness and jo in t ache resulting from  the exercise. In these 
circumstances the researcher amended the tra in ing stimulus to  prevent fu rthe r
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discomfort and lim it the risk o f long-term injury w ithout, where possible, reducing the 
load.
5.3 Secondary outcome measures -  efficacy
Changes in continuous variables were assessed using ANCOVA w ith the dependent 
variable set as the change score between tim e-points (e.g. delta fo llow -up is equal to 
follow -up score minus baseline score). Scatter plots and histograms were subjectively 
assessed to  evaluate the assumptions of linearity, independence, homoscedasticity 
and normality as outlined in chapter 4.
5.3.1 Anthropometry
Data fo r anthropom etric outcome measures are shown in Table 5.2. There was a 
modest reduction in body mass from  baseline in the intervention group compared w ith 
the control group at 13 weeks (A -2 [-3, -1] kg; P=0.007) and 26 weeks (A -2 [-3, -1] kg; 
P=0.010). The MID for changes in body was estimated as ±7.7 kg (Table 5.3) - 
comparison of the 90% Cl o f the change between groups over tim e suggests tha t the 
change, albeit statistically significant, was not clinically meaningful (Figure 5.2). 
Moreover, the effect sizes fo r changes at end-point and fo llow -up were very small 
(d=0.08 and d=0.09, respectively). There were also significant reductions in percentage 
body fat, which was reduced by 1% ([-1, 0]; P=0.002; cf=0.12) at end-point; this 
improvement was maintained at fo llow -up (A -1 [-1, 0] %; P=002; d=0.14). Similar 
observations were also made fo r changes between groups over tim e fo r hip 
circumference (A -2 [-3, 0] cm; P=0.026; d=0.13; clinically trivial) at fo llow -up. Changes 
in hip circumference at 13 weeks were not significant (P=0.102; d=0.07) and deemed 
clinically trivia l. There were no changes in neck circumference and waist circumference 
at end-point or fo llow -up (all P>0.05, d<0.20 and deemed clinically trivia l). In addition 
to  changes in body mass, changes in all o ther anthropom etric outcomes were also 
deemed trivial (Figure 5.2).
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Table 5.3 Distribution-based minimal important differences
Baseline SD pooled MID Direction of improvement
Body mass (kg) 23.1 7.7 4,
Body mass index (kg-rrf2) 6.9 2.3 4,
Body fat (%) 8.3 2.8
Neck circumference (cm) 4.5 1.5 4/
Waist circumference (cm) 15.0 5.0 4/
Hip circumference (cm) 14.6 4.9 4,
Heart rate (beats-m in1) 12.2 4.1 4,
Systolic blood pressure (mmHg) 12.9 4.3 4,
Diastolic blood pressure (mmHg) 8.1 2.7 4,
Serum cholesterol (mmol-L'1) 1.1 0.4 4,
Serum HDL (m m ol-L1) 0.3 0.1 t
Cholesterol to HDL ratio 0.7 0.2 4,
Serum triglycerides (m m ol-L1) 0.8 0.3 4,
Serum LDL (mmol-L'1) 0.9 0.3 4,
Serum C-reactive protein (mg-L1) 2.4 0.8 4,
Serum glucose (m m ol-L1) 1.4 0.5 4/
Serum insulin (mU-L1) 35.4 11.8 4/
HOMA-IR 11.7 3.9 4,
EQVAS 17.6 5.9 t
ISWD (m) 159.7 53.2 t
HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: homeostatic model 
assessment fo r insulin resistance; EQVAS: EuroQol visual analogue scale; ISWD: incremental shuttle 
walk distance; SD: standard deviation; MID: minimal im portant difference. Data based on the 54 
completing participants.
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3Mass BMI PBF Neck Waist 
Variable
Hip
Mass BMI PBF Neck Waist
Variable
Figure 5.2. Changes in anthropometries Comparison of the 90%
confidence interval fo r the change between groups over time against the 
distribution-based minimal im portant difference (MID) at end-point 
(above) and follow-up (below). Green refers to beneficial change; yellow as 
trivial change; and, red as harmful change. BMI: body mass index; PBF: 
percentage body fat.
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5.3.2 Cardiovascular risk
There were no statistical or clinically meaningful changes in systolic or diastolic blood 
pressure at end-point (P=0.547 and P=0.590) or follow-up (P=0.893 and P=0.589). Nine 
patients could not provide blood samples because of poor venous access. Of samples 
collected from 51 participants, eight individuals had raised CRP (>10 mg-L"1) at one or 
more time-points. Those with raised CRP had their complete blood panel at all time- 
points excluded (as specified a priori) and the remaining 43 complete data-sets were 
included in the analysis (21 control; 22 intervention). Three patients provided a small 
sample at one or more time-points which was insufficient for the insulin assay and 
therefore insulin was measured in 40 participants (20 control; 20 intervention). At 
baseline, both groups were classified as eucholesterolaemic, euglycaemic and 
hyperinsulinaemic.
There were no statistically significant changes in serum cholesterol or HDL at end-point 
or follow-up (Table 5.4). These data also had trivial effect sizes. However the 
cholesterol to HDL ratio increased by 0.2 [0, 0.4] at end-point and 0.1 [0, 0.3] at follow- 
up, as evidenced by small effect sizes (d=0.30 and d=0.27, respectively). Comparison of 
the 90% confidence interval of the change with the MID suggested a possibly harmful 
effect of the intervention (Figure 5.3). However, these changes were not statistically 
significant (P=0.167 and P=0.205, respectively) and could be attributed to chance. 
There were no changes in LDL at end-point or follow-up, or for serum triglycerides at 
end-point or follow-up.
CRP was significantly lower at end-point (A -1.3 [-2.2, -0.3] mg-L'1; P=0.028) and was 
deemed to be a moderate effect (cf=0.53). This reduction was maintained at follow-up 
(A -1.3 [-2.3, -0.3] mg-L1; P=0.037) along with the estimate of the effect size [d=0.52). 
Intervention-induced changes in CRP were deemed to be possibly beneficial by 
comparing the confidence interval for the change with the MID (Figure 5.3).
Serum glucose was also reduced at end-point and follow-up (A -0.3 [-0.8, 0.1] mmol-L'1, 
and A -0.3 [-0.8, 0.2] mmol-L'1, repectively). These changes were classified as non­
significant using traditional hypothesis testing (P=0.224 and P=0.267, respectively) 
although the effect size estimates were small (both d=0.24). Serum insulin 
measurements had a large variability at all time-points with the standard deviation
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often being similar in magnitude to  the mean. There were no significant changes 
between time-points, however changes at end-point and follow-up had small effect 
sizes in a positive [d=0.22) and negative direction (c/=-0.20), respectively. Changes in 
glucose and insulin were deemed to be probably triv ia l but possibly beneficial at end­
point. At follow-up changes in glucose were still possibly beneficial and changes in 
insulin had become probably trivial, but possibly harmful.
The HOMA-IR scores fo r insulin resistance did not changed baseline and end-point (A -
1.2 [-6.9, 4.4]; P -0.720) although this modest reduction was associated w ith a small 
effect size (d=0.33). The beneficial effect was lost at fo llow -up (A -1.8, -14,11; P=0.808; 
d=0.03). Improvements in HOMA-IR at end-point were probably trivia l, and changes at 
end-point were unclear as the confidence interval fo r the change between groups over 
tim e spanned the harmful, trivia l and beneficial regions of the graph.
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Figure 5.3 Changes in blood-borne biomarkers Comparison of 
the 90% confidence interval fo r the change between groups over time 
against the distribution-based minimal im portant difference (MID) at end­
point (above) and follow-up (below). Green refers to beneficial change; 
yellow as trivial change; and, red as harmful change. Choi: cholesterol; 
HDL: high-density lipoprotein; C:H: cholesterol to  HDL ratio; Trigs: 
triglycderides; LDL: low-density lipoprotein; CRP: C-reactive protein; 
HOMA: Homeostatic model assessment fo r insulin resistance
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5.3.3 Vascular function
Changes in skin blood flow  in response to iontopheretic ACh and SNP delivery are 
depicted in Figure 5.4 and Figure 5.5, respectively. There were no significant between- 
group differences fo r resting or maximal cutaneous vascular conductance at any tim e- 
point (all P>0.05). Similarly, there were no significant w ithin-group changes fo r resting 
or maximal CVC at end-point or follow-up. There was a large amount o f variability in 
measurements at all tim e-points, w ith the standard deviation being equal to  33 ± 6% 
o f the mean value fo r resting observations and 68 ± 20% o f the mean fo r all dosed 
observations.
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Figure 5.4 Cutaneous vascular conductance (CVC) during ACh iontophoresis.
CVC at rest and in response to seven incremental doses of acetylcholine chloride (ACh) 
iontophoresis at baseline (blue), end-point (red) and follow-up (green) fo r the control group 
(above) and intervention group (below). Data presented are means w ith SD error bars
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Figure 5.5 Cutaneous vascular conductance (CVC) during SNP iontophoresis.
CVC at rest and in response to four incremental doses of sodium nitroprusside (SNP) 
iontophoresis at baseline (blue), end-point (red) and follow-up (green) fo r the control group 
(above) and intervention group (below). Data presented are means w ith SD error bars
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5.3.4 Quality of life
There were no significant changes in four o f the five health domains of the EQ-5D 
survey at e ither tim e-po in t (Table 5.5). There was improvement in the proportion of 
patients reporting less problems perform ing usual activities (such as vacuuming or 
shopping; P=0.044). There was no significant change in self-perceived health (EuroQol 
visual analogue scale; EQVAS) score at end-point (A 3 [-3, 9]; P=0.385; cf=0.17). Despite 
this, there was a significant improvement in EQVAS at fo llow -up o f 9 [3, 14] points 
(P=0.017) tha t was associated w ith a small-to-moderate effect size (d=0.49). The 
change at end-point was deemed probably trivial and at follow -up was probably 
beneficial (figure 5.6).
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Table 5.5 EQ-5D Quality of life outcomes
Change at end-point Change at follow-up
Domain Change Control Intervention P Control Intervention P
M obility Worse 1(3.3) 2 (6.7) 0.099 0(0) 1(3.3) 0.273
Same 28 (93.3) 22 (73.3) 28 (93.3) 24 (80.0)
Better 1(3.3) 6 (20.0) 2(6.7) 5 (16.7)
Self-care Worse 3(10.0) 1(3.3) 0.509 3 (10.0) 0(0) 0.205
Same 26 (86.7) 27 (90.0) 25 (83.3) 28 (93.3)
Better 1(3.3) 2(6.7) 2(6.7) 2(6.7)
Usual activities Worse 5(16.7) 1(3.3) 0.044 3 (10.0) 3 (10.0) 0.375
Same 24 (80.0) 23 (76.7) 24 (80.0) 20 (66.7)
Better 1(3.3) 6(20) 3 (10.0) 7(23.3)
Pain & Worse 2(6.7) 2(6.7) 0.936 2(6.7) 3 (10.0) 0.697
discomfort Same 24(80.0) 23 (76.7) 23 (76.7) 24 (80.0)
Better 4(13.3) 5 (16.7) 5(16.7) 3 (10.0)
Anxiety & Worse 1(3.3) 2(6.7) 0.838 6(20.0) 2(6.7) 0.260
depression Same 25 (83.3) 24 (80.0) 19 (63.3) 24 (80.0)
Better 4(13.3) 4(13.3) 5(16.7) 4 (13.3)
Data presented are count (percentage)
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5.3.5 Exercise capacity
The intervention group lowered resting heart rate by 6 beats per minute compared to  
the control group at end-point (A -5 [-8, -3] beats-min P=0.002; Table 5.6), which was 
deemed possibly beneficial and a small effect (d=0.46). The magnitude of change from 
baseline was reduced at follow-up, no longer statistically significant (A -2 [-5, 1] 
beats-min"1; P=0.165; d=0.27) and considered almost certainly trivial.
Although data were collected fo r all participants, seven post-ISWT datasets (post­
exercise RPE, SBP, DBP, HR and ISWD) were excluded because the participant walked 
the entire 1020 metres at one or more tim e-points (four at baseline and three at end­
point). This ceiling effect was unexpected and dilutes the true treatm ent effect -  
consequently these patients were excluded from  the analysis.
Despite randomisation there was a large difference between groups at baseline fo r 
distance walked in the ISWT (164 m; 639 vs. 475 m; Table 5.1). The increased exercise 
capacity o f the intervention group was also reflected in baseline post-exercise 
measurements of heart rate (148 ± 21 vs. 131 ± 28 beats-min'1) and blood pressure 
(systolic: 192 ± 31 vs. 169 ± 29 mmHg; diastolic: 93 ± 11 vs. 86 ± 15 mmHg). Despite 
this, the perceived exertion from  participants was equal (15 ± 2 vs. 15 ± 2). ISWD 
improved by 94 [58, 132] m (P<0.001) at end-point and by 132 [97, 168] m (P<0.001) at 
follow-up (Figure 5.7). These improvements were associated w ith moderate {d=0.58) 
and large (d=0.82) effect sizes, respectively. Additionally, comparing the 90% 
confidence interval fo r the change w ith the estimated MID suggests tha t changes at 
end-point and follow-up are almost certainly beneficial. Changes in ISWD were in the 
absence of any significant changes in post-exercise physiological measures (heart rate, 
systolic blood pressure and diastolic blood pressure) or perceived exertion (RPE) at 
both end-point and follow-up (all P>0.05) when the improvement in ISWD was used as 
a covariate. Despite no significance small effect sizes were identified fo r changes in 
post-exercise RPE at end-point (A 0.6 [-0.4, 1.7]; P=0.303; d -0.32) and post-exercise 
heart rate at fo llow -up (A -5 beats-min"1 [-14, 4]; P=0.335; cM).21).
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Ex RPE Ex HR Ex SBP Ex DBP ISWD EQVAS
Variable
Ex RPE Ex HR Ex SBP Ex DBP ISWD EQVAS
Figure 5.6 Changes in ISWT data and EQVAS
Comparison of the 90% confidence interval fo r the change 
between groups over tim e against the distribution-based 
minimal im portant difference (MID) at end-point (above) and 
follow-up (below). Green refers to beneficial change; yellow as 
trivial change; and, red as harmful change. Ex RPE: post-ISWT 
rating of perceived exertion; Ex HR: post-ISWT heart rate; Ex 
SBP: post-exercise systolic blood pressure; Ex DBP: post-ISWT 
diastolic blood pressure; ISWD: incremental shuttle walk 
distance; EQVAS: EuroQol visual analogue scale
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Figure 5.7 Changes in incremental shuttle walk distance (ISWD) Line 
plots showing changes in ISWD for the control group (blue) and the intervention 
group (red) over the course of the study. Intervention ISWD have been adapted to 
reflect the differences reported in ANCOVA. +: difference between groups; *: 
significant between groups change from baseline (P<0.001)
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5.3.6 Correlations
Bivariate correlations were assessed on change scores fo r key outcome variables. 
Weak correlations were identified between delta scores fo r BMI and percentage body 
fa t (rs=0.339; P=0.016), ISWD and percentage body fa t (rs=-0.308; P=0.045) and ISWD 
and EQVAS score (rs=0.344; P=0.024) at end-point (Table 5.7). Moderate relationships 
were also identified between delta scores fo r ISWD and BMI (rs=-0.628; PcO.OOl), CRP 
and resting heart rate (rs=0.415; P=0.012) and peak skin blood flow  and resting skin 
blood flow  during the ACh protocol (rs=0.361; P=0.010).
Table 5.7. Correlation coefficients for key variables at end-point
A scores fo r variable 1 at end-point
BMI PBF HR EQVAS CRP Glucose ISWD AChREST AChPEAK
BMI 1.000 .339* .166 .056 .125 -.110 -.628+ -.203 -.039
c
o
CL
PBF 1.000 .139 .013 -.151 -.240 -.308* -.098 .253
T3
C
QJ
HR 1.000 -.126 .415* .100 -.193 -.142 -.008
+-<ro
CM
EQVAS 1.000 -.091 -.219 .344* .153 .094
_QJ
.aro CRP 1.000 .168 -.064 .138 .110
ro> Glucose 1.000 .024 .118 -.024
O*+-
to
ISWD 1.000 .243 .099
ajL_oo AChREST 1.000 .361*
< AChPEAK 1.000
A: change; BMI: body mass index; PBF: percentage body fat; HR: heart rate; EQVAS: EuroQol visual 
analogue scale; CRP: C-reactive protein; ISWD: incremental shuttle walk distance; AChREST: resting skin 
blood flow  before ACh iontophoresis; AChPEAK: peak skin blood flow  during ACh iontophoresis. +: 
PcO.OOl; *: P<0.05. Data presented are Spearman's coefficient
Correlations between changes in key variables at fo llow -up are displayed in Table 5.8. 
A significant moderate correlation was identified between changes in percentage body 
fa t and BMI (rs=0.443; P=0.001). Changes in resting heart rate at end-point were 
weakly correlated w ith changes in BMI (rs=0.324; P=0.017) and percentage body fat 
(rs=0.291; P=0.033). Changes in CRP at fo llow -up were correlated w ith BMI (rs=0.367; 
P=0.023). Changes in ISWD had a m oderate-to-strong correlation w ith  changes in BMI 
(rs=-0.642; PcO.OOl) and a moderate correlation w ith changes in percentage body fat 
(rs=-0.423; P=0.003). Changes in resting skin blood flow  had a strong correlation w ith
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changes in CRP (rs=0.465; P=0.003) and changes in peak skin blood flow were weakly 
correlated with changes in percentage body fat (rs=0.276; P=0.044) and moderately 
correlated with changes in resting skin blood flow.
Table 5.8. Spearman correlation coefficients for key variables at follow-up
A scores for variable 1 at follow-up
BMI PBF HR EQVAS CRP Glucose ISWD AChREST AChPEAK
Q .
BMI 1.000 .443+ .324* -.162 .367* .146 -.642+ -.126 -.097
3
5 PBF 1 . 0 0 0 .291* -.086 .174 .269 -.423+ .038 .276*
_o
O HR 1 . 0 0 0 -.160 -.025 .093 -.104 -.079 -.183
4->
03
fN EQVAS 1 . 0 0 0 .260 -.176 .283 .017 -.096
03
-Q
ro
CRP 1 . 0 0 0 .254 -.216 .465+ .223
03> Glucose 1 . 0 0 0 -.200 .266 .093
* 8
to
03t_
o
u
ISWD 1 . 0 0 0 -.114 -.068
AChRESj 1 . 0 0 0 .445+
< AChPEAK 1 . 0 0 0
A: change; BMI: body mass index; PBF: percentage body fat; HR: heart rate; EQVAS: EuroQol visual 
analogue scale; CRP: C-reactive protein; ISWD: incremental shuttle walk distance; AChREST: resting skin 
blood flow before ACh iontophoresis; AChPEAK: peak skin blood flow during ACh iontophoresis. +: 
P<0.001; *: P<0.05. Data presented are Spearman's coefficient
The strong relationships between ISWD and EQVAS, BMI and ISWD, and BMI and CRP 
were explored further using repeated measures within-subjects modelling. The 
correlation coefficients for the control group were 0.04 (P=0.774), -0.35 (P=0.008) and 
-0.08 (P=0.589), respectively, and for the intervention group were 0.54 (P<0.001), -0.74 
(PcO.OOl) and 0.14 (P=0.334), respectively.
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Chapter 6 -  Discussion
6.1 Overview
This research study aimed to  investigate the feasibility of a pragmatic lifestyle 
intervention in patients being treated fo r OSAS. A secondary aim was to  collect 
prelim inary evidence on effects o f the intervention on im portant health outcomes. The 
main finding o f this study was tha t the intervention was feasible, evidenced by more 
than a quarter o f those invited to participate showing interest in taking part, and those 
who took part being extremely compliant w ith the commitments o f the study. This 
study also demonstrated prelim inary evidence on the efficacy o f the in tervention; 
there were substantial improvements in exercise capacity and markers o f systemic 
inflammation, however there were only modest improvements in body mass and 
composition. Changes in exercise capacity, systemic inflammation and body mass were 
maintained after a 3 months period o f independence, which suggests tha t the benefits 
of the intervention extended beyond the period o f supervision. Reductions in body 
mass of approximately 2 kg suggest tha t the dietary component o f the intervention 
was ineffective and inadequate. Similarly, there were no meaningful changes in tota l 
serum cholesterol evoked by the intervention.
Moreover, all study procedures were completed in the absence o f any adverse events 
(serious or otherwise) suggesting tha t the lifestyle intervention was safe to  deliver. The 
intervention had a favourable impact on metrics o f exercise capacity and systemic 
inflammation tha t were maintained at follow-up after a 12 week period of 
independence, although modest reductions in body mass were disappointing. These 
findings suggest tha t lifestyle interventions based on supervised exercise in OSAS 
require fu rthe r investigation to  maximise efficacy fo r weight loss and assess cost- 
effectiveness.
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6.2 Characteristics
The characteristics of the recruited sample are in agreement w ith other studies in this 
population and w ith widely accepted prevalence rates. Our sample were obese w ith a 
mean BMI o f 40 kg-m'2 -  obese individuals constitute an estimated 70% of OSAS 
patients (Malhotra et al., 2002) suggesting our sample was representative o f the 
m ajority o f OSAS patients. Similarly, despite not stratifying recruitm ent fo r age or sex, 
our sample had a mean age of 55 years and largely consisted of men (77% male). 
These characteristics match the typical OSAS patient which is thought to  be a late 
middle-aged man. The cardiovascular risk profile was also matched to tw o recent 
studies: mean resting blood pressure was 132/75 mmHg (compared w ith 126/77 
(Barnes et al., 2009) and 130/80 mmHg (Tuomilehto et al., 2010); fasting serum 
cholesterol was 4.8 mmol-L'1 (compared w ith 5.3 (Barnes et al., 2009) and 4.6 mmol-L'1 
(Tuomilehto et al., 2010); and, fasting glucose was 5.4 m m ol-L1 (compared w ith 6.1 
(Barnes et al., 2009) and 6.2 mmol-L'1 (Tuomilehto et al., 2010). Although these data 
themselves do not suggest elevated cardiovascular risk, many participants were 
undergoing pharmacological therapy to  manage conditions such as hypertension and 
hypercholesterolaemia. These proportions were nineteen and th irty -five  per cent, 
respectively.
6.3 Feasibility
We recruited the target sample o f sixty patients w ith in  the proposed tim efram e of 18 
months. This recruitm ent was done mostly in batches o f between 8 and 20 patients. 
The main factor affecting the number o f patients recruited per batch was the 
maximum number of patients (specifically in the intervention arm) tha t the researcher 
could accommodate on the study at any one tim e. This was deemed to  be 
approximately 10 staggered over a recruitm ent w indow of up to  six weeks. Other 
lim iting factors included availability of laboratory space (to conduct assessment 
sessions) and of the researcher (who had other study-related activities to perform ). It 
is w orth noting that although availability o f the University-based exercise facility  did 
not directly impact recruitm ent during the course of this tria l, if the tria l had not
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conveniently coincided w ith down-tim e in other studies that this may have been an 
issue. Although personnel is a factor easily addressed in future trials, the size and 
shared nature of the facility are more rigid lim iting factors and should be 
acknowledged.
To recruit the required number of participants a tota l o f 481 recruitm ent packs were 
posted to  participants. These participants were identified using patients' clinic notes 
and three basic criteria (BMI, CPAP compliance and general health) by a member of 
the primary care team. These notes were readily available (stored on-site, not w ith in 
patients' main notes packet) and allowed fo r a rapid initial assessment o f suitability 
(less than 2 minutes per patient). The reviewed documents typically included a le tter 
from  the referring physician, which usually summarised the patients' health 
background and clinical picture, and the previous annual clinic assessment sheet (that 
usually included BMI and the last CPAP compliance data). An alternative method of 
screening would be to  review patients' full notes, which undoubtedly would o ffer a 
much clearer clinical picture of the patients. However the tim e and e ffo rt this would 
require was considered too labour intensive fo r the firs t stage of the recruitm ent 
process and rejected in preference of basic screening. The underreporting of feasibility 
and pilo t studies in peer-reviewed medical journals means there is very little  evidence 
fo r the advantages and disadvantages o f d ifferent screening methods when recruiting 
OSAS patients. Typically in studies tha t report outcome measures, very little  if any of 
the published manuscript is dedicated to  the description and discussion of recru itm ent 
methods used. Recruitment to  clinical trials is often considered to  be the ra te-lim iting 
step fo r the progression o f a study w ith one review reporting only 31% of studies 
achieved the ir initial recruitm ent rate, despite over half having conducted a p ilo t study 
beforehand (McDonald et al., 2006). Indeed, evidence suggests tha t patients are not 
averse to  participating in such research and tha t they understand the importance of 
these studies and the ir role in improving healthcare (Jenkins et al., 2010); poor 
recruitm ent is likely to  be borne out o f discontent of the procedures involved (e.g. 
anything uncomfortable) or logistical issues (e.g. travelling to  and from  the research 
centre and taking tim e o ff work). Recruitment in this study was completed 
independent of routine sleep clinic activities such as annual compliance checks, which 
could have provided an ideal avenue fo r recruitm ent. It is recommended tha t fu ture
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studies try  to  utilise the routine clinical activities of the sleep departm ent to facilitate 
the recruitm ent process. It is also possible tha t patients could be more motivated to 
change lifestyle behaviours after receiving lifestyle advice in sleep clinic appointments, 
especially if such advice is delivered after demonstrating weight gain in the patient 
since the previous appointment. The effects o f such lifestyle advice w ith the provision 
of support have not yet been investigated.
Using the basic screening approach, 69 of 550 patients were overtly unsuitable, mostly 
due to  patients' last BMI measurement being significantly lower than the study entry 
criteria. The screening threshold was BMI>28 kg-rrf2, which although lower than tha t 
required fo r study entry, allowed patients w ith "borderline" obesity (BMI>30 kg-rrf2) to  
still be offered the opportun ity to participate. It is possible tha t the measurements 
were inaccurate or tha t patients had experienced weight gain since then making them  
potentia lly eligible. It was considered unlikely tha t patients below the 28-kg-rrT2 
threshold could have gained enough weight fo r inclusion. Also, borderline CPAP 
compliances were used on the premise tha t usage may have increased follow ing 
encouragement from  respiratory physiologists to  improve wherever possible. Eighteen 
patients were not invited to  participate because of a sustained pattern of low 
compliance over several years w ith no reason to  suspect recent improvement. Only 
nine patients (1.6%) were excluded for obvious comorbidities tha t contraindicated 
participation -  a proportion much lower than tha t encountered fu rthe r down the 
recruitm ent tree (19.5%). These data suggest tha t a more thorough pre-invitation 
screening would reduce the number of ineligible patients in itia lly approached (and 
improve the recruitm ent rate accordingly), however the additional tim e this would 
take and the benefit it would bring should be considered.
Two recruitm ent rates were reported; 12.5% and 15.3%. The form er is the actual 
recruitm ent rate and the latter is the recruitm ent rate from  those patients inferred to 
be eligible. These rates are similar to  recruitm ent rates experienced by similar 
intervention studies from  our centre (Tew et al., 2009; Bourke et al., 2011; Tew et al., 
2012) and studies in other populations w ith high cardiovascular risk (Courneya et al., 
2003; Sniehotta et al., 2011). Moreover, many of the exclusions fo r contraindicative 
com orbidity were fo r safety reasons and it is possible some of these could have been 
included in a clinical environment w ith medically-trained staff close at hand. This
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would raise the recruitm ent rate closer to  20%. These recruitm ent rates are incredibly 
similar to  other exercise-based RCTs in OSAS. Ackel d'Elia et al. (2011) reported a 
recruitm ent rate of 19.3% (47 of 244 patients invited to  take part in the ir exercise 
intervention), Kline et al. (2011) recruited 43 of 400 patients (recruitm ent rate of 
10.8%) invited to  participate in the ir tria l via via telephone or mail, and, Tuom ilehto et 
al. (Tuomilehto et al., 2009) recruited 12.9% (81 of 627) o f patients onto the ir tria l. The 
comparable studies report a range of between 10 and 20% into which both o f our 
recruitm ent rates can be found. In most studies o f this kind, ours included, participants 
have been self-selected (i.e. they have opted to  enrol on the study, knowing tha t they 
were free to w ithdraw  at any tim e w ithout providing a reason). Although we did not 
collect data on the psychological, social or economic characteristics o f our sample, the 
physiological characteristics seem matched to  the typical OSAS population, and 
therefore our findings are likely generalisable. It is possible tha t the characteristics of 
patients enrolling onto OSAS intervention studies do so fo r one or more of the 
fo llow ing reasons: patients motivated to  lose weight or improve fitness; patients w ith 
ample tim e and nothing else to  do; patients who previously enjoyed exercise and 
wanted an opportun ity to  get into in; particularly health-conscious patients who 
enrolled on a clinical tria l fo r a thorough personal health assessment; and patients who 
have had a positive treatm ent experience and want to  "give something back" to  the 
field. Although these ideas are conjecture, there is no evidence in OSAS to  suggest 
which facilitating factors determine whether a patient enrols, or does not.
Participant retention was excellent w ith  90% of participants completing the study. Of 
the six withdrawals, two were fo r changes in health status unrelated to  the study. 
These participants were both in the intervention arm of the tria l and were reluctant to 
w ithdraw  themselves. They were excluded by the study researcher a fter reporting 
problems which could be exacerbated by the demands of the study. Two patients from  
the control arm were unable to attend the end-point or follow-up assessments due to  
changes in the ir professional commitments which made attending the University 
during working hours unfeasible. These participants enquired about the possibility o f 
weekend assessments however this was not possible. Both participants adm itted they 
would not have enrolled if they had been aware of the impending change in 
circumstances. Two participants declined to  provide a reason fo r w ithdrawal but both
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had expressed obvious disappointment to  the ir randomisation. For the firs t four 
dropouts it is encouraging tha t none reported any aspect of the study as the reason fo r 
w ithdrawal. This lends considerable fu rthe r evidence tha t the intervention was 
acceptable fo r OSAS patients. Retention rates in tw o similar studies were similar; Kline 
et al. (2011) retained 38 of 43 participants (88%) and Tuomilehto et al. (2009) retained 
89% o f the ir participants. The retention results fo r Ackel-d'Elia et al. (2011) were less 
convincing; only 13 of 25 participants randomised to  the exercise arm of the tria l, and 
32 of 47 participants enrolled on the tria l, completed the study. This equates to 
retention rates of 52 and 68%, respectively. The authors did not discuss these low 
rates beyond suggesting tha t the less motivated individuals w ithdrew  from  the study. 
Participant w ithdrawal can provide researchers w ith key inform ation to  project 
whether any particular part of the study protocol influenced the staying power, and 
how the intervention might be accepted in a clinical setting. Our data, coupled w ith 
tha t from  tw o similar studies (Tuomilehto et al., 2009; Kline et al., 2011) suggest tha t 
OSAS patients who show interest and enrol onto a lifestyle intervention are likely 
comply w ith its requirements.
Compliance to  study activities was also excellent w ith >95% mean average attendance 
fo r assessment sessions, University-based and home-based exercise sessions. This is 
especially encouraging as 38 participants (63%) were in part- or fu ll-tim e employment. 
Only one similar study has reported compliance w ith study activities; in the study by 
Kline et al., 87 ± 2% of intervention appointments were kept (Kline et al., 2011). This 
percentage is in keeping w ith the current study. These data not only suggest tha t 
patients fe lt they could integrate such an intervention into the ir daily routine, but tha t 
there may have been provision from  the ir employers to  participate (some participants 
described corporate Wellness programs designed to  offer flexible working 
arrangements fo r health-promoting activities). Patients were offered sessions at times 
to  suit the ir preference in the same manner as the NHS Choose and Book system 
(www.chooseandbook.nhs.uk). Some participants preferred sessions before or after 
the ir working day, some worked shift patterns and attended d iffe rent times on 
d ifferent days each week and some utilised flexi-tim e. Participants were offered a 
long-term on-site parking perm it which most reported as being a great fac ilita to r of 
participation as on-street parking near our facility is especially challenging during the
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day. Compliance on this study compares favourably w ith other studies from  our centre 
suggesting tha t our participant-focussed approach promotes adherence. Additionally, 
the provision of a reasonably private non-commercial facility to  conduct exercise in 
likely promoted adherence. Many participants described the ir apprehension towards 
introducing exercise into the ir lives w ithout the support we provided and tha t they 
considered public gymnasiums an intim idating place. They also reported concern that 
in a non-research setting they w ou ldn 't know what to  do -  which they fe lt could cause 
embarrassment.
Our intervention involved a substantial time com m itm ent both at the University and at 
home. The form er required travel to  and from  the University which was subsidised at 
£2.50 a visit, irrespective o f the distance travelled or actual costs incurred. This post­
study reimbursement was likely insufficient to cover costs fo r most participants 
(except those eligible fo r free bus travel). This reduces the likelihood tha t participation 
and compliance were influenced by financial means. Sheffield is a sprawling city w ith a 
large catchment area fo r its hospitals -  o f all participants recruited onto the 
intervention, the furthest afield lived 50 miles away (estimated fastest route) and 
attended 100% of study commitments (balanced w ith married life and fu ll-tim e  
employment).
We investigated the u tility  o f using patients' self-reported CPAP compliance to  
determine e lig ib ility for participation using post hoc verification from  CPAP compliance 
data downloaded from  CPAP machines at the annual review follow ing the end o f the 
study. Although median usage was excellent in both groups, 13 of 60 patients were 
unexpectedly below the inclusion threshold. As participants were not actively 
encouraged to maintain high CPAP usage during the tria l it is possible tha t the purpose 
of the study was misunderstood and patients electively discontinued or reduced the ir 
CPAP therapy. As this was a post-study observation, and completely unexpected, the 
reasons fo r inadequate were not recorded and all patients were still included in the 
analyses. We recommend using up-to-date objective CPAP data to  assess e lig ib ility  in 
fu ture  studies and that continuous encouragement to use CPAP regularly and 
education on its importance be incorporated into any interventions. This could pose 
equipment- and software-related lim itations fo r centres such as ourselves where the
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bulk of research activities take place in a university setting; research centres in 
hospitals should find this straightforward. Moreover, the results of other studies tha t 
have used self-reported compliance w ith CPAP as an inclusion criterion should be 
treated w ith trepidation. An alternative strategy could be to introduce a lag period 
between enrolm ent and randomisation to specifically observe patients CPAP habits, as 
described by Ueno et al. (2009).
6.4 Efficacy
6.4.1 Anthropometry
There were modest reductions in body mass at intervention end-point o f 
approximately 2 kg (less than 2% of original body mass) tha t were maintained at 
follow-up. Although much greater weight loss has been reported in tria ls using VLEDs, 
most intervention studies (especially those w ith an exercise focus) have reported 
lim ited weight loss. This contributes to  a growing body of evidence tha t the weight loss 
is a greater challenge in the OSAS population than in BMI-matched non-OSAS 
counterparts.
The increased physical activity caused by high compliance w ith the exercise aspect of 
the study w ithout accompanying marked weight loss could be explained by a 
compensatory increase in energy intake to  counter increased energy expenditure. 
Although we identified this as a key point in the dietary advice aspect o f the behaviour 
change counselling, it seems the delivery may have been ineffective or the adoption 
low. Another strategy investigated in this study was the efficacy of dietary advice and 
behaviour change counselling delivered by an exercise physiologist. Typically these 
aspects are delivered by individuals w ith specialist training and expertise; however 
w ith three specific aspects to  the intervention (dietary support, exercise tra in ing and 
behaviour change counselling) it was not feasible to  use a multidisciplinary team. Such 
an approach would have reduced the pragmatism of the study and complicated its 
delivery in a healthcare setting. The improvements in exercise capacity at end-point 
and follow-up and the absence of a detraining response suggest tha t the exercise 
aspect and exercise behaviour change aspect were effective. Unfortunately, the
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present study lacks supportive empirical data such as actigraphy or qualitative data 
such as the Godin Leisure Score Index.
A previous research study in our centre included fortn igh tly  healthy eating seminars in 
a pilo t study tha t investigated lifestyle intervention in men w ith prostate cancer 
undergoing androgen deprivation therapy (Bourke et al., 2011). These researchers 
reported a 241 kcal reduction in daily energy intake (based on a four day diet diary) in 
the intervention group. The present study did not conduct post-intervention diet 
diaries, nor did it assess diet diaries fo r macronutrient intake. Diet diaries were used 
principally as a tool to  promote awareness in participants and to  identify overt dietary 
imbalance. It would be beneficial fo r future  studies to  conduct baseline, post­
intervention and follow-up nutritional analysis.
Addressing obesity should be a key goal o f any OSAS intervention as it has the 
potential to  improve mechanical and anatomical contributors to  airway collapse. An 
additional non-OSAS benefit of weight loss includes reduced stress on the skeleton and 
joints. Obesity is independently associated w ith arthritis in the weight-bearing jo ints of 
the lower limbs (i.e. ankles, knees and hips). A rthritis is potentially the most 
debilitating medical condition tha t affects older adults, and its development is 
undoubtedly exacerbated by obesity (Rejesky et al., 2010; Messier et al., 2004). 
Impaired m obility in older adults is a contribu tor to  sedentary behaviour, which in turn 
increases the risk o f cardiovascular disease.
6.4.2 Cardiovascular risk
This study evaluated several aspects of cardiovascular disease risk. Changes in resting 
systolic and diastolic blood pressure were negligible, as were changes in cholesterol, 
triglycerides and LDL. This is perhaps unsurprising as these variables were already 
com fortably w ith in normal range and would not be expected to  change. On the 
contrary, CRP was reduced at 13 weeks (A -1.3 [-2.2, -0.3] mg-L'1) and 26 weeks (A -1.3 
[-2.3, -0.3] mg-L"1). This reflected a reduction o f almost 50% from  baseline values and 
effect sizes were moderate suggesting tha t changes were meaningful. The data 
presented were analysed using the LOCF principle, and after excluding elevated CRP 
values indicative of acute inflammation at any tim e-point. Reanalysis w ithou t these 
stipulations did not affect our findings. It has been demonstrated previously that
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exercise training reduces circulating CRP in humans (Stewart et al., 2007), although 
others have suggested it does not (Hammett et al., 2004). CRP is an im portant marker 
o f systemic inflammation and of risk to  subsequent cardiovascular disease (Ridker et 
al., 2003). Previous research has shown serum CRP concentration to  be proportional to 
the severity o f OSAS (Shamsuzzaman et al., 2002). Furthermore, effective CPAP 
therapy has been shown to  lower CRP (Yokoe et al., 2003). As the m ajority of our 
sample was compliant w ith CPAP therapy, any further reduction in CRP evoked by our 
intervention may reflect fu rthe r reductions in cardiovascular risk. There was no 
relationship between change in CRP and percentage compliance.
It is possible tha t w ith a substantial proportion o f participants not using CPAP on a 
regular basis tha t many patients were still experiencing apnoeic events on the nights 
they were not using CPAP. This should be taken into consideration when evaluating 
our results. Although there is no published evidence on what effects occasional CPAP 
use may have on the variables we explored in the current study, we suggest it may 
o ffer some degree of protective effect in a dose-response manner. This hypothesis is 
explored in study 2 (section 3).
The effect of the intervention on microvascular function is still unclear. As discussed in 
section 4.7.3 the reproducibility o f LDF-assessed skin blood flow  has been questioned, 
and often the utilisation of m ulti-fibre probes and o f multip le probes to  address spatial 
variability is recommended. The current study only used a single single-fibre 
iontophoresis probe. There was large between-participants variance in measurements 
at all tim e-points equal to  between 50 and 80% o f the mean value. Our results are in 
contrast to  Trzepizur et al. (2009) who reported higher CVC in pre-CPAP OSAS patients 
than both o f our groups. This is likely attributable to  the difference is the iontophoresis 
protocols. Walker et al. 2009 showed that regular exercise is associated w ith  higher 
endothelium-dependant vasodilation, however such improvements were not evident 
in the current study. A general assumption during the selection o f a vascular reactivity 
test is tha t the vascular tissue being assessed (i.e. forearm  skin resistance vessels, or 
limb-based conduit artery) is representative of other less-accessible vascular beds of 
interest, such as the coronary or cerebral circulations.
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6.4.3 Exercise capacity
Despite randomisation, there was a large between-group difference at baseline for 
ISWD (A 174 m) and consequently in baseline post-exercise variables (perceived 
exertion, heart rate, systolic blood pressure and diastolic blood pressure). The reasons 
fo r the between-group discrepancy are unclear and three possible mechanisms could 
be implicated. The control group had a greater proportion of beta-blocker usage (7 vs. 
2) which attenuates the exercise-induced tachycardia required to  maximise 
cardiopulmonary function. Moreover, beta-blockers are often prescribed in the 
management o f cardiovascular complaints which themselves could lim it exercise 
capacity. Such a condition is coronary artery disease, which was more common in the 
history of the control group than the intervention group (5 vs. 2). Previous periods of 
ischaemia or infarction could contribute to  impaired myocardial contractility which 
would reduce peak cardiac output and hence reduce exercise capacity. It is o f course 
possible that independently o f all other factors, participants in the control group just 
had a tru ly  lower exercise capacity (in which case the randomisation process, on this 
occasion failed). Participants in the intervention made substantial improvements in 
ISWD at end-point, which were slightly improved upon fu rthe r at end-point.
The improved exercise capacity was absent when assessing the control group data 
which had mean ISWDs of 414, 414 and 410 metres. This observation is in contrast to 
the findings of Fowler et al. (2005) who reported an improvement in ISWD between 
the firs t and second ISWT. Two im portant conclusions can be drawn from  this data. 
Firstly, tha t it is reassuring to  see tha t our approach to  delivering the ISWT was 
sufficient to  elim inate any potential learning effect. This included describing the 
protocol in detail, allowing participants to  become accustomed w ith the course, and to 
play the audio signal briefly to  highlight which sounds to  listen out fo r and what they 
mean. Secondly, and perhaps more im portantly, it seems that basic lifestyle advice 
alone is an insufficient stimulus fo r improving exercise capacity in OSAS patients. 
Despite the aforementioned differences at baseline, the improvements in exercise 
capacity at end-point and fo llow -up should not be undermined. Overall, The ISWT data 
suggest tha t the intervention increased exercise capacity. There was substantial 
improvement in walking capacity over the course of the intervention, which was
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improved fu rther at 26 weeks (changes which were characterised by moderate and 
large effect sizes, respectively). The 16 [10, 22]% and 22 [16, 29]% improvement in 
ISWD in the intervention group at end-point and follow-up, respectively, is similar to  
the 20% improvement in aerobic capacity in the Barnes et al. (2009) study.
Exercise prescription in the current study was variable - each exercise session was 
bespoke to  the participant w ith the design (frequency, intensity, duration and type) 
varied throughout the intervention period making direct comparison w ith  existing data 
difficult. Anecdotally, patients reported increased daily activity and increased 
frequency and duration o f purposeful physical activity, primarily gymnasium tra in ing 
and home-based exercise/walking. Additionally, our assessment o f exercise capacity 
was the ISWT, a test more commonly used in chronic obstructive pulmonary disease. 
This tool was used to  minimise equipment-related lim itations (e.g. maximum weight 
tolerance) tha t restrict recruitment. The ISWT was recently validated by our group 
(Billings et al., 2013) and has been shown to  be reproducible in other populations 
(Fowler et al., 2005). Unfortunately, seven participants completed the ISWT (a tota l 
distance of 1020 m in 12 min) at one or more tim e-points and hence the ir data were 
excluded. Although we were prepared fo r such an eventuality, it was nevertheless 
unexpected. The test was well tolerated by patients and the feasibility o f adding 
additional levels to  the protocol originally described by Singh et al. (1992) -  the audio 
signal follows an arithm etic sequence, w ith each level lasting one m inute and being 
divided into n+2 equal parts (where n=level number; i.e. level four has six shuttles of 
10 s each).
As mentioned previously, improvements in "fitness" are thought to  be more im portant 
than improvements in "fatness" (Blair, 2009). This study has demonstrated substantial 
improvements in exercise capacity are not only achievable in OSAS, but also 
maintainable in the medium-term. Higher exercise capacities are associated w ith  
improved quality of life (especially vitality). Fitness is also predictive o f surgical 
outcomes; surgery presents an immense physiological assault on the body and can 
significantly increase the cardiorespiratory demands of the body at rest. The very 
nature o f OSAS, its reputation fo r remaining undiagnosed fo r years and disrupting 
physiological mechanisms which can lead to  chronic disease and the co-m orb id ity of
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obesity make the need fo r a future surgical procedure plausible. Improving exercise 
capacity and habitual physical activity has numerous intrinsic benefits fo r patients; 
improved self-worth, improved sleep pattern and being able to  meet new friends.
6.4.4 Quality of life
The underpinning purpose of all medical research is to  improve patients' care and 
quality of life. OSAS in its untreated form  can vastly reduce health-related quality of 
life by causing chronic tiredness tha t reduces capacity fo r work- and leisure-related 
activities. The current study demonstrated reduced problems in completing usual 
activities such as housework or shopping. Such improvements can contribute to  the 
maintenance of independence, which in turn can allow patients to  stay more active 
(physically and mentally) and to  perform the ir professional and personal 
commitments. The EQ5D tool has been previously shown to  lack sensitivity in sleep 
patients (Jenkinson et al., 1998), which could explain the lack o f change in several 
health domains.
6.5 Limitations
There are several lim itations in this study tha t need to  be considered when 
interpreting these findings. The non-blinded nature o f the study design introduces the 
possibility o f bias into some measurements. Ideally, assessments are conducted by a 
separate researcher who is blinded to  group allocation and has no acquaintance w ith 
participants -  this makes the results more defendable. The method o f bioelectrical 
impedance analysis used in this study (Bodystat) is not the current gold standard fo r 
assessing body composition. Use of dual-energy x-ray absorption (DXA) scanner would 
have been preferred, however such equipment is very expensive and few  centres are 
fortunate enough to  have access to  them. A lternatively, a more advanced bioelectrical 
impedance analyser capable of measuring fa t mass, skeletal muscle mass and bone 
mineral density should be considered. Such equipment would inform  changes in 
overall body composition.
The effects of the intervention reported in this study may be confounded by the 
personalised, pragmatic nature of the intervention sessions. Exercise prescription was
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variable between participants and was introduced and developed steadily at the ir own 
rates. Consequently, the exercise "dose" probably varied considerably. Another 
methodological lim itation was the relatively short fasting period, which was shorter 
than the ideal 10 hours easily achieved overnight. This could impact on several 
outcome measures tha t are affected by fasting period such as lipid profile, glucose, 
body fa t percentage and skin blood flow  measurements. This lim itation was recognised 
during study design and due to concerns tha t it may affect recru itm ent to  the 
intervention (the primary outcome measure), we stipulated a m inimum fasting period 
o f six hours, which as assessments most often occurred in the morning was, in 
practice, longer.
6.6 Future research
Building on the lim itations o f this study, several changes should be made to  the 
current protocol in future  studies. The dietary advice component o f the in tervention 
should be re-evaluated; this could include incorporation of nutrition is t- or dietician- 
delivered education and advice, or short-term  hypoenergetic d iet to  induce a rapid 
weight-loss phase. Although the current study included no metric to  assess behaviour 
change (other than changes in outcome measures between end-point and follow-up), 
fu ture  studies should assess longer term  behaviours. Tools to  assess this include free- 
living questionnaires and activity diaries, actigraphy, and diet diaries could be repeated 
at each assessment point and assessed fo r nutritional content. These w ill help 
researchers determine changes in behaviour. Perhaps also assessing psychological 
mediators tha t are thought to  be linked to  behaviour change, e.g. changes in exercise 
self-efficacy.
Future work should also incorporate an assessment o f sleep apnoea severity, using 
either home-based PSG or pulse oximetry. These tests would need to  be conducted at 
each assessment point, w ithout simultaneous CPAP therapy and after a sufficient 
wash-out period. The ethical implications o f w ithdraw ing treatm ent would need to  be 
considered; it would be acceptable, although not scientifically robust, to  make this 
aspect of the study optional. It is likely tha t most patients would opt to do it to  find out 
what impact the intervention has had on the severity o f OSAS (w ith m ilder patients
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probably hoping to  have been cured). Also, a more sensitive metric fo r health-related 
quality o f life in sleep disorders would be useful.
Overall, the results presented here merit conducting a larger, m ulti-centre phase three 
tria l w ith changes in OSAS severity as the primary outcome measure. This study should 
also incorporate a longer term  assessment point (perhaps at two years) and evaluate 
the cost-effectiveness of the intervention.
6.7 Summary
This study has shown tha t lifestyle intervention is an attractive opportun ity to  what is 
likely a motivated sub-set o f the OSAS population. It can cause improvements in 
exercise capacity and serum CRP that are maintained after an extended period of 
independence, although no improvements were demonstrated in body mass or serum 
cholesterol. The high compliance rates reported suggest tha t integration o f the 
lifestyle intervention is possible, despite the m ajority o f commitments being during 
working hours. This study has identified some methodological issues tha t require 
addressing before advancing onto repeating the study on a larger scale.
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Section 3 -  Effects of obstructive sleep apnoea syndrome and 
its treatment with CPAP on macrovascular and microvascular 
function
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Chapter 7 -  Introduction
Apnoea can evoke episodes of hypoxaemia and elevated sympathetic nerve activity 
tha t can augment oxidative stress and cause endothelial dysfunction and 
cardiovascular disease (CVD) (Ip et al., 2004; Kuniyoshi et al., 2010). Although CPAP 
represents the gold standard fo r treatm ent o f OSAS, its uptake and daily utilisation is 
sub-optimal. It is thought 8-15% of patients refuse it after an initial tria l (Weaver & 
Grunstein, 2008) and a population study in 38 men, only 11 (29%) were still 
undergoing CPAP after 6 months (Lindberg et al., 2006). It is unclear why compliance is 
so variable and researchers have reported physical (e.g. tolerance of the pressurised 
air), social (e.g. partner's or family's perceptions) and psychological (e.g. patients' 
a ttitude toward change) reasons as im portant factors (Basner, 2007; Kribbs et al., 
1993). As therapeutic CPAP normalises apnoeic frequency it can vastly improve sleep 
quality and reduce daytime somnolence, increase v ita lity  and improve health-related 
quality o f life. However, as not all patients are symptomatic the importance o f nightly 
use can often be underestimated. This is likely to  be a misunderstanding of the 
consequences of OSAS in the long term  and a certain degree o f ignorance from  
patients. A number of studies have assessed the contributory factors to  successful 
adherence to  CPAP and the main physiological indicator fo r long-term  CPAP 
compliance is the ODI and not the symptoms of EDS (Krieger et al., 1996; Kohler et al., 
2010).
Previous work has shown tha t endothelium-dependent vasodilation (NO-mediated) is 
impaired in OSA patients (Carlson et al., 1996; Kato et al., 2000) and tha t untreated 
OSA, rather than obesity, is a major determ inant o f vascular endothelial dysfunction 
(Jelic et al., 2010). Measuring FMD after a distal arterial occlusion can assess vascular 
endothelial function and LDF assessment o f skin blood flow  during PORH and LTH can 
assess general microvascular function (Cracowski et al., 2006). Despite a num ber o f 
short-, medium- and long-term studies assessing endothelial dysfunction in OSAS 
patients receiving CPAP treatm ent versus no treatm ent (Imadojemu et al., 2002; 
Lattimore et al., 2006; Bayram, et al., 2009; Nguyen et al., 2010), there is lim ited 
evidence tha t quantifies the extent to  which low compliance (10%< nightly use <60%)
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attenuates the increased endothelial dysfunction caused by the OSA, compared to 
persons tha t are highly compliant (>80% nightly use, 4 h per night). A study by Jelic et 
al. (2008) showed tha t vascular endothelial dysfunction can be significantly reversed 
w ith 4 weeks o f effective CPAP treatm ent and tha t ineffective treatm ent elicits no 
significant reversal. These results are ambiguous as the researchers grouped persons 
who refused treatm ent and had low compliance together, lim iting interpretation of 
the effect o f low compliance on endothelial dysfunction.
The objectives of this study are to  design and execute a cross-sectional study to  assess 
macro- and microvascular function in patients tha t have low compliance to  CPAP 
therapy and how they compare w ith other OSAS populations and healthy matched 
controls.
The research question is:
• How effective is occasional CPAP use at ameliorating the vascular endothelial 
dysfunction previously reported in OSAS and how is it associated w ith 
anthropom etric variables, cardiovascular risk, quality o f life and exercise 
capacity?
The original hypotheses fo r this study are:
• Vascular endothelial function in low compliance OSAS patients w ill be impaired 
compared w ith high compliance patients and matched controls
• Vascular endothelial function in low compliance OSAS patients w ill be sim ilar to  
untreated OSAS patients
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Chapter 8 -  Methods
8.1 Study design
This was a four-arm , cross-sectional study tha t investigated vascular function in four 
groups: (1) OSA patients established on CPAP therapy fo r at least 3 months w ith high 
compliance (>80% nightly use fo r >4 h per night, OSA-HC); (2) OSA patients established 
on CPAP therapy fo r at least three months w ith low compliance (10%< nightly use 
<60% fo r >4 h per night; OSA-LC); (3) untreated OSA patients (OSA-UN); and, (4) age- 
and BMI-matched controls (OSAS-free).
The primary comparison was the difference in percentage flow-m ediated dilatation 
between the high-compliance group and the low-compliance group. The secondary 
comparison was between the low-compliance group and the untreated OSA group. 
This study was sponsored by Sheffield Teaching Hospitals NHS Foundation Trust (STH- 
16309) and funded by the Sheffield Thoracic Institute. This research was carried out in 
accordance w ith the Declaration of Helsinki o f the W orld Medical Association and 
ethics approval was provided by the Sheffield Research Ethics Committee 
( ll/Y H /0 4 17 ). This study was registered on an international clinical trials database 
(h ttp ://w w w .clin ica ltria ls.gov; NCT01619748)
8.1.1 Outcome measures
The primary outcome measure was flow-mediated dilatation (FMD) of the brachial 
artery in response to  forearm occlusion assessed using vascular ultrasound. Secondary 
outcome measures were: changes in skin blood flow  in response to  a local heating 
stimulus, measured using laser Doppler flow m etry; changes in skin blood flow  in 
response to a 5-min proximal arterial occlusion, measured using LDF; exercise capacity 
using the ISWT; and, cardiovascular risk assessed by measuring established risk factors 
(e.g. blood pressure, cholesterol, HDL and smoking status). All outcome measures were 
assessed during one visit tha t lasted approximately 2.5 hours.
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8.1.2 Sample size calculation
To our knowledge, FMD has not previously been studied in a homogenous low- 
compliance group. We anticipate FMD will be similar between low-compliance and 
untreated OSAS patients because of the acute effects of even one night w ithou t CPAP. 
Similarly, previous research has shown CPAP therapy to  improve AHI to  tha t of non- 
OSAS. Therefore, we based our sample size estimation on mean values and standard 
deviations fo r differences in percentage FMD reported by Tanriverdi et al. (2006). This 
study reported a group of pre-CPAP OSAS patients (our surrogate OSA-LC group) w ith 
an FMD of 4.57 ± 1.3% compared w ith OSAS-free controls (our surrogate OSA-HC 
group) w ith an FMD of 6.34 ± 0.83%. These groups had a common SD of 1.15%. Using 
nQuery sample size calculator (Statistical solutions Ltd., Cork, ROI), a 2-tailed study 
design, a power o f 90% and an alpha value o f 0.05, we estimated needing 10 
participants in both primary groups. Because this calculation is based on surrogate 
data, we will conservatively double the sample size to  n=20 per group.
8.2 Recruitment
Two recruitm ent strategies were used. Strategy 1 populated the entire OSA-HC and 
OSA-LC groups and contributed to  the population o f the OSA-UN group. Strategy 2 
contributed to  the OSA-UN group and populated the entire OSAS-free group.
8.2.1 Strategy 1 - recruitment of patients from local sleep clinics
8.2.1.1 Untreated group
Pre-CPAP patients were recruited from  the sleep clinic at Northern General Hospital, 
Sheffield, UK. They were in itia lly approached during routine consultation w ith a 
respiratory physiologist after the ir overnight sleep test and before commencing CPAP 
therapy. The physiologist briefly assessed the ir e lig ib ility (CPAP compliance, BMI, 
general health) and if suitable provided a quick overview of the research and a 
recruitm ent pack (invitation le tter and participant inform ation sheet; appendix 9 and 
10, respectively). If the patient was interested they were referred to  a study researcher 
to  discuss the study in more detail. Patients who showed interest in participating but
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could not attend the assessment session before starting CPAP therapy were re­
assessed fo r e lig ibility after the ir 3-month tria l.
8.2.1.2 High-compliance and low-compliance groups
Patients established on CPAP were recruited from  the sleep clinic at Northern General 
Hospital, Sheffield, UK. They were in itia lly approached during routine consultation w ith 
a senior respiratory physiologist after the ir 3-month CPAP trial. The physiologist briefly 
assessed the ir e lig ib ility (CPAP compliance, BMI, general health) and if suitable 
provided a quick overview of the research. If the patient was interested they were 
given a participant inform ation sheet and referred to  the chief investigator to discuss 
the study in more detail.
8.2.2 Strategy 2 - recruitment of obstructive sleep apnoea syndrome-free 
control participants from the community
Study researchers contacted local interest groups in the vicinity of Sheffield Hallam 
University. Contacted groups included, but were not lim ited to, the Sheffield branch of 
the University of the Third Age (sU3A) and Sheffield branch of the National Association 
o f Retired Police Officers (sNARPO).
Those who showed interest were contacted via telephone by a study researcher. They 
were given a brie f overview of the study, given an opportun ity to  ask questions and 
asked some pre-screening questions to  ensure they met the elig ib ility criteria. They 
were then posted an invitation le tte r (appendix 11), participant inform ation sheet 
(appendix 12) and reply envelope and given tim e to  consider participation.
8.2.3 Familiarisation and overnight polysomnography
Volunteers were invited in to  Sheffield Hallam University to  meet a study researcher 
and discuss the study in a similar process to  tha t described in section 4.2.2 
(background to  the department, purpose and design o f the study, techniques and 
equipment involved, medical history, questions and w ritten informed consent; 
appendices 13 and 14).
Additionally, those participants recruited from  the community underwent overnight 
dual-channel polysomnography using a portable ApnoeaLink device (ResMed, 
Oxfordshire, UK) validated fo r accurate measurement of AHI (Erman et al., 2007). The
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first channel records nasal airflow (via a disposable nasal cannula and internal pressure 
transducer) and the second channel records capillary blood oxygen saturation (using a 
finger pulse oximeter and internal light source). This test was conducted on a 
convenient night in the participants' own home. During familiarisation participants 
were given instructions on how to set up the device and an opportunity to practice 
setting up in front of the researcher. The device was returned the following morning 
and data were assessed automatically using the manufacturer's software (ApnoeaLink, 
ResMed, UK) and subsequently verified manually to ensure apnoeas and desaturations 
had been correctly identified. A minimum of four hours of data were required to 
determine the presence or absence of OSAS using standard criteria (AHI/ODI).
8.3 Inclusion criteria
Inclusion was determined on the basis of the following criteria:
•  Aged 18-85 years of age
• Body mass index >30 kg-m'2
• No contraindications to exercise testing such as unstable angina, severe 
hypertension or joint/muscle problems
•  Suitable OSAS/treatment status for one of the trial arms
o Compliant with CPAP (>75% nights; >4 hours per night (OSA-HC) 
o Low compliance with CPAP (10% < nights < 60%; >4 hours per night 
(OSA-LC)
o Confirmed OSA (AHI/ODI >10 events-h'1) and never treated with CPAP 
(OSA-UN)
o Absence of OSA confirmed with overnight dual-channel 
polysomnography (OSAS-free)
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8.4 Exclusion criteria
Participants were excluded if they met any of the follow ing criteria:
•  Pregnant or post-menopausal females undergoing hormone replacement 
therapy or oral contraceptive therapy
• Males undergoing testosterone replacement therapy
• Body mass >180 kg (for safety reasons; 180 kg is the manufacturers maximum 
weight tolerance fo r a key piece of equipment)
•  Volunteers w ith any mental impairm ent making consent unethical
8.5 Primary outcome measures
8.5.1 Vascular function
Vascular function assessments were performed under conditions previously described 
(Section 4.7.3). All participants were asked to complete an overnight fast (>8 h) and 
refrain from  exercise fo r >24 h, caffeine fo r >12 h and smoking fo r >12 h (Thijssen et 
al., 2011). OCP-free pre-menopausal females were tested between days 1 and 7 of 
the ir menstrual cycle (Hashimoto et al., 1995; Corretti et al., 2002; Harris et al., 2010). 
Three m ultifibre laser Doppler probes were used, each probe consisted o f a 7-fibre 
integrating probe (PF 413, Perimed AB) housed in a separate therm ostatic heating disc 
(PF 450, Perimed AB) as shown in Figure 8.1. Patients were allowed to  take medication 
as normal; it has been shown previously tha t n itrate-free vasodilator therapy has no 
acute (Gokce et al., 2002) or chronic (Benjamin et al., 2004) effects on endothelium - 
dependent vasodilation.
Disposable double-sided adhesive rings (PF 105-1, Perimed AB) were used to  position 
the probes securely. Each probe was connected to  an independent laser unit (PF 5010) 
and heating unit (PF 5020) and placed on the volar aspect o f the right forearm , 
between the w rist jo in t and the cuff on sites previously described (see section 4.7.3.) 
w ith a stable resting perfusion (usually 10-30 PUs) and tota l backscatter. Each heating 
disc was set to an initial tem perature of 33 °C.
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8.5.1.1 Post-occlusion reactive hyperaemia
A pneumatic cuff attached to  a rapid in fla tion/defla tion system (E20 rapid cuff 
in fla to r/A G lO l cuff in fla tor air source, D.E. Hokanson Inc., Bellevue, WA, US) was 
placed around the forearm immediately distal to  the elbow jo in t. Resting blood flow  
data were recorded fo r at least 5 min before in itiating the occlusion protocol. Proximal 
arterial occlusion was performed by inflating the pneumatic cuff to  200 mmHg (or 50 
mmHg suprasystolic, whichever was greater) fo r 5 min (Yamamoto-Suganuma & Aso, 
2009). Post-deflation skin blood flow  was recorded fo r 3 min or until skin blood flow  
had returned to normal (Yamamoto-Suganuma & Aso, 2009). These data were saved 
fo r fu ture  offline analysis. A recovery period sufficient to  allow skin blood flow  to 
return to  baseline (at least 3 min) was allowed before in itiating the local heating 
protocol.
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Figure 8.1 PF 450 integrating probe
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8.5.1.2 Local thermal hyperaemia
To investigate the skin hyperaemia response to  local heating, the tem perature of the 
heating discs surrounding the LDF probes were increased at a rate o f 1 °C10s 1 to  a 
tem perature o f 42 °C (Tew et al., 2010). Thereafter, this site was continuously heated 
at 42 °C fo r 30 min, after which the tem perature of the heating discs were increased to 
44 °C fo r a fu rther 10 min to  elicit maximum vasodilation (Van Duijnhoven et al., 2009). 
Data were continuously recorded fo r subsequent offline analysis. Experimental set-up 
is depicted in Figure 8.2.
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Figure 8.2 Experimental set-up (study 2)
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8.5.1.3 Flow-mediated dilatation
FMD is a dilatation in response to increased arterial flow. It is most easily measured in 
the limbs (arms for adults, legs for children) in vessels 3-6 mm in diameter (Celermajer 
et al., 1994). Increased flow can be stimulated by a temporary distal occlusion causing 
ischaemia in the unperfused tissue. This period of ischaemia releases local 
neurotransmitters that dilate local arterioles. Upon deflation there is a large increase 
in brachial artery blood flow caused by a greater pressure gradient between the 
axillary artery and forearm arterioles (primarily mediated by the reduced resistance in 
the arterioles caused by dilation). Higher flow rates increase the shear stress stimulus 
on the endothelial cells lining the lumen of the brachial artery. Shear stress is a 
frictional force applied by the flow of blood on the luminal surface of blood vessels. 
Dilation is the normal physiological response to increased flow via the shear stress 
mechanism, which is triggered by an increase in eNOS expression and an increase in 
NO production (as outlined in section 4.7.3.3). NO stimulates vascular smooth muscle 
relaxation and subsequent arterial dilation. In the presence of endothelial dysfunction, 
FMD is impaired because of reduced expression of eNOS, interrupting the normal 
physiological response mid-cascade, which causes a higher overall shear stress on the 
arterial lumen. FMD was reported as an absolute change from baseline (mm) and as a 
percentage of the baseline diameter.
FMD (mm) — DIAMpEAK — D I A M Baseline
™ D (%) =  d ia m DIAM—  x 100)U1AMbaseline
Arterial blood flow was calculated using simultaneous arterial diameter and blood 
velocity measurements. It was assumed that the internal circumference of the brachial 
artery was circular, and hence flow rate was calculated as follows.
FLOW RATE (m l  ■ min-1) = n x (0.5 x DIAM)2 x MEAN BLOOD VELOCITY
136
To address the covariate nature o f baseline arterial diameter in FMD, changes in 
brachial artery diameter were scaled using allometric modelling (Atkinson et al., 2013). 
In brief, values fo r baseline diameter and peak diameter were transformed using loge, 
and the difference between them was used in a univariate ANCOVA w ith  baseline 
diameter as a covariate.
Shear rate can be considered an estimate o f the shear stress w ithou t accounting for 
blood viscosity. . A number of equations to  estimate the shear stimulus have been 
proposed. Pyke & Tschakovsky (2007) proposed shear rate to be equal to  mean blood 
ve locity-d iam etef \  Thijssen et al. (2008) included a constant of 4 in the same equation 
fo r shear rate (4-velocity-diam eter1). Padilla et al. (2009) developed this form ula to 
calculate shear stress by measuring blood viscosity using viscometry 
(4-viscosity-velocity-diameter1). Finally, M itchell et al. (2004) used the same form ula to  
calculate shear stress, but instead of measuring blood viscosity they applied an
assumed value -  this is weak because viscosity is variable between individuals,
especially those found in a clinical setting. Methodological approaches to  the 
assessment o f FMD and its related statistics seems to  be far less standardised than the 
experimental protocol, and hence comparing shear stimuli between studies should be 
done carefully, w ith particular attention to  the calculation used by the investigators. 
For the current study, shear rate was calculated as below.
4 x  M EAN BLOOD VELOCITY
SHEAR RATE  ( s ' 1) = -------------------------------------------------
v y D IA M
Occlusions o f 5 min in duration are most commonly used as a compromise between
participant com fort and physiological response; occlusions o f greater than 4.5 min are 
thought to  induce maximal dilatation (Leeson et al., 1997). Furthermore, longer 
occlusions make fidgeting more likely -  increasing the d ifficulty o f perform ing a 
manual scan and probably decreasing the overall quality of the scan. A lternative 
methods of assessing endothelial function include intravenous acetylcholine 
adm inistration coupled w ith quantitative angiography or strain-gauge 
plethysmography and harvesting endothelial cells. These alternatives are more 
invasive and w ith in a research setting would likely impede recruitm ent o f volunteers.
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According to  good clinical practice, it is unethical to  put participants through more 
invasive procedures than is necessary.
Endothelial-dependent dilation of the brachial artery in response to ipsilateral forearm 
cuff occlusion was measured using a vascular ultrasound scanner (Terason t3000CV 
ultrasound system (V4.7.4), Terason, USA) and a 7-MHz linear array probe (7L3, 
Terason, USA). Data were recorded using screen-capture software (Camtasia, 
TechSmith, Okemos, Ml, USA; this assessment was conducted using the cuff occlusion 
described in section 8.5.1.1). Using the ultrasound scanner, an optim ised longitudinal 
view of the brachial artery was located on the medial aspect o f the right upper-arm. 
The image was optim ised by manipulating scan depth, focus depth, gain, compression, 
noise rejection and time-gain compensation.
The optimised longitudinal image was recorded fo r 1 min using screen capture 
software. A fter 1 min the forearm cuff was inflated to  200 mmHg (or 50 mmHg 
suprasystolic) and the recording paused. A fter 5 min the cuff was deflated and the 
recording resumed fo r a fu rthe r 3 min. The recorded screen capture was saved fo r 
fu ture  offline analysis (see 8.5.3).
8.5.1.4 GTN-mediated dilatation
Glyceryl trin itra te  (GTN) is a NO-donor and induces vasodilation independently o f the 
vascular endothelium by activating guanylate cyclase in VSMCs directly. In a clinical 
setting it is used in the treatm ent o f angina pectoris; patients are prescribed a GTN 
pump spray to  carry w ith them to  use during episodes o f chest pain. GTN dilates the 
coronary vasculature and can alleviate symptomatic pain and reduce the risk o f cardiac 
ischaemia. In a research setting, it is most commonly used to  assess endothelium - 
independent vasodilation during vascular ultrasound assessments and has been since 
the inception of FMD. GTN has a short half-life (3 min) and is quickly metabolised by 
the liver, making it suitable fo r use w ith in clinical trials. Because o f the potential risk of 
nitrates toxicity and the unpleasant side-effects o f headaches and light-headedness, 
participants' suitability fo r GTN adm inistration was determ ined using medical history 
data and the follow ing criteria:
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•  Not currently taking medication listed in the contraindications section of GTN in 
the British National Formulary 56
•  Not currently taking medication tha t contain nitrates
•  No clinical history of hypotension (<100 systolic blood pressure)
•  No overt renal or liver disease
Endothelial-independent dilation of the brachial artery in response to  a 400 pg dose of 
GTN (Coro-Nitro Pump Spray, Ayrton Saunders Ltd., W irral, UK) delivered sublingually 
was measured using vascular ultrasound imaging. Using the ultrasound scanner, an 
optim ised longitudinal view of the brachial artery was located on the medial aspect of 
the upper-right arm. Once in place, a 1-min baseline recording of the longitudinal view 
was recorded. After one min GTN was delivered sublingually by another researcher. 
The image of the artery was recorded fo r an additional six minutes. Blood pressure was 
monitored regularly on the contralateral arm using an automated blood pressure 
machine.
8.5.2 Offline laser Doppler flowmetry analysis
All LDF recordings were analysed once the final participant had completed the study. 
PWS 2.5 software was used to  take mean average readings from  areas o f interest 
which included baseline flow, biological zero and peak flow  (Figure 8.3). The duration 
o f these areas was the longest consecutive period thought to  represent each phase, 
and was typically between 5 s and 2 min. Furthermore, the tim e between reperfusion 
and peak flow , tim e to half recovery and the duration of the hyperaemic response. The 
area under the curve (AUC) o f the hyperaemic response was calculated using the 
trapezoidal rule, accounting fo r differences in baseline skin blood flow  between 
participants.
2_/i(*i+l -*i) + °-56'i+l - V i K X i + l - X i )  
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For the LTH data, areas o f interest included the baseline flow, initial peak, nadir, 
plateau phase, and maximum flow  were calculated over periods of at least one min. As 
w ith PORH, particular times were noted; tim e to initial peak and tim e to plateau phase. 
Mean values fo r each section were divided by the simultaneous MAP to  convert into 
CVC. Although dispute exists regarding the best way to  present skin blood flow  data, 
this data was presented as raw CVC values; we have previously shown this method of 
data presentation to  be reproducible (Tew et al., 2010).
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Ayy^ily
Figure 8.3. Example analysis areas for PORH and LTH. A: p o rh  first area: baseline flow; 
second area: biological zero; th ird area: peak flow. B: Enlarged PORH showing times measured; top line: 
time to peak; middle line: time to half peak; bottom  line: hyperaemia duration. Not shown: AUC, 
calculated as the integral product from  cuff release to the end of the hyperaemia. C: LTH; first area: 
baseline flow; second area: initial peak; th ird  area: nadir; fourth area: plateau; fifth  area: maximal flow ; 
top line: time to peak; second line: tim e to plateau.
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8.5.3 Offline vascular ultrasound analysis
Recorded data were analysed at a later date. Raw screen capture data (.camrec) were 
compressed using Audio Video Interleave (.avi) form at and transferred to VirtualDub 
(V I.9.11, Freeware, Avery Lee) fo r compression. These files were then cropped 
according to the stage of the scan (FMD scans were separated into a baseline file (1 
m inute; ~900 frames) and a post-deflation file (3 minutes; ~2700 frames); GTN scans 
were not cropped and were kept as 7-min files (~6300 frames). Compressed files were 
then opened in Brachial Analyser fo r Research (v5.6.19, Medical Imaging Applications 
LLC, USA) fo r automated diameter and flow  analysis.
Brachial artery diameter was tracked on a frame-by-frame basis by defining a region of 
interest (ROI) encompassing a good portion of the artery w ith clearly defined walls. 
Distance was calibrated using the depth scale on the image (Figure 8.4). Brachial artery 
mean blood velocity was measured by aligning the ROI over the Doppler flow  data. 
Time and flow  rate were calibrated using the x- and y-axis, respectively. Flow data 
were analysed on a frame-by-frame basis using an integral algorithm. Diameter and 
flow  data, once analysis were complete, were checked visually fo r va lid ity and 
exported into a M icrosoft Excel tem plate programmed to  "sm ooth" data. As arterial 
ultrasound is a manual technique, the quality of recorded images is determ ined by the 
skill o f the practitioner and the stillness o f the participant. Therefore, small 
movements from  either can result in some frames w ithout discernible walls. Therefore 
we only included frames w ith a high level of confidence (i.e. 90%) and w ith in a 1 SD 
trend of previous data points. To reduce the impact o f erroneous measurements 
further, practitioners often smooth data by taking median values over a period of 2-5 
seconds (30 to  75 frames on our system). We calculated the median value of 75 
consecutive frames, w ith a 15-frame (20%) overlap from  one median to  the next for 
both variables in a similar way to  Thijssen et al. (2008). Baseline diameter and flow  
were taken as the mean value o f the smoothed baseline data.
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8.6 Secondary outcome measures
8.6.1 An thropometry
Stature, body mass, and neck, waist and hip circumferences were measured using 
techniques previously described (section 4.7.1). Body fa t percentage was assessed 
using bioelectrical impedance (InBody 720, BioSpace, South Korea). This system uses a 
tetrapolar 8-point tactile electrode system (2 per limb) and measures impedance (1, 5, 
50, 250, 500 and 1000 kHz) and reactance (5, 50 and 250 kHz) at predeterm ined 
frequencies. The valid ity o f InBody 720 in the assessment of body fa t percentage is 
currently unclear. Some research groups have reported good agreement w ith e ither 
MRI or DXA, whereas some consider it to  provide an underestimate (Sun et al., 2005).
8.6.2 Blood-borne biomarkers
To assess selected blood-borne biomarkers we used CholesTech reflectance 
photom etry (CholesTech Systems, USA). We used a single-use analysis cassette 
capable of measuring glucose, cholesterol, high-density lipoprotein levels and 
triglycerides. Blood was drawn from  the capillary beds in the fleshy part o f the tip  of 
the finger using a single-use lancet. Blood was collected into a capillary tube and 
inserted into a CholesTech device. All blood-drawing techniques were conducted using 
sterile procedures.
8.6.3 Questionnaires
Daytime tiredness was assessed using the ESS (appendix 15). This too l was 
administered in accordance w ith the published guidelines. The EuroQOL-5D-5L 
(EuroQol Executive Office, 3068 AV Rotterdam, Netherlands) questionnaire was used 
to  characterise patients quality of life. This is an enhanced version of the EQ-5D-3L 
questionnaire used in study 1, providing 5 levels o f response fo r each domain (no 
problems, slight problems, moderate problems, severe problems and unable to) 
(Appendix 16).
8.6.4 Exercise capacity
Exercise capacity was assessed using the ISWT as previously described (section 4.7.5.). 
Additionally, blood pressure was repeatedly measured fo r five minutes starting
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immediately after test term ination and getting the participant into a seated position. 
Heart rate and recovery tom e post-exercise were also recorded simultaneously.
8.7 Statistical analyses
Data were assessed for normality, skew, kurtosis and homogeneity o f variance using 
statistical tests (e.g. Shapiro-Wilk test and Levene's test) and visual inspection of data. 
Parametric data were presented as mean ± SD and non-parametric data as median 
[interquartile  range]. Groups were compared in pairs using independent samples t- 
tests or chi-squared tests. Effect sizes [d) were calculated by dividing the difference 
between comparison groups by the pooled standard deviation. Relationships between 
key variables were assessed using Spearman's correlations. Statistical significance was 
set at P<0.05. Data were analysed using the SPSS 21.0 statistical package (SPSS, IBM 
corporation, Armonk, NY, USA).
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Chapter 9 -  Results
9.1 Baseline characteristics
In tota l, forty-five  participants were recruited and populated the groups as follows: 
high-compliance (n=20); low-compliance (n=14); untreated OSA (n=6) and OSAS-free 
controls (n=5). Only the high-compliance group recruited to target and w ith in  the 
proposed tim efram e. Baseline characteristics are described in Table 9.1. There were no 
differences in characteristics between the four groups. There was a higher prevalence 
o f coronary artery disease in the OSA-HC group versus the OSA-UN and OSAS-free 
groups. The prevalence of other comorbidities were similar between the OSAS groups, 
but d ifferent to  the non-OSAS group where no participants reported suffering from  
hypertension or diabetes. Approximately half of participants were ex-smokers and all 
groups except the OSA-HC group had one current smoker. Medication use was similar 
between OSAS groups. No listed medication was reported in the OSAS-free group.
Due to  under-recruitm ent in the OSA-UN and OSAS-free groups, all descriptions and 
discussions hereafter will concern the primary comparison between the OSA-HC and 
OSA-LC groups, unless otherwise stated. Some statistically significant comparisons may 
still be indicated w ith in tables using superscript symbols, but not necessarily be 
discussed.
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Table 9.1 Baseline characteristics (study 2)
OSA-HC OSA-LC OSA-UN OSAS-free
Characteristics
Participants (n) 20 14 6 5
Age (years) 57 ±9 511 11 5 8 1 7 53 19
Sex (male/female) 17/3 11/3 5/1 4/1
Body mass (kg) 116 ± 22 106 1 15 108 1 10 1001 5
Stature (cm) 17518 175 1 9 177 1 8 178 112
Body mass index (kg-m 2) 38 17 35 1 7 35 1 3 32 + 4
Resting heart rate (beats-min"1) 63 18 691 12 601 5 57 + 5
Systolic blood pressure (mmHg) 1321 20 138 1 18 1301 10 124 + 11
Diastolic blood pressure (mmHg) 7 9 1 9 8 0 1 9 851 6 77 + 4
Co-morbidities
Coronary artery disease 6 (30) 2(14) 0(0) 0(0)
Hypertension 8 (40) 8(57) 3(50) 0(0)
Diabetes 4(20) 4(29) 1(17) 0(0)
Current smoker 0(0) 1(7) 1(17) 1(20)
Ex-smoker 12(60) 7(50) 3(50) 2(40)
Medication
Beta-blocker 4(20) 0(0) 0(0) 0(0)
ACE inhibitor 6(30) 4(29) 1(17) 0(0)
Calcium channel antagonist 2(10) 2(14) 2 (33) 0(0)
Diuretic 4(20) 2(14) 0(0) 0(0)
Statin 7(35) 3(21) 1(17) 0(0)
Platelet inhibitor 6 (30) 1(7) 0(0) 0(0)
OSA-HC: high CPAP compliance; OSA-LC: low CPAP compliance; OSA-UN: untreated OSAS; OSAS-free: 
no OSAS. ACE: angiotensin converting enzyme. Data are presented as mean 1 SD, median [IQR], or 
frequency (%)
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9.2 Macrovascular function
FMD was assessed in all participants; however post-study analysis was not possible for 
two patients because of the corruption of source data (OSA-HC: n=19; OSA-LC: n=13; 
Table 9.2). A further two patients in the OSA-LC group were contraindicated to GTN 
administration and there did not undertake GTN-mediated dilatation assessment 
(OSA-HC: n=19; OSA-LC: n = ll)  There were no between-group differences for baseline 
diameter between groups or between experiments. Allometric FMD was higher in the 
OSA-HC group compared with OSA-LC group (Figure 9.1), although this difference was 
not considered significant (4.6% vs. 3.3%). Absolute dilatation was approximately 0.2 
mm in all groups and time to peak dilatation (FMD) was approximately one minute 
(except for the OSA-UN group, 38 ± 8 s). Allometrically-scaled GTN-mediated dilatation 
was similar in both groups at approximately 13%. GTN-mediated dilatation in these 
groups was greater than FMD percentage (PcO.OOl).
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Table 9.2 Macrovascular function
OSA-HC OSA-LC OSA-UN OSAS-free
Flow-mediated dilatation
Baseline diameter (mm) 4.9 ± 0.8 4.8 ± 0 .8 4.9 ± 0.4 4.7 ± 0.8
Peak diameter (mm) 5.1 ± 0 .8 4.9 ± 0.8 5.2 ± 0 .4 5.0 ± 0.9
Traditional FMD (%) 4.6 ± 4 .1 3.3 ± 3 .0 4.6 ± 2 .1 4.8 ± 1.1
Allometric FMD (%) 4.6 ± 3 .6 3.3 ± 3 .6 4.6 ± 3 .1 4.8 ± 2.8
Absolute FMD (mm) 0.2 ± 0 .2 0.2 ± 0 .1 0.2 ± 0 .1 0.2 ± 0 .1
Time to peak diameter (s) 58 ± 4 0 65 ± 4 6 38 ± 8 *+ 55 ± 2 2
Time to peak flow (s) 14 ± 5 13 ± 4 13 ± 4 14 ± 3
Shear rate AUC 13744 ± 5535 16127 ± 7496 12800 ± 3399 17014 ± 5761
Baseline flow (mL-min'1) 98 ± 3 8 114 ± 59 113 ± 77 95 ± 3 2
Peak flow (mL-min’1) 687 ± 223 7 1 1 ± 198 855 ± 356 767 ± 3 1 0
GTN-mediated dilatation
Baseline diameter (mm) 4.9 ± 1.5 4.4 ± 1.2 5.1 ± 0 .4 4.7 ± 0.9
Peak diameter (mm) 5.5 ± 1.7 4.8 ± 1.0 6.0 ± 0 .6 5.3 ± 1.0
GTN dilatation (%) 12.8 ± 3.4 10.3 ± 6.7 17.9 ± 1 0 .6 13.2 ± 5 .7
Allometric GTN dilatation (%) 13.4 ± 5 .1 13.1 ± 5 .7 18.1 ± 7 .6 12.8 ± 7 .5
GTN dilatation (mm) 0.7 ± 0 .3 0.4 ± 0.2 0.9 ± 0 .5 0.6 ± 0.3
OSA-HC: high CPAP compliance; OSA-LC: low CPAP compliance; OSA-UN: untreated OSAS; OSAS- 
free: no OSAS; FMD: flow-mediated dilatation; UC: area under the curve (integral); GTN: glyceryl 
trinitrate; *: P<0.1 vs. OSA-HC; +: P<0.1 vs. OSA-LC. Data are presented as mean ± SD or mean [95% 
Cl].
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Figure 9.1 Macrovascular function in high- and low- 
compliance patients. Top: Allometric flow  mediated- 
dilatation; middle: time to peak diameter; bottom: shear rate 
area under curve. OSA-HC: high compliance; OSA-LC: low 
compliance. Data are mean ± SD
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9.3 Microvascular function
All patients completed the microvascular assessments (Table 9.3). There were no 
differences in variables between the OSA-HC and OSA-LC groups in both LDF protocols. 
CVC in the peak PORH was lower in the untreated group compared w ith the high- 
compliance group (0.732 ± 0.22 vs. 0.959 ± 0.253 APU/mmHg; P=0.049). Also, between 
the same two groups there was a trend for a longer tim e to  peak in the untreated 
group (12 ± 11 vs. 8 ± 4 s; P=0.066). These data combined suggest the hyperaemic 
profile was displaced rightwards and downwards. There were no notew orthy 
differences in the LTH response.
Table 9.3 Microvascular function
OSA-HC OSA-LC OSA-UN OSAS-free
Post-occlusion reactive hyperaemia
Baseline CVC (APU/mmHg) 0.201 ± 0.041 0.19410.050 0.205 1 0.070 0.21610.070
Biological zero CVC (APU/mmHg) 0.072 ±0.03 0.06610.022 0.06610.015 0.09110.050
Peak CVC (APU/mmHg) 0.959 ± 0.253 0.90210.281 0.732 10 .22* 0.827 10.243
Time to peak CVC (s) 8 ± 4 8 1 3 121 l i t 101 5
Time to half peak CVC (s) 40 ± 21 321 18 52 1 39 57 139
Hyperaemia duration (s) 130 ± 36 108 1 48 110149 148 1 56
Area under curve 6327 ± 2543 6569 1 7368 5038 1 3276 5973 1 2692
Local thermal hyperaemia
Baseline CVC (APU/mmHg) 0.206 ± 0.052 0.20310.062 0.21110.071 0.21410.073
Initial Peak CVC (APU/mmHg) 1.65 ± 0.477 1.60410.479 1.535 1 0.407 1.3910.413
Nadir CVC (APU/mmHg) 1.493±0.497 1.30710.532 1.425 ±0.39 1.195 10.295
Plateau CVC (APU/mmHg) 2.04410.602 1.9821 0.631 1.86210.459 1.838 10.453
Maximal CVC (APU/mmHg) 2.1710.599 2.25410.64 2.061 0.595 1.927 10.398
Time to peak CVC (s) 2141 33 202 1 23 220 1 16 206 1 26
Time to plateau CVC (s) 11271 177 10921 133 1060 1 69 1067 1 156
OSA-HC: high CPAP compliance; OSA-LC: low CPAP compliance; OSA-UN: untreated OSAS; OSAS-free: no 
OSAS; CVC: cutaneous vascular conductance; APU: arbitrary perfusion units; *: P<0.05 vs. OSA-HC; +: 
P<0.1 vs. OSA-LC. Data are presented as mean ± SD
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9.4 Anthropometry
Anthropometric outcome measures are shown in Table 9.4. There was a lower mean 
waist circumference in the low-compliance group compared with the high-compliance 
group (116 ± 13 vs. 125 ± 15 cm; P=0.046). The OSAS-free group was markedly 
different in several anthropometric variables compared with the high-compliance 
group. Body mass (100 ± 5 vs. 116 ± 22; P=0.008), body mass index (32 ± 4 vs. 38 ± 7; 
P=0.019), waist circumference (108 ± 6 vs. 125 ± 15; P=0.001) and fat mass (33 ± 6 vs. 
46 ± 17; P=0.007) were all significantly lower.
Table 9.4 Anthropometric outcome measures
OSA-HC OSA-LC OSA-UN OSAS-free
Manual anthropometry
Body mass (kg) 116 ± 2 2 106 ± 15 108 ± 10 100 ± 5+
Body mass index (kg-m'2) 38 ± 7 35 ± 7 35 ± 3 32 ± 4 +
Neck (cm) 44 ± 3 44 ± 3 44 ± 4 41 ± 3
Waist (cm) 125 ± 15 116 ± 1 3 * 110 ± 24 108 ± 6+
Hip (cm) 121 ± 16 118 ± 13 121 ± 8 114 ± 4
Bioelectrical impedance
Skeletal muscle mass (kg) 40 ± 6 38 ± 6 38 ± 6 38 ± 6
Fat mass (kg) 46 ± 17 39 ± 14 40 ± 9 33 ± 6 +
Body fat (%) 39 ± 8 36 ± 10 37 ± 8 33 ± 7
Right arm (kg) 4.3 ± 0.8 4.1 ± 0 .7 4.1 ± 0 .7 4.0 ± 0 .7
Left arm (kg) 4.2 ± 0 .8 3.9 ± 0.8 4.1 ± 0 .6 4.0 ± 0 .7
Trunk (kg) 31.9 ± 4 .7 31.0 ± 4 .2 31.0 ± 3 .7 30.6 ± 3 .8
Right leg (kg) 11.3 ± 4 9.9 ± 1.6 10.1 ± 1 .6 10.4 ± 1.7
Left leg (kg) 10.6 ± 1 .7 10 ± 1.6 10.2 ± 1 .8 10.5 ± 1.8
OSA-HC: high CPAP compliance; OSA-LC: low CPAP compliance; OSA-UN: untreated OSAS; OSAS-free: no 
OSAS; *: P<0.05 i/s. OSA-HC; +: P<0.05 vs. OSA-HC
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9.5 Cardiovascular risk
There were no differences in the cardiovascular risk profile between the OSA-HC and 
OSA-LC groups (Table 9.5). Fasting HDL and glucose measurements were higher in the 
untreated group compared with the high-compliance group. Daytime somnolence was 
higher in the low-compliance (10 ± 4 vs. 5 ± 4; P=0.001) and untreated (9 ± 3 vs. 5 ± 4; 
P=0.014) OSAS groups compared with the high compliance group.
Table 9.5 Cardiovascular risk and questionnaire outcomes
OSA-HC OSA-LC OSA-UN OSAS-free
Cardiovascular risk
Cholesterol (mmol-L’1) 4.3 ± 1.1 4.9 ± 1.6 5.4 ± 1 5.9 ± 1.4
HDL (mmol-L’1) 0 .8 +  0.2 1 ± 0.2 1.1 ± 0 .2 * 0.9 ± 0 .2
non-HDL (mmol-L’1) 3.5 ± 1 .1 3.9 ± 1.6 4.3 ± 0.9 5 ±  1.4
Glucose (mmol-L'1) 6 ± 0 .9 5.6 ± 1 5.2 ± 0 .5 * 5.1 ± 0 .3
Systolic blood pressure (mmHg) 132 ± 20 138 ± 18 130 ± 1 0 124 ± 11
Diastolic blood pressure (mmHg) 79 ± 9 80 ± 9 85 ± 6 77 ± 4
Questionnaires
EQVAS 72 ± 1 8 70 ± 1 3 60 ± 2 4 80 ± 12
Epworth Sleepiness Scale 5 ± 4 10 ± 4 + 9 ± 3 + 8 ± 4
OSA-HC: high CPAP compliance; OSA-LC: low CPAP compliance; OSA-UN: untreated OSAS; OSAS-free: no 
OSAS; HDL: high-density lipoprotein; EQVAS: EuroQol visual analogue scale; *: P<0.05 vs. OSA-HC; +: 
P<0.001 vs. OSA-HC
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9.6 Exercise capacity
Four participants in the OSA-HC group and one in each of the untreated and non-OSAS 
groups did not conduct the incremental shuttle walk test (Table 9.6). Reasons included 
high blood pressure (n=5) and injury (n=l). The OSAS groups were all similar with 
distance walked in the ISWT, post-exercise heart rate and post-exercise RPE. The OSAS- 
free group walked significantly further than each of the OSAS groups. This was 
matched with a higher post-exercise heart rate compared with the OSA-UN group only 
151 ± 12 vs. 130 ± 12 beats-min'1; P=0.040). Heart rate recovery at one minute was 
also similar between the OSA-HC and OSA-LC groups (-34 ± 14 vs. -28 ± 15 beats-min'1; 
P=0.291).
Table 9.6 Exercise capacity
OSA-HC OSA-LC OSA-UN OSAS-free
Immediately post-exercise 
Distance walked (m) 
Heart rate (beats-min-1) 
RPE
562 ± 269 
140 ± 22 
15 ± 2
575 ± 288 
139 ± 23 
17 ± 3
564 ± 135 
130 ± 12 
16 ± 2
808 ± 1 5 8 * £+ 
1 5 1 ± 12* 
17 ± 2
One minute post-exercise 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Heart rate (beats-min'1)
176 ± 21 
92 ± 9  
106 ± 23
187 ± 25 
93 ± 12 
110 ± 23
178 ± 26 
92 ± 12 
95 ± 12+
189 ± 33 
94 ± 8  
112 ± 14+
Three minute post-exercise 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Heart rate (beats-min'1)
156 ± 20 
83 ± 8  
81 ± 1 6
166 ± 2 1  
84 ± 11 
87 ± 16
160 ± 34 
90 ± 10 
82 ± 1 1
159 ± 24 
85 ± 6  
88 ± 7
Five minute post-exercise 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Heart rate (beats-min'1)
141 ± 16 
79 ± 11 
79 ± 1 4
146 ± 16 
80 ± 12 
85 ± 16
144 ± 17 
84 ± 9  
80 ± 14
141 ± 8  
78 ± 5  
81 ± 8
OSA-HC: high CPAP compliance; OSA-LC: low CPAP compliance; OSA-UN: untreated OSAS; OSAS-free: no 
OSAS; RPE: Rating of perceived exertion; *: P<0.05 vs. OSA-UN +: P<0.1 vs. OSA-LC; t :  P<0.1 vs. OSA-UN; 
£: P<0.05 vs. OSA-HC. Data presented are mean ± SD.
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Chapter 10 -  Discussion
10.1 Overview
The aims of this study were to  investigate the effects o f OSAS and its trea tm ent w ith 
CPAP on vascular function using a cross-sectional study design. We compared macro- 
and microvascular function between four groups: OSAS patients w ith high compliance 
to  CPAP, OSAS patients w ith low compliance to  CPAP, untreated OSAS patients and 
OSAS-free controls. Recruitment to  this study was poor, particularly in the low- 
compliance, untreated OSAS and OSAS-free controls. In view of a lim ited sample size, 
the results o f the study suggest low-compliance patients may have impaired 
macrovascular function compared w ith  patients w ith high compliance. Patients w ith 
low compliance were also shown to  have daytime somnolence, compared to  high- 
compliance patients, and despite this both groups had similar self-perceived health- 
related quality o f life. These findings are prelim inary and must be verified in a larger 
study.
10.2 Vascular function
There were no statistically significant differences between the OSA-LC and OSA-HC fo r 
percentage FMD regardless of the method of data presentation, however, percentage 
FMD was 28% lower in the OSA-LC group compared w ith the OSA-HC group using the 
traditional method (4.6 ± 4.1% vs. 3.3 ± 3.0%; P -0.313) and after a llom etric scaling (4.6 
± 3.1% vs. 3.3 ± 2.8%; P=0.331). Although the large SDs overlapped considerably, the 
between-group differences were associated w ith a small effect size (cf=0.35). There is a 
physiological basis fo r the presence of a difference tha t could be masked by the large 
variability. Dissimilarly, the mean dilatation in response to  sublingual GTN 
adm inistration was similar in both group (13.4 ± 5.1% vs. 13.1 ± 5.7%; P=0.895; d=0.02) 
which suggests that the difference in FMD was caused by impaired endothelial 
function or NO bioavailability, and not reduced vascular compliance or VSMC dila tor 
capacity. There was a larger shear rate area under the curve to  peak dilatation in the 
OSA-LC group compared w ith the OSA-HC, although again the large variability  in
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measurement lim its interpretation. That aside, the effect size was small at d=0A3. 
These data suggest that endothelium-m ediated arterial dilatation is impaired in 
patients not regularly undertaking CPAP therapy, evidenced by smaller dilatation in 
response to  a larger eliciting stimulus. To our knowledge, this is the firs t study to  
assess FMD in a homogenous group of low-compliance OSAS patients, although a 
previous study has compared FMD between OSAS patients and matched controls and 
OSAS patients during a CPAP intervention (Jelic et al., 2008). That study did include 
low-compliance patients however they were allocated to  a mixed group along w ith 
patients who refused to  undergo CPAP therapy. The ratio was approximately 3:1 in 
favour o f untreated patients, and this group will hereafter be referred to  as non­
responders. The study reported pre-CPAP mean baseline FMD percentage to  be 3.1 ± 
4.2% and 4.9 ± 4.5% fo r the responders and non-responders, respectively - the authors 
did not report baseline characteristics fo r the responders and non-responders, this 
makes it d ifficu lt to  explain the difference between means. A fter the intervention the 
responders increased FMD to 6.7 ± 4.2% and the non-responders to  5.6 ± 4.5%, which 
equated to  effect sizes o f d=0.83 and d=0.15. The Jelic et al. (2008) study did not 
report GTN-mediated dilatation so we are unsure how the current study compares to 
the samples previously reported fo r endothelium -independent vasodilatation. Jelic and 
colleagues also stratified the ir sample into three tertiles: OSAS-free (AHI< 5 events-h'1); 
m ild-to-m oderate OSAS (5< AHI <20 events-h1); and, moderate-to-severe OSAS 
(AHI>20 events-h'1). These tertiles had significant trends fo r im portant indicators of 
vascular health, which showed decreasing vascular health w ith increasing AHI, 
including eNOS (P=0.001), P-eNOS (P=0.001), COX-2 (P=0.001), endothelial progenitor 
cells (EPCs; P=0.001) and of course FMD (P=0.001); only eNOS was significantly 
d ifferent between the tw o OSAS tertiles (P<0.05). This study provided compelling 
evidence fo r the reduced repair capacity o f the vascular endothelium in OSAS.
FMD has been previously reported to be 9.6 ± 1.6% (Ip et al., 2004) in patients having 
undertaken 4 weeks of CPAP therapy, which was almost tw ice the ir pre-CPAP FMD (5.1 
± 1.4%). Improvements in FMD have been reported after shorter CPAP durations; 
Ohike et al. (2005) demonstrated an im provem ent from  3.3 ± 0.3% to  5.8 ± 0.4% 
(P<0.01; mean ± SEM) after one week of CPAP therapy. The mechanism by which 
effective CPAP therapy improves endothelial function is thought to  be clear;
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elim ination o f apnoea reduces oxidative stress and sympathoexcitation-induced 
vasoconstriction (which increase luminal shear stress on the vascular endothelium), 
allowing the endothelium to  repair itself and improve function.
The effects o f d ifferent levels o f CPAP therapy on microvascular function remain 
unclear. Contrary to  expectation, there were no noteworthy differences between the 
OSA-HC and the OSA-LC groups fo r any o f the variables investigated. These results can 
be interpreted in tw o  ways: 1) low compliance to  CPAP therapy does not reduce 
microvascular function in OSAS; or 2) the current study was insufficiently powered to  
detect any differences. Although evidence in the literature suggests tha t OSAS is 
associated w ith impaired microvascular function, which is reversed w ith  effective CPAP 
therapy, the current study could not reproduce this finding. A major strength o f this 
protocol was the use of three seven-fibre probes, which allows fo r the measurement 
of skin blood flow  across up to  21 sites. This helps to  reduce the impact of spatial 
variability in the cutaneous distribution o f microvessels.
10.3 Secondary outcomes
10.3.1 Anthropometry
Body habitus was similar between groups although the low-compliance group had a 
smaller waist circumference. This difference could be attributed to  the higher 
proportion of female participants in the OSA-LC versus the OSA-HC groups. A similar 
non-significant difference in mean waist circumference was identified in the Billings et 
al. study (Billings et al., 2013). The anthropom etric characteristics of the OSA-HC group 
in particular closely match the intervention and control groups in study 1. CPAP alone 
has been shown to have no effect on obese middle-aged OSAS patients.
10.3.2 Cardio vascular risk
Blood-borne biomarkers representing cardiovascular risk were similar between the 
OSA-HC and OSA-LC groups. Surprisingly, the OSA-UN group had higher HDL and lower 
glucose than the OSA-HC group. The form er is unlikely to  be meaningful as the 
cholesterol to  HDL ratio was less favourable in the OSA-LC group. The absence o f a 
between-group difference fo r glucose is not surprising. Yang et al. (2012) perform ed a
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meta-analysis on fasting blood glucose in OSAS. They pooled nine studies o f mixed 
design and assessed the impact of regular CPAP on fasting glucose and found 
inconclusive evidence fo r any effect in non-diabetic or diabetic OSAS patients 
(although the latter conclusion was based on tw o studies only). Our groups contained 
a m ixture of diabetic and non-diabetic patients and mean glucose concentrations were 
similar to  the studies included in the Yang et al. (2012) meta-analysis.
10.3.3 Questionnaires
Self-perceived health-related quality o f life was similar between all groups, however 
daytime tiredness was much higher in the OSA-LC and OSA-UN groups (10 ± 4 and 9 ± 3 
vs. 5 ± 4 in the OSA-HC group). The latter comparison is not a new finding, w ith 
numerous studies having reported reductions in daytime somnolence in response to 
CPAP therapy. This is a logical finding as these patients are probably having 
fragmented sleep due to  frequent apnoea stimulating microarousals. There is little  
evidence in the literature tha t discusses tiredness in OSAS patients tha t are not CPAP- 
intolerant but are unable to achieve an acceptable level o f compliance.
This study used CPAP compliance fo r the three months prior to  study entry to 
determ ine which group patients would be allocated to. The reasons fo r low 
compliance were not investigated in the current study and hence a number of 
phenotypes were probably included: patients unable to tolerate CPAP through chronic 
sinus blockage; patients unable to  tolerate CPAP because of claustrophobia; patients 
not wanting to  use CPAP because of a lack of daytime symptoms (and perhaps a 
misunderstanding of the role of CPAP in preventing chronic disease); and, patients 
refusing to  wear the CPAP mask having just entered into a new relationship. Each of 
these reasons was mentioned anecdotally to  the chief investigator during this study. 
The underlying causes of low compliance need to  be conclusively identified and 
addressed, and obviously fo r patients unable to tolerate CPAP on a nightly basis it is 
im portant fo r researchers and health professionals to  understand if occasional CPAP 
offers any benefit, or whether it is simply resource wastage. Douglas et al. (1998) 
conducted a systematic review of the effects o f CPAP on daytime tiredness and 
daytime functioning and concluded that CPAP can effectively improve both. In the 
current study, the OSA-LC group showed no decrement in health-perceived quality of
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life. There was no correlation between ESS and EQVAS, suggesting tha t although many 
patients were tired during normal daytime activities, participants did not consider this 
tiredness to  negatively affect the ir health. This has been shown before (Sforza et al., 
2013). Bollig et al. suggested tha t encouragement and support to improve CPAP 
compliance is everyone's job  and tha t problems encountered w ith CPAP use should be 
resolved as soon as possible to  reduce the amount o f tim e patients spend w ithout 
treatm ent and to  improve the likelihood of successful adherence in the future.
10.3.4 Exercise capacity
Distance walked in the ISWT was similar in all three OSAS groups, which were each 
significantly lower than the OSAS-free group. The ISWDs reported in the current study 
are higher than those in the Billings et al. (2013) study, which is likely due to  the 
differences in testing centre and the delivery o f the test. Our ISWT protocol allows 
patients to  jog during the test to increase speed, whereas the original Singh et al. 
(1992) protocol used by Billings et al. (2013) does not explicitly condone this. Both 
studies suggest there is no difference in exercise capacity between high- and low- 
compliance patients. The characteristics o f the OSAS-free group suggest it was not 
matched fo r age, sex, BMI and com orbidity as was proposed at the outset. This group 
also under-recruited and w ith only four participants completing the ISWT, therefore 
only weak conclusions can be drawn. There were no differences in post-exercise heart 
rate or RPE, or in the rate o f heart rate and blood pressure recovery in the high and 
low-compliance groups. Indeed, heart rate recovery a fter one min was similar to  non- 
OSAS control groups in other studies (Chien et al., 2011; Kline et al., 2012).
10.4 Limitations
10.4.1 Recruitment and sample size
The proposed recruitm ent target and timescale was 80 participants in fou r months; 
this study recruited 45 participants in seven months. A provisional pre-study 
assessment o f e lig ibility suggested 10 and 5 patients per week would be eligible to 
participate in the OSA-HC and OSA-LC groups. Assuming a 30% recru itm ent rate 
(higher than study 1 because of the personal in-clinic approach, the low-intensity
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demands of the study, the minimal time com m itm ent (2 visits) and the flexible nature 
o f appointm ent setting) it was expected tha t recruitm ent o f the primary groups would 
be complete w ith in 4 months. Recruitment was much more problematic than 
anticipated. The high-compliance patients were recruited w ith  relative ease, and 
although recruitm ent for this group lasted five months, this was because the 
researcher recognised the abundance of participants and the willingness of them to  
participate, and as a result reduced the proportion of tota l recruitm ent activities 
focussed on this group. Despite an informal pre-study assessment of e lig ib ility rate, 
once recruitm ent started the number of eligible patients to recruit from  was vastly 
reduced. This could be Lasagna's Law in action, which anecdotally states tha t potential 
patient pool is often much smaller as soon as a study starts to  recruit, and then 
increases again once recruitm ent is finished. Recruitment o f low-compliance patients 
was lim ited by several reasons.
Firstly, the proportion of all patients attending sleep clinic tha t met the inclusion 
criteria fo r this group was relatively low. This was because many patients tha t were 
struggling w ith compliance were not obese, and they also tended to  be younger w ith 
personal (e.g. childcare) and professional (e.g. employment) commitments tha t made 
taking a morning o ff to  participate in voluntary research (w ith no overt benefit to  the 
patient) d ifficult. Attitudes towards research in this patient group were also negative; 
this could reflect general attitude towards healthcare and CPAP compliance could 
predict willingness to  participate in research. It was expected tha t interest in the study 
from  low-compliance patients would closely match tha t o f the high-compliance group 
because the ir sub-optimal compliance probably reflects discontent w ith CPAP as a 
treatm ent. If this study had provided strong evidence tha t vascular endothelial 
function was no different from high-compliance patients and significantly (and 
meaningfully) greater than untreated patients, then a fo llow -up study to  assess a 
w ider range of health outcomes in this sub-population would be merited and the 
evidence from  those studies, could inform policy fo r the management o f OSAS 
patients; in particular, how patients w ith sub-optimal compliance are treated. It could 
show tha t alternate nights o f usage provide the m ajority o f the benefits o f nightly 
usage (in the absence of EDS). This o f course is not supported by the current results. A 
final lim iting factor in the recruitm ent o f CPAP patients was clinic attendance.
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Recruitment fo r this study was done on a face-to-face basis, which meant tha t the 
researcher attended regular clinics at Northern General Hospital. This is not a tim e- 
effective method of recruitm ent; however it was chosen to  seamlessly integrate into 
the routine activities of the sleep clinic. It would be more effective in future to  try  and 
involve the hospital-based nurses, doctors and physiologists in the recruitm ent 
process. Also patients tha t missed appointments were often those w ith a history of 
borderline usage. Because of a major finding of study 1 (that previous CPAP 
compliance checks and self-reported compliance is not a reliable indicator of actual 
compliance), recruitm ent fo r study 2 took place during and imm ediately a fter CPAP 
compliance checks. As a result, patients who did not attend, did not bring the ir CPAP 
machine, or brought corrupted memory cards were not approached to  take part. 
Finally, recruitm ent of control participants was difficult. Previous studies in our centre 
have not had d ifficulty recruiting control participants from  local interest groups. It was 
expected tha t due to  the short, low-intensity nature of the study com m itm ent tha t 
recruitm ent o f 20 control participants would not be difficult. The main barrier to 
participation was the overnight OSAS screening fo r covert presence of the disease. 
A fter attending fam iliarisation some patients were reluctant to participate a fter finding 
out tha t if OSAS was suspected that the ir general practitioner may refer them to  a 
sleep specialist fo r confirmation. If confirmed and of at least moderate severity, CPAP 
therapy would be likely, and compliance w ith CPAP would be im portant otherwise 
the ir driving licence could be jeopardised. Despite iteration o f the negative 
consequences of untreated OSAS to  health, many participants declined the overnight 
PSG and hence to  participate. Public awareness of OSAS is not high and discussing a 
condition tha t involves periods o f no breathing and may require nightly use of a 
machine tha t blows high-pressure air into the airway can seem a daunting prospect. 
A ltogether, this study did not recruit to  target and hence all results should be 
interpreted w ith caution.
The FMD assessment as a surrogate marker o f vascular endothelial health requires 
technical expertise. We followed the recommendation of Corretti et al. (2002) tha t 
practitioners perform more than 100 supervised scans to develop and assess 
competencies. Vascular imaging is a manual technique tha t requires a skilled 
practitioner to  not only optim ise an image of the brachial artery, but to  keep it
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optim ised throughout the scan (this includes surfing movement in the patients arm if 
they cough, sneeze or flinch). As the scanned image is a two-dimensional cross-section 
of the brachial artery it is d ifficu lt to  be certain that the imaged segment is actually the 
true diameter; only a few  degrees of deviation would produce an image of a chord (a 
cross-sectional view of the same vessel that has a shorter w idth than the diameter 
that, fo r all intents and purposes would appear the same). To address these issues 
researchers often apply a rolling smoothing technique to  raw data to  try  and remove 
outliers tha t could distort measurements. There is no universally accepted smoothing 
method and changing from  3 s, to  4 s to  5 s rolling median average w ill likely reduce 
the peak diameter reading.
10.5 Future research
Unfortunately the current study did not have appropriate statistical power to  answer 
the principal research question. It is anticipated tha t w ith modifications to  the 
recruitm ent strategies and revision of expected recruitm ent rates and goals tha t 
enough patients could be recruited to  answer our research questions. Data from  the 
current study can be used to estimate a sample size fo r a future study. This estimate 
(as it is based on internal prelim inary data) can be more accurate than using data from  
other centres as it takes into account site-based factors such as outcome variance. 
Using an alpha level of 0.05, a beta (power) o f 80% and a 2-tailed study design the 
current data suggest needing 83 participants per group to  detect a significant 
difference. As there is no need to  account fo r participant w ithdrawal, and including the 
current data w ith no changes to  protocol (thereby making it an internal p ilot) we 
would need to  recruit and additional 64 high-compliance patients and 70 low- 
compliance patients. Modifications to the recruitm ent strategies would be needed to  
achieve this.
10.6 Summary
Vascular endothelial function was the primary outcome measure in this study. We 
identified potential evidence of impaired vascular endothelial function in OSAS
162
patients w ith low-compliance to  CPAP therapy compare w ith high compliance patients. 
The reliability o f these findings is unclear because the OSA-LC group did not recruit to 
target and may lack the scientific power to identify significant differences. This under­
recruitm ent was because the prevalence of these patients was lower than expected, 
and the ir willingness to  participate in research was also lower, compared w ith the ir 
high-compliance counterparts. Encouragement (or interventions) to  improve CPAP 
usage in patients tha t are CPAP to lerant should be delivered by the primary care team.
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Chapter 11 -  Summary of findings
This research broadly aimed to investigate the physiological effects o f d ifferent 
treatm ent strategies in OSAS. Both studies recruited patients tha t were undergoing 
CPAP therapy in the local NHS Foundation Trust. CPAP is currently the preferred 
treatm ent and is approved by the National Institute fo r Care and Health Excellence fo r 
its efficacy at elim inating apnoea and its cost-effectiveness. However tw o  significant 
issues are associated w ith it. Firstly, CPAP is a management therapy and w ill not cure 
the condition, which means patients must use a machine that is often uncomfortable 
and embarrassing fo r the foreseeable future. Secondly, because of its arduous nature 
not all patients can tolerate CPAP on a nightly basis. Therefore it is im portant to 
investigate alternative treatm ent pathways fo r OSAS patients, and to  develop 
understanding of the short-, medium- and long-term physiological effects o f partially- 
treated OSAS.
Endothelial function has regularly been shown to  be impaired in OSAS; a deficit that 
can be ameliorated w ith regular CPAP therapy (of even short durations). There were 
no changes in endothelium-dependent or -independent vasodilation identified in study 
one, which may be attributable to  the use of a single fibre LDF probe (because 
microvascular function has previously been shown to  suffer from high spatial 
variability). This issue was addressed in study tw o by using three seven-fibre probes to 
measure skin blood flow  (which increases the fibre count from 1 to  21). Study tw o  also 
used d ifferent provocation tests because of equipment-related issues. Comparisons 
between the OSA-HC and OSA-LC groups did not identify any differences any o f the 
measured variables. Study tw o also investigated macrovascular function by assessing 
FMD. No significant differences were identified between the high- and low-compliance 
groups, although the OSA-LC group was slightly lower (A 1.3 [-1.3, 3.94]%) and was 
associated w ith a small effect size [d=0.35). As study tw o did not recruit to  target and 
FMD was the primary outcome measure, it is possible tha t the comparison lacked the 
necessary power. Furthermore, this technique is associated w ith a large am ount of 
inherent variability tha t may have contributed to  the lack of statistical significance.
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The participants in both studies were clinically obese. The lifestyle intervention had 
minimal effect on body mass, and the triv ia l changes observed did not result from  a 
profound change in body composition (i.e. body mass will not change if reductions in 
fa t mass coincide w ith increases in muscle mass). In study tw o the low-compliance 
group tended to  have a lower body mass and a smaller waist circumference which 
could reflect the higher proportion of female participants.
The participants in study one had a number o f raised cardiovascular risk factors. BMI 
was high (although we intentionally recruited only obese patients), serum insulin was 
high and serum CRP was high. Although not all participants were optim ally com pliant 
w ith CPAP, compliance did not correlate w ith any o f the aforementioned factors. In 
study two, there was no difference in cardiovascular risk factors between the high- and 
low-compliance patients, although patients in both groups were borderline glycaemic 
and pre-hypertensive. These studies have demonstrated that despite CPAP therapy, 
OSAS patients may still have an increased cardiovascular risk profile; however the 
frequency of CPAP use did not seem to  significantly affect risk, so even occasional 
CPAP therapy may have protective effects.
In study one the ISWD in the intervention group at end-point and fo llow -up was 724 ± 
193 m and 737 ± 179 m, respectively, which are not dissimilar from  the 808 ± 158 m 
observed in the OSAS-free group of study 2. This could be evidence o f a reversal o f 
OSAS-induced reductions in exercise capacity not achieved by CPAP therapy alone. 
W ith low cardiorespiratory fitness earmarked as a more im portant risk factor fo r 
cardiovascular disease than smoking or obesity, improved fitness is not to  be 
underestimated. Future research is required to  address whether these short-term  
changes in exercise capacity and behaviour translate into long-term  increases in 
habitual physical activity. Although self-perceived quality of life was sim ilar between 
groups in study one, there was no marked improvement in self-perceived health- 
related quality o f life until fo llow-up, when the intervention group had increased 9 
points from  baseline. In study two, health-related quality o f life reflected trea tm ent 
status, w ith OSAS-free being greatest and the OSAS groups decreasing proportionate ly 
to  treatm ent (i.e. OSA-HC>OSA-LC>OSA-UN). Unsurprisingly, the OSA-LC and OSA-UN
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groups presented w ith a higher daytime somnolence tha t the OSA-HC group, which 
highlights the importance of regular CPAP use to  reduce daytime tiredness.
This thesis has reported a number of findings not previously published in the medical 
literature.
1) Our pragmatic lifestyle intervention was feasible to deliver. Although previous 
studies have provided evidence fo r the feasibility of delivering similar lifestyle 
interventions in OSAS, this is the firs t to be conducted w ith in  the NHS and the 
U.K. and the firs t to assess the efficacy of basic dietary advice and behaviour 
change counselling delivered by an exercise physiologist. Recruitment fo r this 
study was good, exemplified by recruitm ent rates that closely matched those 
reported in studies conducted in Finland, Brazil and the United States of 
America. Compliance w ith study-related activities was excellent and in excess 
of the studies reported by Kline et al. (2011) and Tuomilehto et al. (2009), 
which suggests the method of delivery promoted adherence. Lastly, there were 
no adverse events emphasising the safety o f the delivered in tervention.
2) The intervention improved key health outcomes such as exercise capacity and 
serum C-reactive protein, which were maintained after 3 months of 
independence. The lifestyle intervention evoked improvements in some key 
health outcomes. Improvements in exercise capacity were identified using the 
ISWT as a metric. Maintenance of higher fitness levels at fo llow -up shows an 
absence of the detraining response to  w ithdraw ing the exercise stimulus -  this 
suggests tha t patients may have continued regular exercise and maintained the 
improvement. Increased fitness and regular exercise has several benefits, 
including reduced age-related decline in lean muscle mass and bone density. 
Reductions in CRP indicate a reduced state o f systemic inflam m ation and an 
overall lower risk, if sustained long term , of developing cardiovascular disease. 
These findings are im portant because they suggest that this pragmatic lifestyle 
intervention could improve the overall clinical picture o f OSAS patients.
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3) Self-reported CPAP compliance is an unreliable indicator of true compliance.
This was an incidental finding from  study one, which recruited patients that 
self-reported using CPAP therapy on a regular basis (defined as >4 h-night-1 on 
>75% nights). Post-study compliance verification highlighted many patients 
(almost 25%) had overestimated the ir usage beyond the inclusion criteria. This 
was unexpected and not discovered until the final participant had completed 
the study, and the reasons fo r the over-estimation are unclear. This could have 
been an innocent mistake, or an attem pt to  gain illegitimate entry to  the study. 
Studies assessing CPAP compliance will usually use objective data from  CPAP 
memory cards; however this was not feasible. Although recru itm ent took place 
from  a local Trust, study activities took place in the University, which did not 
have the appropriate hardware or software to easily assess this. We could have 
collected cards, assessed them and returned them to  patients' days later; 
however this would have posed logistical and financial problems.
4) It is difficult to recruit low-compliance patients onto research trials, and 
recruiting newly diagnosed patients is also difficult without interrupting the 
patient pathway. There are a lim ited number o f trials tha t have specifically 
sought to  recruit low-compliance patients - usually a retrospective study design 
will allocate participants to one group or the other, depending on the ir 
treatm ent status. The accidental recruitm ent o f low-compliance patients in 
study one informed the design o f study two, as undertreated patients seemed 
to  be more common in our OSAS population. We recruited d ifferent sub-sets of 
the OSAS population into a cross-sectional study design, and encountered 
problems recruiting low-compliance patients. It is likely tha t patients tha t have 
poor compliance w ith CPAP may be less interested in participating in OSAS 
research. The precise reasons influencing the participation o f low-compliance 
patients in medical research is yet to be determined.
5) Vascular function seems impaired in low-compliance patients versus high- 
compliance patients, although further work is needed to confirm this. This 
finding is based on the difference in mean values and a small effect size. This
168
difference was not statistically significant suggesting the study may have been 
underpowered. There is currently no evidence in the literature regarding what 
effect occasional CPAP use has on reversing the OSAS-induced impairment in 
vascular endothelial function. These, and other, data about key health 
outcomes in low-compliance OSAS-patients are important to discern and could 
inform the way that this sub-population are treated. Moreover, the current 
data allow a more precise sample size estimation to be conducted to base a 
future study upon.
Future research should adapt the intervention and perhaps incorporate specialist 
support (e.g. nutritionist) to promote greater weight loss and evaluate the effects of 
the lifestyle intervention on indices of OSAS severity. We have also shown that the use 
of self-reported CPAP compliance is inadequate and an unreliable metric of true 
compliance, and recommend that future studies use only objective compliance from 
the CPAP machine to determine eligibility. This research has provided promising 
evidence to support the role of lifestyle intervention in a motivated subset of OSAS 
patients. Undoubtedly, such an intervention would not be indicated in all patients. 
Lifestyle intervention would probably be most efficacious when delivered in 
conjunction with nightly CPAP therapy. Furthermore, the effects of the intervention 
should be investigated in patients with sub-optimal CPAP compliance and CPAP 
intolerance. Finally, the effects of low compliance on vascular endothelial function 
should be reinvestigated by recruiting a larger number of patients. Such studies would 
provide evidence that could have implications for the way patients that struggle to 
reach optimal compliance are managed in the NHS.
Word count: 45537
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EFFECTS OF A LIFESTYLE INTERVENTION ON EXERCISE CAPACITY, QUALITY OF LIFE, BODY 
MASS/COMPOSITION AND CARDIOVASCULAR RISK IN PATIENTS BEING TREATED FOR OBSTRUCTIVE
SLEEP APNOEA
D ear.....................................................
We are undertaking a research study to investigate the feasibility and effectiveness o f a 12- 
week lifestyle intervention fo r patients being treated fo r obstructive sleep apnoea. The results 
o f this research could ultim ately prove to  be o f significant benefit to  such patients by 
providing new insights into the effects o f lifestyle modification on various aspects o f health. 
You might have been selected as being a suitable patient from  attending the hospital or 
because you have been involved in a previous study. Please find enclosed a participant 
inform ation sheet, which describes the study in detail and answers the most frequently asked 
questions.
A member of the research team will be phoning you shortly to  see if you would be interested 
in participating in this study and will gladly answer any questions you m ight have. It is 
im portant to  note tha t there is no pressure to  participate in this study and if you do not wish 
to be contacted about this study please phone James Moss on 0114 2252262 or 07738240670 
before 16th October.
Yours sincerely,
Dr Stephen Bianchi 
Respiratory Physician 
Royal Hallamshire Hospital
SLEEP APNOEA RESEARCH STUDY
Yes. I am interested in taking part in the above named study. I understand 
tha t a member of staff will be contacting me, regarding this study.
No, I am not interested in taking part in the study
N a m e : _____________________________
Telephone Number: __________________________
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PARTICIPANT INFORMATION SHEET 
Version 3: 12th October 2009 
EFFECTS OF A LIFESTYLE INTERVENTION ON EXERCISE CAPACITY, 
QUALITY OF LIFE, BODY MASS/COMPOSITION AND CARDIOVASCULAR RISK 
IN PATIENTS BEING TREATED FOR OBSTRUCTIVE SLEEP APNOEA
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it will involve for you. 
Please take time to read the following information carefully. Talk to others about the 
study if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part.
What is the purpose of the study?
Obstructive sleep apnoea (OSA) is a common disorder characterised by interrupted 
breathing while sleeping. It is associated with cardiovascular problems such as high 
blood pressure, heart attack and stroke. Furthermore, many OSA patients are 
overweight and have impaired quality of life. Lifestyle interventions incorporating 
exercise training, dietary advice and behaviour change have been shown to elicit 
favourable changes in exercise capacity, quality of life, body mass/composition and 
cardiovascular risk in a range of patient groups. However, no study has investigated 
the impact of lifestyle modification on such health outcomes in patients being treated 
for OSA. This study will address this issue by investigating the effects of a lifestyle 
intervention on exercise capacity, quality of life, body mass/composition and 
cardiovascular risk in patients with OSA.
Why have I been invited to take part?
You have been invited to take part because you are being treated for OSA.
Do I have to take part?
It is up to you to decide. We will describe the study and go through this information 
sheet, which we will then give to you. We will then ask you to sign a consent form to 
show you have agreed to take part. If you do decide to take part, you will be free to 
withdraw at any time, without giving a reason. This would not affect the standard of 
care that you receive.
Part 1
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What will happen to me if I take part?
Your involvement in the study will last for about 26 weeks. During the first week you 
will undertake two assessment visits as detailed below. You will then be assigned to 
a lifestyle intervention group or a usual care control group. The group that you are 
assigned to will be decided by chance (randomly) and you will have an equal chance 
of being in each of the two groups. If you are in the lifestyle intervention group, you 
will receive supervised exercise training, dietary advice and behaviour change 
counselling for 12 weeks. If you are in the control group, you will receive an 
educational booklet detailing healthy eating and exercise guidelines but no 
supervised or structured intervention. At the end of the 12-week intervention period, 
you will redo the two assessment sessions. You will then be asked to complete the 
assessments for a third time, 12 weeks after the end of the intervention. After this, 
you might also be asked to attend a focus group meeting, in which we will ask for 
your feedback about the study.
What will the assessment visits involve?
There will be two assessment visits at the beginning of the study, at the end of the 
12-week intervention period, and at 12 weeks after then end of the intervention. On 
each occasion it is essential that no food or caffeine is consumed for four hours 
before the assessment session and that you refrain from exercise and alcohol for 24 
hours prior to the session.
Visit 1: Sheffield Hallam University
You will attend the research centre at Sheffield Hallam University for a medical 
examination to assess whether or not you are eligible to take part in the study. 
During this assessment, we will assess your blood pressure, height, weight, and 
body composition. We will also perform a resting electrocardiogram (ECG) to assess 
the rhythm and electrical activity of your heart. If you are deemed suitable for 
participating in this study, we will then take a 10 ml (two teaspoon) sample of blood 
from a vein which will be used to assess circulating glucose, insulin and lipoprotein 
concentrations. We will then ask you to complete a shuttle-walk test. During this test 
you will be asked to walk up and down a 10-m course. The walking speed will start 
slow, increase slightly each minute, and will be determined by an audio signal. The 
test will end when either you are too breathless to continue, you fail to complete two 
consecutive shuttles within the time allowed, or if you achieve 85% of your maximum 
heart rate. Overall, this visit will last around 1 hour.
Visit 2: Sheffield Hallam University
Your second assessment session will also take place at Sheffield Hallam University. 
On this visit, the blood flow in the small vessels of the skin will be assessed using a 
technique called iontophoresis. This technique involves the placement of electrodes 
onto the skin surface of your forearm. We will clean and shave the areas where
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these electrodes are to be placed. Once the electrodes are in place skin blood flow 
will be stimulated using tiny amounts of drugs that will be delivered into the skin by 
applying a small electric current through the electrodes. The drugs used are 
acetylcholine and sodium nitroprusside. These drugs have been used in this way 
previously in many research volunteers over many years with no reported side 
effects. You may feel some 'tingling' of the test area during this test but this should 
not cause you any discomfort. Only the very small blood vessels in the skin that we 
are investigating will be affected by this technique. Blood pressure will be taken 
throughout this test session. During this session, we will also ask you to complete 
some quality of life questionnaires. Overall, this visit will last around 1 hour.
The lifestyle intervention programme
Once you have completed the two visits you will be assigned randomly (i.e. like 
tossing a coin) to one of two groups. One of the groups will undertake a lifestyle 
intervention programme and one will not. If you are in the lifestyle intervention group, 
you will receive exercise training sessions (60 minutes per session) three times a 
week, dietary advice, and behaviour change counselling for 12 weeks. For the first 
four weeks, all of the exercise sessions will be supervised at Sheffield Hallam 
University. Between weeks 4 to 12, the supervised sessions will gradually be 
replaced with home-based exercise. The exercise sessions will involve light-to- 
moderate intensity aerobic and resistance exercises. If you are assigned to the 
control group, you will receive an educational booklet detailing healthy eating and 
exercise guidelines but no supervised or structured intervention.
After the lifestyle intervention programme
You will repeat visits 1 and 2 above within 1 week of finishing, and then again about 
12 weeks after finishing. All repeat visits will be completed at Sheffield Hallam 
University.
What are the disadvantages of taking part?
The procedures that we are using in this research are all well established techniques 
which have been used in other patient groups in numerous research studies without 
any significant side effects being reported. Therefore the only side effects that we 
would expect you to experience are the minor side effects associated with the test 
procedures described above.
What if I do not wish to take part?
This will in no way affect your treatment.
What if I change my mind during the study?
You are free to withdraw from the study at any time without affecting your treatment. 
What are the possible benefits of taking part?
We cannot promise that the study will help you but the information we get from this 
study might help improve the treatment of people with obstructive sleep apnoea.
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Will my involvement in the study be kept confidential?
Yes. We will follow legal and ethical practice and all information about you will be 
handled in strict confidence. Any information about you that leaves the research 
centres will have your name and address removed so that you cannot be recognised 
from it.
What will happen to the information from the study?
It is anticipated that the results of the study will be presented at scientific meetings 
and published in a scientific journal. These overall results will be available to you; 
however, it will not be possible to produce an individualised report of your 
performance.
What if there is a problem?
Any complaint about the way you have been dealt with during the study or any 
possible harm you might have suffered will be addressed. Detailed information on 
this will be given in Part 2.
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision.
Part 2
What if I have further questions or would like more information about the 
study?
If you would like more information about the study you are invited to contact:- 
Mr Garry Tew Sheffield Hallam University Tel 0114 225 2358
Dr John Saxton Sheffield Hallam University Tel 0114 225 4414
Dr Stephen Bianchi Royal Hallamshire Hospital Tel 0114 271 1740
What happens if I have a complaint?
If you have any cause to complain about any aspect of the way in which you have 
been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms are available to you and are not 
compromised in any way because you have taken part in a research study. If you 
have complaints or concerns, please contact the project supervisor Dr John Saxton, 
Tel 0114 225 4414. Or alternately you can use the normal hospital complaints 
procedure and contact Professor Chris Welsh, Medical Director, Sheffield Teaching 
Hospitals NHS Foundation Trust, Tel 0114 271 2178 or you can use the normal 
University complaints procedure and contact the University Secretary and Registrar, 
Liz Winders, Tel 0114 225 2051.
What if I am harmed?
In the event that something does go wrong and you are harmed during the research 
study, there are no special compensation arrangements. If you are harmed as a 
result of someone’s negligence then you could have grounds for legal action for 
compensation, but you might have to pay your legal costs.
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What will happen to the samples I give?
The blood samples taken at visit one will be stored at either the Royal Hallamshire 
Hospital or Sheffield Hallam University. Any excess not required for analysis will be 
discarded.
Who is organising and funding the research?
This study is being organised and lead by staff at The Centre for Sport and Exercise 
Science, Sheffield Hallam University and Sheffield Thoracic Institute, Royal 
Hallamshire Hospital. This study is being funded by Sheffield Hospitals Charitable 
Trust and the Sleep Apnoea Trust.
Who has reviewed the study?
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed by the South Yorkshire Research Ethics Committee.
Further information/independent advice
If you require any further information or independent advice about this study, please 
contact the Patient Advisory Liaison Service (PALs) on Tel 0114 271 2450 (Royal 
Hallamshire Hospital) or Tel 0114 271 5759 (Northern General Hospital).
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Appendix 3
QSASTUDY 
PARTICIPANT DETAILS AND MEDICAL SCREENING
STH STUDY 
NUMBER:
15488 DATE:
PATIENT ID
NUMBER:
Name: DOB:
Address:
Telephone: h: m: w:
E-mail:
Consultant: Hospital:
GP:
Practice:
Current
Medication:
BMI:
Waist/hip/neck circumferences:
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OSA history:
Walking aid? O  Yes O  No Details:
a.
Past History
1. Medical History 
Family History Present Symptoms
Have you ever had? Y N Have any im m ediate  Y N Have you recently  Y N
fam ily  had? had?
High blood pressure
Any heart trouble
Arterial disease
Lung disease
Asthma
Diabetes
Epilepsy
Arthritis
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □
Heart attacks
High blood pressure
High Cholesterol
Stroke
Diabetes
Early death
Other family illness
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □
Chest pain/d iscom fort
Shortness of breath
Heart palpitations
Dizzy spells
Frequent headaches
Frequent colds
Back pain
O rthopaedic problem s
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □ 
□ □
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If you answered yes to any of the above, please give brief details
b. Have you had to consult your doctor in the last 6 months? Yes j j No j j
If yes, please give details
c. Do you currently have any form of muscle or joint injury?
If yes, please give
details
d. Have you had to suspend normal activity in the last 2 weeks 
If yes, please give details
Yes
e. As far as you are aware, is there anything that might prevent you from 
successfully completing the assessments outlined to you?
Yes ] ”oD
2. Lifestvle Habits
Smoking
a. Do you currently Smoke?
If yes, what do you smoke and how much per day
Yes Q
b. Are you a previous smoker?
If yes, how long is it since you stopped and how much did you smoke?
Yes No
Yes □ N0D
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Drinking
c. Do you drink any alcohol? 
If yes, do you have?
An occasional drink
Yes
A drink every day More than one drink a day □
d. Do you drink any caffeinated drinks?
If yes, how many cups/glasses a day?
Coffee Tea
Yes
Soft Drinks
Physical Activity
e. How would you describe your occupational Sedentary |~~j Light | ~ |  M oderate j j Heavy j j 
activity level?
f. Do you currently engage in any physical activity? 
If yes, what type?
Yes on
On average: How often? tim es/w eek For How long? time/session
If blood samples are to be taken, please answer the following questions:
a) Are you suffering from any known serious infection? Yes No
b) Have you had jaundice within the previous year? Yes No
c) Have you ever had any form of hepatitis? Yes No
d) Are you HIV positive? Yes No
e) Have you had unprotected sexual intercourse with any person from Yes No
an HIV high risk population?
f) Have you ever been involved in intravenous drug use? Yes No
g) Are you haemophiliac? Yes No
* i f  the answer to any o f the above is Yes then piease discuss the nature o f the problem.
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3. Future Goals
a. How important is your health to you?
at all Q  Slightly Moderately Quite a bit Q  ExtremelyNot
b. What else is important?
Social Life ||J  Family Work j j Other - please specify
c. What are your main reasons for attending the session?
Feel healthier Fitness QJ Weight loss j j
Look better J^ J Manage my illness Q  Other-please specify
d. What personal health and wellness goals would you like to achieve within the next 6 months?
e. What do you feel will affect your ability to achieve this?
Signature: Date:
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Appendix 4
Sheffield Teaching Hospitals
NHS Foundation Trust
Sheffield Hallam
University
CONSENT FORM 
Version 3: 12th October 2009
Effects of a lifestyle intervention on exercise capacity, quality of life, body mass/composition 
and cardiovascular risk in patients being treated for obstructive sleep apnoea
the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.
3. I understand that relevant sections of any of my medical notes and data collected during the 
study may be looked at by individuals from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these individuals to have access to 
my records.
4. I give permission for my GP to be informed of my participation in this research.
5. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
Please initial box
1. I confirm that I have read and understand the information sheet dated for
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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Appendix 5
OSA STUDY - HOME EXERCISE SESSION(S) 
DATA COLLECTION SHEET (WEEKS 5-12)
STH STUDY NUMBER: 15488 WEEK:
PATIENT ID
NUMBER:
1. HOME SESSION(S) DATE...............  TIME
Suggested Exercise Achieved Exercise
Activity
(walking,
swimming
etc)
Intensity
(RPE Scale)
Time
(minutes)
Additional
Comments
Intensity - Borg's RPE Scale
6
7 Very, very light
8
9 Very light
10
11 Fairly Light
12
13 Somewhat hard
14
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Activity
Monday Type of Exercise:
Duration: Intensity (RPE):
Tuesday
Type of Exercise:
Duration: Intensity (RPE):
Wednesday
Type of Exercise:
Duration: Intensity (RPE):
Thursday
Type of Exercise:
Duration: Intensity (RPE):
Friday
Type of Exercise:
Duration: Intensity (RPE):
Saturday
Type of Exercise:
Duration: Intensity (RPE):
Sunday
Type of Exercise:
Duration: Intensity (RPE):
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Appendix 6
Three bay Diet Diary
I t  is important that you note down everything tha t you eat and drink in the three 
days covered by this diary, including things consumed away from home, e.g. snacks or 
alcohol. This is important because i f  items are missed out the resulting analysis will 
not produce a true picture of your diet and we will not be able to compare it  to the 
other diaries you will complete over the course of this study. Try to be as honest as 
possible, your responses will not be shown to the group.
When recording items in the diary you should enter the type of food or drink 
consumed and approximate quantity, e.g. two slices of toast or a can of coke. Where 
possible try  to list the d iffe ren t food items separately and in as much detail as 
possible, e.g. two slices of toast with a thin layer of butter and two teaspoonfuls of 
jam. Quantities can be reported as common measures where applicable, such as a 
cup/mug of tea or a spoonful of jam, otherwise please try  and estimate the weight,
e.g. 8oz steak. For ready meals, please note the pack weight and proportion consumed,
e.g. half an 800g lasagne.
Also, please record the approximate time you consumed the item and whether it  was a 
snack or part of a meal. This will help us build a picture of your daily eating pattern.
To save you from having to note down how you take your tea and coffee every time 
please complete the following two statements:
I  usually drink my tea with milk /  no milk and___ teaspoonfuls of sugar
I  usually drink my coffee with milk /  no milk and teaspoonfuls of sugar
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Date Time Meal or Food Consumed Quantity
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Appendix 8
A •
Health Questionnaire
English version for the UK 
(validated for Ireland)
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By placing a tick in one box in each group below, please indicate which statements 
best describe your own health state today.
Mobility
I have no problems in walking about d
I have some problems in walking about d
I am confined to bed □
Self-Care
I have no problems with self-care d
I have some problems washing or dressing myself d
I am unable to wash or dress myself d
Usual Activities (e.g. work, study, housework, family or 
leisure activities)
I have no problems with performing my usual activities d
I have some problems with performing my usual activities d
I am unable to perform my usual activities d
Pain/Discomfort
I have no pain or discomfort d
I have moderate pain or discomfort d
I have extreme pain or discomfort d
Anxiety/Depression
I am not anxious or depressed d
I am moderately anxious or depressed d
I am extremely anxious or depressed d
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To help people say how  good or bad a health state is, 
we have drawn a scale (ra the r like a the rm om eter) on 
which the  best state you can imagine is marked 100 and 
the  w ors t state you can imagine is marked 0.
Best
imaginable
100
9iL0
We w ou ld  like you to  indicate on th is scale how good 
or bad you r own health is today, in you r opin ion. 
Please do th is by draw ing a line from  the  box below  to  
w hichever po in t on the scale indicates how  good or 
bad your health state is today.
6_!t0
3 it0
0
W orst
imaginable
224
Appendix 9
Sheffield Teaching Hospitals
NHS Foundation Trust
OSA VERSION 1: 14th April 2011
Sheffield Hallam 
University
Effects of obstructive sleep apnoea and its treatment on macrovascular and microvascular function
Dear
We are undertaking a research project to investigate the effects of obstructive sleep apnoea and its 
treatment on blood vessel function. Obstructive sleep apnoea is a medical condition causing people to stop 
breathing at regular intervals during sleep. This puts significant strain on the heart and the blood vessels. 
Please find enclosed a participant information sheet which describes the study in detail and answers the 
most frequently asked questions.
Your participation in the study would involve being part of a sleep apnoea group, which we will compare to 
two other groups of patients with sleep apnoea and a control group. The study involves two visits to our 
department, at times to suit you. Parking permits can be arranged if necessary. It is important to note that 
there is no pressure to participate in this study. Please contact the research team to let them know if you are 
interested in taking part, or do not wish to be contacted again. Please telephone James Moss on 0114 22 5  
2262  or 07738 240670  or return the reply slip below in the enclosed freepost envelope before
Yours sincerely,
Dr Stephen Bianchi
Consultant Physician in Respiratory Medicine 
Northern General Hospital
Yes. I am interested in taking part in the above named study. I understand that a member of staff will 
be contacting me, regarding this study.
No, I am not interested in taking part in the study
SLEEP APNOEA RESEARCH STUDY
Name:
Telephone Number:
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Appendix 10
Sheffield Teaching Hospitals
NHS Foundation Trust
§)
Sheffield Hallam
University
OSA VERSION 2: 5th January 2012 
Participant Information Sheet
EFFECTS OF OBSTRUCTIVE SLEEP APNOEA AND ITS TREATMENT ON
MACROVASCULAR AND MICROVASCULAR FUNCTION
Invitation
We would like to invite you to take part in a research study. Before you decide, we need you to 
understand why the research is being done and what it would involve for you. Please take time to 
read the following information carefully. Ask us if there is anything that is not clear or if you would 
like more information. Please take time to decide whether or not you wish to take part.
What is the purpose of the project?
Obstructive sleep apnoea (OSA) is a common breathing disorder characterised by repeated 
episodes of upper airway collapse during sleep, which results in elevated blood pressure, sleep 
disturbance and increased risk of heart attack and stroke. To reduce risk and improve sleep 
quality, patients are usually treated with continuous positive airway pressure (CPAP), which 
involves wearing a special face mask during the night to help keep the airways open. CPAP should 
be used every night for sleeping, however, not all patients use their mask on a daily basis. 
Therefore, the purpose of this study is to investigate how well occasional CPAP use protects the 
cardiovascular system of OSA patients compared to daily use and to no use.
Why have I been invited?
You have been invited either because you have previously shown an interest in sleep apnoea 
research at Sheffield Hallam University or because you have been identified as potentially suitable 
from a recent OSA annual check.
Do I have to take part?
It is up to you to decide whether or not to be involved with this research. If you do decide to take 
part you will be given this information sheet to keep and asked to sign a consent form. If you
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decide to take part you are still free to withdraw at any time without giving a reason. Your future 
care will not be affected if you choose not to take part and you will not be contacted again by our 
research office.
What will happen to me if I agree to take part?
Your involvement in this study will involve one or two visits to the research facility at Sheffield
Hallam University (Centre for Sport and Exercise Science, Collegiate Hall, Collegiate Crescent
Campus, just off Ecclesall Road). These visits can be scheduled at a time to suit you.
Are there any expenses or payments involved?
Unfortunately we are not able to offer any payment or financial support for visits, however we can 
arrange a free permit for on-site parking should you choose to drive.
What will the visit to Sheffield Hallam University involve?
During your first visit to Sheffield Hallam University, a study researcher will take a medical history 
to assess your eligibility for this study. After this we will demonstrate or explain all of the main 
testing procedures that you will be required to complete as part of this study. If you are deemed 
provisionally eligible, and you are still interested in participating, then you will be asked to sign a 
consent form. Final eligibility will be determined by a consultant respiratory physician. For this 
session, you will need to bring a list of all the medications that you taking.
This session will be performed in the morning, after you have completed an overnight fast (no food) 
and avoided products containing tobacco and caffeine for at least 6 hours. At the beginning of this 
session, we will use simple non-invasive techniques to measure your height, weight, body fat 
percentage, and neck, waist and hip circumferences.
After this, we will assess your large blood vessel function using ultrasound. This test involves 
measuring the change in size of the largest blood vessel in your upper arm in response to an 
increase in arm blood flow. The increase in arm blood flow is produced by placing a blood 
pressure cuff on your upper forearm and inflating it to a high pressure for 5 minutes. You may 
experience some pins and needles in your hand and fingers during this procedure, but this will go 
away when the pressure is removed. We will also attach two non-invasive probes to the surface of 
the forearm using double-sided tape. These probes will non-invasively measure skin blood flow 
before, during, and after the cuff inflation. This assessment will last approximately 15 minutes.
After a recovery period, we will heat the probes to 42 °C (the temperature of bath-water) and 
measure changes in skin blood flow. This may be uncomfortable, but not painful, and after a 
couple of minutes the sensation will feel much milder. This assessment will last approximately 45 
minutes.
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After another recovery period, the response of the blood vessel to glyceryl trinitrate (GTN) will be 
measured. GTN is taken as a spray under the tongue and occasionally causes short-term (less 
than 10 minutes) feelings of light-headedness.
After a suitable recovery period we will then take a couple of drops of blood from the fleshy part of 
the fingertip. This procedure may involve a moment of discomfort when the surface of the skin is 
broken..
Finally, we will ask you to complete a shuttle-walk test. During this test you will be asked to walk 
up and down a 10 metre (11 yards) course. The walking speed will start slow and increase slightly 
each minute. The test will end when either you are too breathless to continue, you fail to complete 
two consecutive shuttles within the time allowed, or if you achieve 85% of your maximum 
calculated heart rate.
Will my taking part in the study be kept confidential?
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence, except if there is an issue of safety, in which case we will let your GP know, as well as 
yourself. Some parts of your medical records and the data collected for the study will be looked at 
by only authorised persons from the research team.
What will happen if I don’t want to carry on with the study?
You can withdraw from the study at any time and, if necessary, let us know if you no longer want to 
be contacted. If you do wish to drop out, you do not have to give a reason. Information collected 
may still be used.
What if there is a problem?
If you have any cause to complain about any aspect of the way in which you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not compromised in any way because 
you have taken part in a research study.
If you have any complaints or concerns, please contact the study manager, James Moss on (0114) 
225 2262 
OR
You can use the normal University complaints procedure and contact the following person:
Dr. Liz Winders, ‘Registrar and Secretary’ of Sheffield Hallam University, telephone (0114 225 
2051)
OR
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You can use the normal hospital complaints procedure and contact Professor Chris Welsh, Medical 
Director, Sheffield Teaching Hospitals NHS Foundation Trust, Tel 0114 271 2178
Why do you want to tell my GP that I am taking part in the study?
If you take part in any clinical trial then the research team is required to inform your GP, this will 
also make sure your GP is aware of anything you might do in the study that could potentially 
influence your medical care. However, your GP will not be given any of the information we collect 
from you.
What are the possible risks and benefits of taking part in this research?
The tests in which you have a blood pressure cuff inflated on your arm will probably cause some 
slight discomfort and feelings of pins and needles in your hand and fingers. These feelings are 
usually mild and they soon go away once the cuff is deflated. Taking GTN can sometimes make 
people feel light headed or nauseous for around 10 minutes afterwards. The risk of this procedure 
is low. You will be lying down and closely monitored during this procedure.
What if I am harmed?
If you are harmed by your participation in this study, there are no special compensation 
arrangements. If you are harmed due to someone's negligence, then you may have grounds for 
legal action, but you may have to pay for it.
What will happen to the results of the research study?
This research will take place over the next year, after which the results will be presented at 
academic conferences and published as academic reports in scientific journals. You will not be 
identified in any presentation, report or publication. You will be provided with an overview of the 
main study findings.
Who is organising and funding the research?
The research is organised by Sheffield Hallam University in collaboration with Sheffield Teaching 
Hospitals NHS Foundation Trust.
Who has reviewed the study?
All research in the NHS is looked at by an independent group of people, called a Research Ethics
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and
given a favourable opinion by Sheffield Research Ethics Committee.
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Contact for further information:
For study specific information, please contact James Moss, Centre for Sport and Exercise Science, 
Sheffield Hallam University, Sheffield, S10 2BP, Tel: 0114 2252262
For general enquiries about taking part in research at Sheffield Hallam University, please contact 
Stephen Gilbert, Centre for Sport and Exercise Science, Sheffield Hallam University, Sheffield, S10 
2BP, Tel: 0114 2255413
THIS INFORMATION SHEET IS FOR YOU TO KEEP. THANK YOU FOR YOUR TIME AND
HELP.
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Appendix 11
Sheffield Teaching Hospitals
NHS Foundation Trust
§)
Sheffield Hallam
non-OSA VERSION 1: 14th April 2011 University
Effects of obstructive sleep apnoea and its treatment on macrovascular and microvascular function
Dear
We are undertaking a research project to investigate the effects of obstructive sleep apnoea and its 
treatment on blood vessel function. Obstructive sleep apnoea is a medical condition causing people to stop 
breathing at regular intervals during sleep. This puts significant strain on the heart and the blood vessels. 
Please find enclosed a participant information sheet which describes the study in detail and answers the 
most frequently asked questions.
Your participation in the study would involve being part of the control group, which we will compare to three 
groups of patients with sleep apnoea. The study involves two visits to our department, at times to suit you. 
Parking permits can be arranged if necessary. It is important to note that there is no pressure to participate in 
this study. Please contact the research team to let them know if you are interested in taking part, or do not 
wish to be contacted again. Please telephone James Moss on 0114 2 25  2262  or 07738 240670  or return the 
reply slip below in the enclosed freepost envelope before .........................................
Yours sincerely,
Dr Stephen Bianchi
Consultant Physician in Respiratory Medicine 
Northern General Hospital
Yes. I am interested in taking part in the above named study. I understand that a member of staff will 
be contacting me, regarding this study.
No, I am not interested in taking part in the study
SLEEP APNOEA research study
Name:
Telephone Number:
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Appendix 12
Sheffield Teaching Hospitals
NHS Foundation Trust
§ >
Sheffield Hallam 
University
non-OSA VERSION 3: 7th August 2012 
Participant Information Sheet
EFFECTS OF OBSTRUCTIVE SLEEP APNOEA AND ITS TREATMENT ON 
MACROVASCULAR AND MICROVASCULAR FUNCTION
Invitation
We would like to invite you to take part in a research study. Before you decide, we need you to 
understand why the research is being done and what it would involve for you. Please take time to 
read the following information carefully. Ask us if there is anything that is not clear or if you would 
like more information. Please take time to decide whether or not you wish to take part.
What is the purpose of the project?
Obstructive sleep apnoea (OSA) is a common breathing disorder characterised by repeated 
episodes of upper airway collapse during sleep, which results in elevated blood pressure, sleep 
disturbance and increased risk of heart attack and stroke. To reduce risk and improve sleep 
quality, patients are usually treated with continuous positive airway pressure (CPAP), which 
involves wearing a special face mask during the night to help keep the airways open. CPAP should 
be used every night for sleeping, however, not all patients use their mask on a daily basis. 
Therefore, the purpose of this study is to investigate the how well occasional CPAP use protects 
the cardiovascular system of OSA patients compared to regular use and to no use.
Why have I been invited?
You may have been invited because you have shown an interest in this research by contacting a 
member of the research team or because you have shown an interest or participated in our 
research in the past.
Do I have to take part?
It is up to you to decide whether or not to be involved with this research. If you do decide to take 
part you will be given this information sheet to keep and asked to sign a consent form. If you
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decide to take part you are still free to withdraw at any time without giving a reason. Your future 
care will not be affected if you choose not to take part and you will not be contacted again by our 
research office.
What will happen to me if I agree to take part?
Your involvement in this study will involve two visits to the research facility at Sheffield Hallam 
University (Centre for Sport and Exercise Science, Collegiate Hall, Collegiate Crescent Campus, 
just off Ecclesall Road). These visits can be scheduled at a time to suit you.
Are there any expenses or payments involved?
Unfortunately we are not able to offer any payment or financial support for visits, however we can 
arrange a free permit for on-site parking should you choose to drive.
What will the visit to Sheffield Hallam University involve?
Visit 1: Medical screening, habituation and preparation for home sleep study (45 minutes)
During your first visit to Sheffield Hallam University, you will undergo a brief medical assessment to 
assess your eligibility for this study. After this we will demonstrate or explain all of the main testing 
procedures that you will be required to complete as part of this study. If you are deemed eligible, 
and you are still interested in participating, then you will be asked to sign a consent form. For this 
session, you will need to bring a list of all the medications that you taking.
You will be required to undergo a home-based, overnight sleep test. This device will record your 
breathing patterns and measure fingertip oxygen levels during sleep. You will be shown how to set 
this up.
If the sleep test suggests the presence of an undiagnosed sleep disorder we will, with your 
permission, notify you GP and allow them to decide the best course of action. You will be reminded 
of your responsibility to drive in accordance with the Road Traffic Act (1988) which stipulates that 
drivers should not drive when they are excessively tired.
This first visit to our facility should last around 45 minutes.
Visit 2: Blood vessel function tests (-2 .5  hours)
This session will be performed in the morning, after you have completed an overnight fast (no food 
for 12 hours) and avoided products containing tobacco and caffeine for at least 6 hours. At the 
beginning of this session, we will use simple non-invasive techniques to measure your height, 
weight, body fat percentage, and neck, waist and hip circumferences.
After this, we will assess your large blood vessel function using ultrasound. This test involves 
measuring the change in size of the largest blood vessel in your upper arm in response to an 
increase in arm blood flow. The increase in arm blood flow is produced by placing a cuff on your
233
upper forearm and inflating it to a high pressure for 5 minutes. You may experience some pins and 
needles in your hand and fingers during this procedure, but this will go away when the pressure is 
removed. We will also attach two non invasive probes to the surface of the forearm using double­
sided tape. These probes will measure skin blood flow before, during, and after the cuff inflation. 
This assessment will last approximately 15 minutes.
After a recovery period, we will heat the probes to 42 °C (the temperature of bath-water) and 
measure changes in skin blood flow. This may be uncomfortable, but not painful, and after a 
couple of minutes the sensation will feel much milder. This assessment will last approximately 45 
minutes.
After another recovery period, the response of the blood vessel to glyceryl trinitrate (GTN) will be 
measured. GTN is taken as a spray under the tongue and occasionally causes short-term (less 
than 10 minutes) feelings of light-headedness.
After a suitable recovery period we will then take a couple of drops of blood from the fleshy part of 
the fingertip. This procedure may involve a moment of discomfort when the surface of the skin is 
broken.
Finally, we will ask you to complete a shuttle-walk test. During this test you will be asked to walk 
up and down a 10 metre (11 yards) course. The walking speed will start slow and increase slightly 
each minute. The test will end when you are too breathless to continue, you fail to complete two 
consecutive shuttles within the time allowed, or if you achieve 85% of your maximum calculated 
heart rate.
Will my taking part in the study be kept confidential?
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence, except if there is an issue of safety, in which case we will let your GP know, as well as 
yourself. Some parts of your medical records and the data collected for the study will be looked at 
by only authorised persons from the research team.
What will happen if I don’t want to carry on with the study?
You can withdraw from the study at any time and, if necessary, let us know if you no longer want to 
be contacted. If you do wish to drop out, you do not have to give a reason. Information collected 
may still be used.
What if there is a problem?
If you have any cause to complain about any aspect of the way in which you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and you are not compromised in any way because 
you have taken part in a research study.
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If you have any complaints or concerns, please contact the study manager, James Moss on (0114) 
225 2262 
OR
You can use the normal University complaints procedure and contact the following person:
Dr. Liz Winders, ‘Registrar and Secretary’ of Sheffield Hallam University, telephone (0114 225 
2051)
OR
You can use the normal hospital complaints procedure and contact Professor Chris Welsh, Medical 
Director, Sheffield Teaching Hospitals NHS Foundation Trust, Tel 0114 271 2178
Why do you want to tell my GP that I am taking part in the study?
If you take part in any clinical trial then the research team is required to inform your GP, this will 
also make sure your GP is aware of anything you might do in the study that could potentially 
influence your medical care. However, your GP will not be given any of the information we collect 
from you.
What are the possible risks and benefits of taking part in this research?
The tests in which you have a blood pressure cuff inflated on your arm will probably cause some 
slight discomfort and feelings of pins and needles in your hand and fingers. These feelings are 
usually mild and they soon go away once the cuff is deflated. Taking GTN can sometimes make 
people feel light headed or nauseous for around 10 minutes afterwards. The risk of this procedure 
is low. You will be lying down and closely monitored during this procedure.
Part of the screening procedure involves overnight testing for sleep apnoea. This is a common but 
underdiagnosed medical condition which can put you at higher risk for cardiovascular disease. 
Routine screening is uncommon without GP referral - if we diagnose this condition we may refer 
you to a specialist at Northern General Hospital.
What if I am harmed?
If you are harmed by your participation in this study, there are no special compensation
arrangements. If you are harmed due to someone's negligence, then you may have grounds for
legal action, but you may have to pay for it.
What will happen to the results of the research study?
This research will take place over the next year, after which the results will be presented at 
academic conferences and published as academic reports in scientific journals. You will not be 
identified in any presentation, report or publication. You will be provided with an overview of the 
main study findings.
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Who is organising and funding the research?
The research is organised by Sheffield Hallam University in collaboration with Sheffield Teaching 
Hospitals NHS Foundation Trust.
Who has reviewed the study?
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and 
given a favourable opinion by Sheffield Research Ethics Committee.
Contact for further information:
For study specific information, please contact James Moss, Centre for Sport and Exercise Science, 
Sheffield Hallam University, Sheffield, S10 2BP, Tel: 0114 2252262
For general enquiries about taking part in research at Sheffield Hallam University, please contact 
Stephen Gilbert, Centre for Sport and Exercise Science, Sheffield Hallam University, Sheffield, S10 
2BP, Tel: 0114 2255413
THIS INFORMATION SHEET IS FOR YOU TO KEEP. THANK YOU FOR YOUR TIME AND
HELP.
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Appendix 13
Sheffield Teaching Hospitals
NHS Foundation Trust
Sheffield Hallam
University
Consent form
VERSION 1: 14th April 2011
Effects of obstructive sleep apnoea and its treatm ent on macrovascular and microvascular
above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving 
any reason, without my medical care or legal rights being affected.
3. I understand that relevant sections of any of my medical notes and data collected during the study may 
be looked at by individuals from regulatory authorities or from the NHS Trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to have access to my records.
4. I give permission for my GP to be informed of my participation in this research.
5. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
function
Please initial box
1. I confirm that I have read and understood the information sheet dated for the
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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Appendix 14
Sheffield Teaching Hospitals
NHS Foundation Trust
Consent form 
non-OSA VERSION 1: 28th June 2012 
Effects of obstructive sleep apnoea and its treatment on macrovascular and microvascular
function 
Please initial box
1. I confirm that I have read and understood the information sheet da ted .................................. ........
for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.
3. I understand that relevant sections of any of my medical notes and data collected during 
the study may be looked at by individuals from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission for these individuals to 
have access to my records.
4. I give permission for my GP to be informed of my participation in this research.
5. I give permission for an overnight sleep study to be performed to investigate the possibility 
of existing undiagnosed sleep disordered breathing/obstructive sleep apnoea.
6. I give permission for the research team to notify my GP of the result of the sleep study if 
it suggests that further investigations may be required.
7. I am aware that should a positive diagnosis of sleep-disordered breathing/obstructive 
sleep apnoea be made that it is my responsibility to ensure I drive in accordance 
with the Road Traffic Act (1988) and that further investigations may be required.
8. I agree to take part in the above study.
NHS
Sheffield Hallam 
University
Name of Patient Date Signature
Researcher Date Signature
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Appendix 15
Epworth Sleepiness Scale
The Epworth Sleepiness Scale is used to determine the level of daytime sleepiness. Use the 
following scale to choose the most appropriate number for each situation over the past two weeks. 
Even if you don’t usually do this activity, please give your best estimate:
0 = would never doze or sleep.
1 = slight chance of dozing or sleeping
2 = moderate chance of dozing or sleeping
3 = high chance of dozing or sleeping
Name:____________________________Date:____________________
Situation Chance of Dozing or Sleeping
Sitting and reading
Watching TV
Sitting inactive in a public place
Being a passenger in a motor vehicle for an
hour or more_________________________________________ ____
Lying down in the afternoon
Sitting and talking to someone
Sitting quietly after lunch (no alcohol)
Stopped for a few minutes in traffic
Total score ____
239
Appendix 16
Health Q uestionna ire
English version for the UK 
(validated for Ireland)
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By placing a tick  in one box in each group below, please indicate which sta tem ents 
best describe you r own health state today.
Mobility
I have no problems in walking about Q
I have slight problems in walking about □
I have moderate problems in walking about Q
I have severe problems in walking about □
I am unable to walk about d
Self-Care
I have no problems with self-care □
I have slight problems washing or dressing myself □
I have some problems washing or dressing myself □
I have severe problems washing or dressing myself □
I am unable to wash or dress myself □
Usual Activities {e.g. work, study, housework, family or 
leisure activities)
I have no problems with performing my usual activities □
I have slight problems with performing my usual activities □
I have some problems with performing my usual activities □
I have severe problems with performing my usual activities □
I am unable to perform my usual activities □
Pain/Discomfort
I have no pain or discomfort □
I have slight pain or discomfort □
I have moderate pain or discomfort □
I have severe pain or discomfort □
I have extreme pain or discomfort □
Anxiety/Depression
I am not anxious or depressed □
I am slightly anxious or depressed □
I am moderately anxious or depressed □
I am severely anxious or depressed □
I am extremely anxious or depressed □
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To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion. 
Please do this by drawing a line from the box below to 
whichever point on the scale indicates how good or 
bad your health state is today.
Best
imaginable
100
9 ^ 0
5 " 0
3][0
2110
1110
0
Worst
imaginable
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